Functional and Epidemiological Characterization of

Non-Synonymous Single Nucleotide Polymorphisms in IRAK2 by Wang, Hui
  
 
Dissertation 
 
Submitted to the 
Combined Faculties for the Natural Sciences and for Mathematics 
of the Ruperto-Carola University of Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
 
 
Presented by 
M.Sc. Hui Wang  
Born in: Henan province, P.R.China 
Oral-examination: 28
th
 June 2013 
 
 
  
  
 
 
Functional and Epidemiological Characterization of 
Non-Synonymous Single Nucleotide Polymorphisms in 
IRAK2 
 
 
 
 
 
 
Referees: Prof. Dr. med. Hans-Georg Kräusslich 
 
Prof. Dr. Alexander Weber 
 
  
  
  
This thesis was conducted at the German Cancer Research Center (Deutsches Krebs 
forschungs zentrum, DKFZ) Heidelberg and Department of Immunology of Tübingen 
University, Germany; both are under the supervision of Prof. Dr. Alexander Weber. 
This thesis is the presentation of my original research work and every effort has been 
taken to specifically indicate the work done in collaboration with others, and is 
referenced with names for the contributions of collaborators. I hereby declare that the 
following thesis is my own work and has been written by the undersigned and without 
any assistance from third parties. Furthermore, I confirm that no sources have been 
used in the preparation of this thesis other than those indicated. 
 
 
Heidelberg, 11
th
 April 
 
--------------------------------------------- 
 
 
  
  
  
Acknowledgement 
 
First I would like to thank my Ph.D. supervisor Prof. Dr. Alexander Weber. He provided 
me the valuable opportunity to do my Ph.D. in his group. During the four-year study, 
his selfless scientific discussion and guidance support me to accomplish the goal of my 
Ph.D. project and let me understand the world of molecular biology. Meanwhile, as a 
foreigner, Alex also helped me a lot in my private life.  
I also would like to thank the Chinese Scholarship Council who sponsored me for the 
four-year study. Without their support, I could not concentrate on my research. 
I appreciate the opportunity to work both at the German Cancer Research Centre 
(DKFZ) in Heidelberg and at the University of Tübingen, both of which provided me an 
excellent scientific working environment and an opportunity to get to know the other 
areas of research, as well as cooperation with other colleagues. In particular, I would 
like to express my thanks to Dr. Markus Feuerer and Dr. David Richard who provided 
me with many research tools and techniques. Additionally, I am very thankful for the 
technical help which I obtained from and Dr. Tore Kempf and Gabriella Siszler, who 
work at the core facility of DKFZ.  
I also thank for the help from Tübingen to help us setting up the new lab. Particularly, 
Dr. Kevin Dannehy and Beate Pömmerl helped me to conquer the technical problems of 
retroviral transduction. I also highly appreciate the help from my lab mates. Particularly, 
I would like to express my special gratitude to my “private teacher” -Julie George, who 
taught me from the basic plasmid extraction to design a small intact experiment and 
helped me with many trivial things of the lab life. Additionally, Dr. Tica Pichulik also 
helped me a lot in the end of Ph.D. work and translated the Abstract into German. I 
also thank our lab technicians Birgit Kaiser and Sabine Dickhöfer, they both helped me 
a lot in preparing constructs or conducting experiments. 
In the end I would like to express my thanks to my parents and Xu who constantly have 
supported and encouraged me during my Ph.D. time. I also appreciate their 
understanding and patience for me. 
  
  
Abstract 
Toll-like receptors (TLR) play an essential role in innate immunity, in which they 
indentify invasive pathogens and initiate the immune responses to eliminate the 
pathogens. Interleukine-1receptor-associated kinases are key kinases in the TLR 
signalling pathway where they integrate signals from activated receptor complexes to 
then induce the activation of downstream transcription factors NF-κB, AP-1 and IRFs. 
It is known that IRAK4 deficiency in humans is related with recurrent pyogenic 
bacterial infections which can be lethal without any facilitation of health care and 
antibiotics. In light of this fact, this study focuses on analysing the general role of 
IRAK2 on the pathogenesis of certain kinds of diseases. 
Known non-synonymous single nucleotide polymorphisms (SNPs) of IRAK2 were 
selected from the NCBI SNP database, which served as probes to gain insights of the 
molecular functions of IRAK2. The SNPs of interest were screened by overexpressing 
the constructs of variants into a human cell line and detecting the activation of NF-κB. 
IRAK2 R214G and L392V decreased the activation of NF-κB and the production of 
IL-8. Although R214G and L392V varied the interaction intensity with IRAK2 and 
IRAK4, these two variants still maintained the interaction with the downstream 
signalling partner TRAF6. Interestingly, IRAK2 R214G and L392V both reduced the 
ubiquitination levels of TRAF6. The ubiquitination of TRAF6 is an essential step for 
the NF-κB activation. Moreover, when stimulating human IRAK2 WT reconstituted 
murine Irak2 knockout macrophages with TLR2, 4 and 7 ligands, the TNF-α 
production was massively enhanced. Meanwhile, phosphorylation of p38, p65, ERK 
was enhanced as well. Intriguingly, the phosphorylation of Akt was only observed in 
the IRAK2 WT reconstituted macrophages. Additionally, the R214G and L392V 
reconstituted macrophages reduced the transcriptional activation of Il-1β and Il-6 in 
comparison to IRAK2 WT.  
The epidemiological analyses revealed that IRAK2 R214G (rs35060588) reduced the 
survival time of colorectal cancer patients; IRAK2 L392V (rs3855283) significantly 
reduced the auto clearance of HCV in patients who are then susceptible to become a 
chronic HCV infection; additionally L392V also increased the possibility of 
progression from gastritis to gastric cancer. Collectively, this information would be 
helpful for the future personalized therapy. 
  
  
Zusammenfassung 
Toll-like Rezeptoren (TLR) spielen eine wichtige Rolle in der angeborenen 
Immunantwort, da sie invasive Pathogene identifizieren und eine Immunantwort 
initiieren um das Pathogen zu eliminieren. Interleukin-1 Rezeptor-assoziierten Kinasen 
sind wichtige Kinasen in der TLR Signalkaskade, die Signale von verschiedenen 
aktivierten Rezeptorkomplexen integrieren, was schließlich zur Aktivierung der 
Transkriptionsfaktoren NF-κB, AP-1 und IRFs führt. Es ist bekannt, dass eine IRAK4 
Defizienz im Menschen mit wiederkehrenden pyogenen bakteriellen Infektionen einher 
geht, welche ohne medizinische Behandlung und die Gabe von Antibiotika tödlich 
enden können. Angesichts dessen untersucht diese Studie die grundliegende Rolle von 
IRAK2 in der Pathogenese von verschiedenen Krankheiten.  
Bekannte nicht synonyme Einzelnukleotid-Polymorphismen (SNPs) in IRAK2 wurden 
aus der NCBI SNP Datenbank selektiert und dienten als Mittel, um die molekulare 
Funktion von IRAK2 zu untersuchen. Die interessanten SNPs wurden überprüft, indem 
Konstrukte von verschiedenen Varianten in einer humanen Zellenlinie überexprimiert 
und die Aktivierung von NF-κB gemessen wurde. IRAK2 R214G und L392V zeigten 
eine verringerte Aktivierung von NF-κB und Produktion von IL-8. Obwohl R214G und 
L392V unterschiedliche Interaktionsstärken zu IRAK2 und IRAK4 aufweisen, 
konnten diese beiden Varianten die Interaktion zu ihrem Signalpartner TRAF6 
bewahren. Interessanterweise reduzierten IRAK2 R214G und L392V allerdings die 
Ubiquitinierung von TRAF6, ein wichtiger Schritt für die Aktivierung von NF-κB. 
Außerdem führte die Stimulierung von murinen Irak2 knockout Makrophagen, die mit 
wildtype IRAK2 konstituiert wurden, zu einer massiv erhöhten Produktion von TNF-α. 
Die Stimulierung wurde mit TLR2, 4 und 7 Liganden durchgeführt. Auch die 
Phosphorylierung von p38, p65 und ERK war in diesen Zellen erhöht. 
Interessanterweise konnte die Phosphorylierung von Akt nur in den IRAK2 
rekonstituierten Makrophagen nachgewiesen werden. Die Makrophagen, die mit 
R214G und L392V rekonstituiert wurden, wiesen eine reduzierte Transkription von 
Il-1β und Il-6 im Gegensatz zu wildtyp IRAK2 auf.  
Die epidemiologische Analyse hat gezeigt, dass IRAK2 R214G (rs35060588) die 
Überlebenszeit von Patienten mit Kolorektalkarzinom verringert. IRAK2 L392V 
(rs3855283) hingegen reduziert die spontane Eliminierung von HCV und begünstigt 
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einen chronischen Krankheitsverlauf. Zusätzlich erhöht L392V das Risiko, dass sich 
aus einer Gastritis ein Margenkarzinom entwickelt. Zusammen könnten diese 
Ergebnisse hilfreich für die zukünftige Entwicklung einer personalisierten Therapie 
sein.
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1.1 The human immune system 
The immune system can recognize and eliminate exogenous pathogens which invade 
and cause infection and diseases in humans. Additionally, it can distinguish and remove 
endogenous oncogenic cells, cellular debris, and other toxic substances. In general, the 
tenet of the immune system is keeping the human organism in a stable and healthy 
condition[1]. However, pathogens can avoid the detection and neutralization of the 
immune system by quickly evolving and adapting to the surrounding environment. 
Correspondingly, multiple defence mechanisms have also evolved to identify and 
eradicate pathogens. Therefore, the immune system can be divided into two parts: the 
innate immune system and the adaptive immune system. The former serves as the first 
barrier to protect organisms against pathogens. As we know, even a unicellular 
organism has a rudimentary immune system that can resist bacteriophage infection by 
the means of enzymes. Additionally, plants and insects have a basic innate immune 
system as well, as phagocytosis, antimicrobial peptides called defensins and the 
complement system [1].  
In humans, the innate immune system includes macrophages, dendritic cells, natural 
killer cells, natural killer T cells, eosinophil, basophils and neutrophils. All of these 
cells can produce pro-inflammatory cytokines, chemokines or interferon immediately 
when they recognize exogenous pathogens [2]. One important function of macrophages 
is the phagocytosis, which can clean aged cells and remove dead cellular debris in the 
late stage of infection. Another important role of macrophages is antigen presentation 
which bridges the innate and the adaptive immune system. After ingesting and 
digesting a pathogen, macrophages can present an antigen of a pathogen to T cells that 
can induce the adaptive immune system [2]. Other than macrophages, dendritic cells 
are present in tissues which are in contact with the external environment, such as the 
skin and the lining of the nose, lungs, stomach and intestines. After being activated by 
the pathogens, dendritic cells migrate to the lymph node where they present the antigen 
to T cells or B cells to initiate and shape the adaptive immune response. Meanwhile, 
certain dendritic cells can produce a high amount of interferon after the recognition of 
viruses [3]. On the other hand, eosinophils are responsible for fighting against 
multicellular parasites and certain invertebrates [4]. Along with mast cells and 
basophils, they also play a role in allergic reactions [4]. Neutrophils, are the most 
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abundant type of polymorphonuclear cells in mammals. They play an essential role in 
innate immunity. Because of the high migration ability, they can quickly congregate at 
the centre of an infection at the early phase of inflammation, especially for those caused 
by bacterial infection, environmental exposure and some cancers[4]. Moreover, 
neutrophils can detect chemokines gradients of interleukine-8 (IL-8), and interferon 
gama (IFN-gama), which lead to neutrophils migration. Additionly, neutrophils can 
express and release cytokines, which in turn amplify inflammatory reaction. 
Furthermore, since neutrophils have Fc receptor for opsonin.They can internalize and 
kill microorganisms and particles that are coated in opsonins via phagocytosis and 
degradation [4].  
The initial response of innate immunity to the pathogen invasion is vital for 
eliminateing the bacterial conserved pathogen associated molecular pattern (PAMP). 
However, in the face of the variable and quickly evolving viruses or bacterium, a more 
efficient adaptive immunity is needed to produce a strong and specific antibody. The 
adaptive immune system can then induce specific memory to a pathogen to protect our 
body against secondary invasion [2]. The adaptive immune system only exists in jawed 
vertebrates, as well as human beings. It is highly adaptable because of the somatic 
hypermutaion and V (D) J recombination [5]. This feature triggers a small number of 
genes to generate a vast number of different antigen receptors, which are further 
uniquely expressed on each individual lymphocyte. Moreover, these irreversible and 
specific changes are inherited by the progeny cells. Consequently, the memory T cells 
and memory B cells are generated and become the keys of long lived specific immunity 
[6]. T cells and B cells are the major types of lymphocytes for adaptive immunity. T 
cells play a major role in cell- mediated immune response. CD8+ T cells, also known as 
cytotoxic T cells, identify the specific antigens which are present by MHC-I molecular 
and majorly produced by viruses and cancer cells. CD4+ T cells, also known as T 
helper cells, assist other immune response, such as maturation of B cells, into plasma 
cells and memory B cells [2]. Once they are activated, they begin dividing rapidly and 
differentiating into several subtypes, such as TH-1, TH-2, TH-3 and TH-17, which release 
different cytokines to regulate the immune response [7]. Regulatory T cells are also 
known as suppressor T cells. The major function of them is to reduce T cell mediated 
immunity [8]. On the other hand, the main functions of B cells are taking part in the 
humoral immune response, producing specific antibodies against exogenous antigen 
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and developing into memory B cells[9].  
The human immune system is complicated and includes a lot of sophisticated defence 
mechanisms. Innate immunity serves as the first fence to eradicate pathogens. Once the 
infection surpasses a certain threshold, adaptive immunity can be activated by the 
innate immunity and boost the immune response in unspecific and specific way[2]. 
Meanwhile, the immune system produces certain types of suppressive cytokines to 
balance the immune response. Alltogether, innate immunity and adaptive immunity 
cooperate with each other and keep the homeostasis of the organisms. 
1.2 The pattern recognition receptors 
One unique feature of the innate immunity is the ability to detect noxious substances 
and this recognition is mediated by counterparts that one part was encoded in human 
genome and another part was encoded by the genomes of different species. 
Interestingly, the selective advantage provided by the recognition of the components of 
the host, usually implies a selective weakness to the pathogens [10]. CA Janeway 
pointed out that this conflict directs the evolution of innate immunity toward 
recognition of invariant molecular constituents of the infectious agents. Conservation 
of these molecular structures indicates that they are shared by large groups of pathogens. 
Thus, this work suggested that the innate immune system would detect the presence of 
infection via recognition of conserved microbial pathogen-associated molecular 
patterns (PAMPs) by germ-line encoded receptors. Therefore, they were named pattern 
recognition receptors (PRRs) [6]. Current research indicates that PRRs are also 
detecting molecular from non-pathogenic molecular (i.e. DAMPs) and responsible for 
recognizing endogenous molecules which were released from damaged cells, thus 
termed as damage-associated molecular patterns (DAMP) [11]. It is now becoming 
clear that innate immunity is not only responsible for the early pathogen invasion and 
elimination, but also for initiating, shaping and checking adaptive immunity [12]. For 
example, innate immunity determine the origin of the antigen, the type of infection 
(pathogen class), the extent and duration of infection, and finally, the requirement for 
immediate defence or future defence. However, not all PRRs are equal in terms of their 
ability to trigger adaptive immunity. Thus, this phenomenon encouraged research on 
the mechanism of each type of PRRs.  
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PRRs are expressed not only in macrophages and DCs but also in epithelial cells, 
endothelial cells, and fibroblasts[13]. According to the localization in terms of cellular 
structure of PRRs, they can be divided into three major groups: extracellular soluble 
PRRs, transmembrane PRRs and cytoplasmic PRRs (Figure1.1).  
 
Figure 1.1: Major PRRs in human innate immunity (modified from Ranjan, Bowzard et al., 2009) 
The major components of soluble PRRs are complement, C-reactive protein, serum 
amyloid protein and mannose-binding protein. They are mostly synthesised in the liver 
and kept at a certain concentration in the plasma. When they recognize the pathogen, 
they can modulate and strengthen innate immunity. The transmembrane PRRs include 
Toll-like receptors (TLRs) and C-type lectins. Dectin-1 and Dectin-2 are the major 
members of C-type lectins. They can identify β-glucans from fungal pathogens such as 
Candida albians. The cytosolic PRRs can be separated into two groups based on their 
mechanism of activation. The first group includes the retinoic acid-inducible gene I 
(RIG-I)-like helicases receptors (RLRs), and the second group is nucleotide-binding 
oligomerization domain containing (Nod)-like receptor (NLR) family, it includs Nod1 
and Nod2. Both of them directly detect cytosolic PAMPs and activate various signalling 
pathways[14]. Additionally, the second group contents of NALP3, NLRC4. They are 
involved in the formation of inflammasomes, which activate caspase-1 and release 
mature IL-1 . Different from transmembrane PRRs, cytosolic PRRs can distinguish 
intracellular infections from extracellular infections, cell-intrinsic infections from cell 
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-extrinsic infection, and pathogenic microorganisms from harmless, commensal 
microorganisms [12]. Therefore, the following paragraph will describe the Toll-like 
receptors (TLRs), the retinoic acid inducible gene I (RIG)-like receptors (RLRs) and 
Nod like receptor in a detailed way. 
Table 1.1: Major PRRs and their ligands (modified from Takeuchi and Akira 2010) 
1.2.1 The Toll- like receptors/interleukin-1 receptor superfamily 
1.2.1.1 The Toll-like receptors 
The Toll-like receptor family is one of the best researched PRR families. Toll was first 
found and named by Dr. Christiane Nüsslein-Volhard in Drosophila in 1985. It was 
thought initially vital only for the development of embryonic dorsoventral polarity[15]. 
PRRs Localization Ligands organisms 
Toll-like receptors 
  
TLR1 Plasam membrane triacyl lipoprotein Bacteria 
TLR2 Plasam membrane lipoprotein Bacteria, viruses, parasites 
TLR3 endolysosome dsRNA Virus 
TLR4 Plasam membrane LPS Bacteria 
TLR5 Plasam membrane Flagellin Bacteria 
TLR6 Plasam membrane Diacyl lipoprotein Bacteria, Viruses 
TLR7/8 endolysosome ssRNA Bacteria, Viruses 
TLR9 endolysosome cPG-DNA Bacteria, Viruses,protozoa 
TLR10 endolysosome unknown Unknown 
C-type lectin receptors 
  
Dectin-1 cytoplasm β-Glucan Fungi 
Dectin-2 cytoplasm β-Glucan Fungi 
RIG-1 like receptors 
  
RIG-1  cytoplasm 
short dsRNA, 5' triphosphate 
dsRNA 
RNA virus, DNA virus 
MDA5 cytoplasm long dsRNA RNA virus (Picornaviridae) 
LGP2 cytoplasm unknown RNA virus, DNA virus 
NOD-like receptors 
  
NOD1 cytoplasm bacterial peptidogylcans Bacteria 
NOD2 cytoplasm bacterial peptidogylcans Bacteria 
NALP1 cytoplasm broad ligand specificity PAMP OR DAMP 
NALP3 cytoplasm broad ligand specificity PAMP OR DAMP 
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However, Dr. Jules A Hoffmann discovered in 1996 that this dorsoventral regulatory 
gene also plays an essential role in the innate immunity as well. Toll can stimulate 
NF-κB activation after recognizing fungi [16]. The first human TLR was found in 1994 
by Nomura and his colleagues [17], mapped to a chromosome in 1996 [18] and named 
TLR4. TLR4 was first described as a receptor for LPS in mice [19]. Meanwhile, 
activation of TLR4 triggers both innate and adaptive immunity [20]. In turn, the other 
TLRs were investigated sequentially. Till now, 10 TLRs have been identified in humans, 
out of which 9 TLRs are well characterized (Table 1.1). Particularly, TLR1 to 9 are 
conserved in both human and mice. As type I integral membrane glycoproteins, TLRs 
consist of a N-terminal leucine-rich repeat (LRRs) domain, a transmembrane region 
and a cytoplasmic signalling domain homologous to interleukin 1 receptor (IL-1R), 
named as Toll/IL-1R homology (TIR) domain [21]. The extracellular LRR domain 
contains19-25 tandem LRR motifs which includes the motif XLXXLXLXX or 
conserved amino acid residual XψXXψXXXXFXXLX (ψ=hydrophobic residue) is 
24-29 amino acid in length [22]. Each LRR domain is composed of an   helix and a   
strand. It was mapped that LRR will form a horseshoe structure [23].  
Based on the location and activation of different pro-inflammatory cytokines, TLRs can 
be divided into two subgroups. TLR 1, 2, 4, 5, 6 are primarily expressed on the plasma 
membrane, and can recognize PAMPs derived from bacteria, fungi and protozoa. 
Whereas TLR 3, 7, 8 and 9 are exclusively expressed in the lysosome or endosome 
membrane and can identify nucleic acid disintegrated from viruses and bacteria, but 
also from the host [13, 23]. 
Each TLR identifies certain type of molecular pattern of microorganisms (Figure 1.2.a 
and b). For instance, TLR2 forms heterodimer with either TLR1 or TLR6 to recognize 
its ligands. TLR1/TLR2 identifies triacylated lipopeptides, while TLR6/TLR2 
recognizes diacylated lipopeptides [13]. The crystal structure of the human 
TLR1/TLR2 was first described in 2007. It indicates that binding of the triacylated 
lipopeptides (Pam3CSK4) induces the hetrodimerization of TLR1 and TLR2. The 
ectodomains of TLR1/TLR2 form an “M” shape. The two ester bound lipid chains of 
Pam3CSK4 are submerged into a hydrophobic pocket of TLR2, while the amide –bound 
lipid chain is inserted into a hydrophobic space in TLR1 [24]. Activation of TLR2 will 
induce various pro-inflammatory cytokines production, except for type I IFNs. 
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However, recent research indicates that type I IFNs will be produced after viral 
infection of TLR2 inflammatory monocytes [25].  
The ligand of TLR4 is Lipopolysaccharide (LPS), which is derived from 
Gram-negative bacteria [19, 20, 26]. However, transfecting TLR4 with myeloid 
differentiation factor 2 (MD2) can trigger 2-3 folds NF-κB activation than transfecting 
TLR4 alone into HEK293T cells [27]. Moreover, the crystal structure of TLR4-MD2 
indicates that MD-2 binds to TLR4 and generates a hydrophobic space for interaction 
with LPS [28]. Later, it was proved that two complexes of TLR4-MD2-LPS form a 
horseshoe shape by homodimerization [29]. TLR4 can recognize viruses via binding to 
viral envelope proteins [23]. TLR4 has the ability to induce IFN-β production [30]. 
TLR5 recognizes flagellin [31]. Flagellin is the main component of bacteria flagella, 
the motility apparatus of many microbial pathogens. The crystal structure of a 
Salmonella flagellin revealed that flagellin domains consists of N- and C- terminal   
helix chains(D0), the central   helix chain (D1), and the hypervariable central region 
with β sheets(D2 and D3). TLR5 specifically recognizes the constant domain D1 in 
flagellin[32]. TLR5 is mainly expressed on epithelial cells, monocytes, and immature 
DCs.[23]. Particularly, TLR5 is only expressed on the basolateral of epithelial cells in 
the intestine. Thus, it can only distinguish the bacteria which have invaded into the 
epithelial cells and trigger NF-κB and TNF-  activation [31]. Moreover, it was found 
that TLR5 highly expressed in the lung, which seems to play an important role in 
cleaning pathogens in the respiratory tract.  
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Figure 1.2 A: plasma membrane located TLRs and their ligands (Kawai and Akira 2010) 
TLR3 is responsible for double strand RNA which is produced during viral infection, as 
a replication outcome or a by product of symmetrical transcription in DNA viruses [33]. 
TLR3 is expressed widely in conventional dendritic cells, epithelial cells, astrocytes 
and glioblastoma cells in the brain [23]. After binding the ligand, TLR3 can activate 
NF-κB activation and the production of the type I interferon (IFNs) [33]. A recent study 
indicates that TLR3 is crucial for the production of IL-12p40 [34]. The crystal structure 
of TLR3 shows that two ecodomains homodymerized and generated a 
glycosylation-free face which binds by polyinosinic polycytidylic acid (poly I:C), a 
synthetic dsRNA analog. Interestingly, it was found that TLR3 deficiency is related 
with recurrent Herpes simplex encephalitis (HSE) [35]. 
Human TLR7 is homologous with TLR8, and both of them locate on the X 
chromosome. TLR7/8 recognizes single strand RNA (ssRNA) as well as small 
synthetic compounds (imidazoquinolines). TLR7 and TLR8 are expressed on the 
endosome membrane. Due to the low pH value in the endosomes, it is easy for viruses 
to release ssRNA. TLR7 can also recognize the RNA derived from bacteria such as 
Group B Streptococcus [36]. Triggering TLR7/8 has also been shown to have 
conflicting effects on HIV replication: on the one hand, it suppresses HIV replication in 
acute ex vivo-infected lymphoid tissue; on the other hand, it stimulates the release of 
HIV virions from latently infected cells. Furthermore, TLR8 mediated NF-κB 
activation is solely involved in releasing the latent HIV [37]. TLR9 is mainly expressed 
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on the plasmacytoid dendritic cells (pDC) and identify viral DNA, such as herpes 
simplex virus 1 (HSV-1) and murine cytomegalovirus (MCMV), both of which contain 
many of unmethylated CpG motif. It can induce TLR9 activation and produce 
pro-inflammatory cytokines and type I IFN [38-40]. Furthermore, TLR9 can recognize 
the pigment hemozoin of malaria [41, 42].  
 
Figure 1.2 B:  Endolysosome membrane located TLRs and their ligands (Kawai and Akira 
2010) 
Current research shows that TLRs are very important for the host defense against the 
pathogen invasion. The different location and dynamic mobility are key features of 
TLRs for them to distinguish self and non self ligands [43].  
1.2.1.2 The interleukin-1 receptor family 
Although interleulin-1 receptor family (IL-1R) is not a PRR, it encompasses the 
similar conserved TIR domain with TLR family. Hence, the delineation of IL-1R 
family is presented here. The discovery of interleukin-1 receptor (named as type I IL-1 
receptor (IL-1RI) was a critical step to understand the pro-inflammatory cytokines 
signalling pathway[44]. The IL-1RI has extracellular three immunoglobulin (Ig) 
domains, but the intracellular domain has not been fully defined at that time. Later 
discovery revealed that the cytosolic region of IL-1RI had significant homolog to the 
Drosophila protein Toll [45]. This demonstration led to the definition of the 
IL-1R/Toll-like receptor superfamilly. Due to the homologus cytosolic domain, it was 
termed as the Toll/IL-1R (TIR) domain in 1998. So far, three subgroups in the 
 11 
IL-1R/Toll-like receptor superfamily have been identified, which depending on the 
extracellular region of the protein has homology to the immunoglobulin-like, or to the 
leucine- rich repeat motif like Toll receptor, or to the adaptor protein(no extracellular 
domain) (Figure 1.3) [46].  
 
Figure 1.3 The IL-1R/TLR superfamily (Luke A.J. O’Neill, 2008) 
The immunoglobulin domain sub-group, which is also named the IL-1RI like group, 
consists of 9 members. Except for the single immunoglobulin IL-1R-related molecule 
(SIGIRR), which only has one Ig extracellular domain, all the rest have three Ig 
domains. IL-1RI and the IL-1 receptor accessory protein (IL-1RAcP) are two 
components of type I IL-1 receptor complex. The agonists of IL-1RI complex are IL-1 , 
IL-1β and the naturally occurred antagonist IL-1RA. IL-1RAcP was found by using 
specific monoclonal antibody (mAb) 4C5 to block IL-1β binding to IL-1RI. However, 
it binds to IL-1RAcp which is highly homologous to IL-1R [47]. Research revealed that 
lacking IL-1RAcP cannot induce IL-1 response. However, transfecting IL-1RAcP to 
the cells can rescue the IL-1 activation and NF-κB activation [48]. IL-1RAcP may be 
internalised into the cell and interacte with the down steam protein interleukin-1 
receptor associated kinase (IRAK) [48, 49]. Analogous to IL-1 receptor complex, the 
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IL-18 receptor (IL-18R) and IL-18 receptor accessory protein (IL-18AcP, also known 
as IL-18AcpL) form the IL-18 receptor complex[46], which also requires IRAK to 
induce NF-κB activation [50]. The agonist of IL-18 receptor complex is IL-18. ST-2 
and IL-1RAcp have been identified to be the receptor complex for IL-33[51]. IL-33R 
activation NF-κB requires TRAF6 to recruit IRAKs for initiating signalling 
transduction. In general, the IL-1RI family share the intracellular signalling pathway 
with TLRs-NF-κB starting from MyD88 (see figure1.4). Activation of TLRs produces 
pro-inflammatory cytokines such as IL-6 and pro-IL-1β. Then the pro-IL-1β can be 
matured and released to further activate IL-1 receptors. 
 
Figure 1.4 The cross talk between TLRs and IL-1R signalling pathways (modified from Dunne 
and O’Neil, 2003) 
Overall, IL-1 family are the general growth factors for T lymphocytes. IL-1 majorly 
regulates Th17 cells[52], IL-18 promotes Th1cells and IL-33 regulates Th2 cells [46]. 
(Figure1.5) 
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Figure 1.5 Process IL-1 receptor family and their ligands (Luke A.J. O’Neill, 2008 ) 
The other two subgroups are the LRR subgroup (10 members) and adaptor subgroup (5 
members). Although the TIR domain is a hallmark for the whole family, little is known 
about this domain. It seems that it is very important to mediate homotypic interactions 
with other TIR domain [21]. The activation of TLR/IL-1 superfamily reveals that the 
receptor TIR domain homo/hetro dimerization is required for downstream activation. 
TIR domain dimerization is used for recruiting the adaptor proteins which also contain 
the TIR domain to induce further signalling (see figure1.3). The signalling pathway of 
each TIR domain containing protein will be described in section 1.3 
1.2.2 The RIG-I-like receptors family 
The RIG-I-like receptors (RLR) family consists of retinoic-acid-inducible protein I 
(RIG-I), melanoma differentiation-associated gene 5 (MDA-5), and laboratory of 
genetics and physiology 2 (LGP-2) [53]. Structural analyses demonstrated that RIG-I 
and MDA-5 are comprised of two N-terminal caspase recruitment domains (CARDs), a 
central DEAD box helicase/ATPase domain, and a C-terminal regulatory domain, while 
LGP-2 does not have CARDs (Figure 1.6) 
 
Figure 1.6 The schematic diagram of RLR family members (Meylan, Tschopp et al. 2006) 
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RLRs are located in the cytoplasma. It was verified that they are the receptor to 
recognize cytoplasmic dsRNA [54]. As aforementioned, TLR3 is also the detector of 
dsRNA. However, TLR3 cannot recognize the dsRNA when the viruses occur into the 
cytoplasma. Type I IFN can still be produced even in fibroblasts and cDCs without 
MyD88 and TRIF [55], indicating that RLR are essential for detecting viruses and 
compensate for TLR signalling. Similar experiments also confirmed that MDA-5 is a 
RNA sensor [56]. In contrast to RIG-I and MDA-5, LGP-2 binds to RNA whereas it 
seems to play a dominant-negative role [57]. Some researches indicats that LGP-2 is 
dispensable in the RIG-I like receptor signalling pathway. Later researches indicate 
that the ligands for RIG-I and MDA-5 are different. RIG-I prefers to recognize 
relatively short dsRNA(<1kb), while MDA-5 can identify long dsRNA [58]. The 
finding has been confirmed by EMCV (produces long dsRNA during replication) and 
VSV (generates short dsRNA during replication) which were recognized by MDA-5 
and RIG-1 respectively. The presence of a 5’ triphosphate at the end of dsRNA greatly 
enhances RIG-1 induced type I IFN secretion amount. C-terminal domain of RLR is 
responsible for interacting with dsRNA. Current research shows that RIG-I and LGP-2 
have similar RNA binding loops in the C-terminal domain. However, the MDA-5 RNA 
binding loop looks much flatter due to opened confirmation of loop. It may imply that 
MDA-5 has weaker interaction with dsRNA [59, 60]. 
The CARD domains of RLRs are the effect domain to trigger a signalling cascade. The 
N-terminal of CARDs interacts with IFN-β promoter stimulator 1(IPS-1) (also called 
VISA, Cardiff and MAVS) [61-64]. IPS-1 contains a N-terminal CARD domain as well. 
According to the evidence that RIG-1 and MDA-5 are recruited by IPS-1, and IPS-1 
can be an adaptor protein of the RLR signalling pathway. By over-expressing IPS-1 into 
human cells, it can trigger type I IFN and NF-κB activation [23]. Interestingly, the 
C-terminus of IPS-1 harbours a transmembrane region which targets IPS-1 to the 
mitochondrial outer membrane. However, when IPS-1 is released from mitochondria to 
the cytoplasm or is located to endoplasmic reticulum, it can no longer induce IRF and 
NF-κB activation. It is inferred from the experiments that IPS-1 is cleaved and released 
by the HCV viral protease NS3/4A [13]. IPS-1 activates TBK1 and IKK-ε then TBK 
and IKK- ε phophorylate IRF-3 and IRF-7. FADD and RIP1 can also interact with 
IPS-1 via non-CARD domains to trigger NF-κB activation [23]. Both TLR3 and RIG-I 
receptors identified dsRNA. However, TLR3 recognize the dsRNA which presents in 
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endosome and RIG-I receptor identify dsRNA in cytoplasm (See figure 1.7). 
 
Figure 1.7 Sensing of viral dsRNA by TLR3 and RLR (Meylan, Tschopp et al. 2006) 
1.2.3 The Nod-like receptor family 
The nucleotide binding oligomerization domain (NOD)-like receptor family (also 
called NLR) is involved into sensing intracellular pathogens and danger associated 
molecular pattern (PAMPs and DAMPs) [65]. The proteins in this family consist of 
three domains which have the similar structure with disease resistant R proteins found 
in plants[66]. The three domains are N-terminal domain, central nucleotide–binding 
domain and C-terminal LRR domain. The central domain is a nucleotide–binding 
domain (NBD), which is responsible for self-oligomerization and dNTP activity. The 
C-terminus of NLRs is a series repeats of the LRR motifs. It is responsible for 
identifying PAMPs or DAMPs. The LRR folds back and covers the NBD domain in 
static situation to avoid self-oligomerization. However, when LRR is activated by 
PAMPs or DAMPs, the NBD domain is exposed and directs the oligomerization [67]. 
The NBD domain has similar structure with AAA+ domain family, which are apt to 
form hexamers or heptamers. Thus, NLRs might form structure with this size as well. 
At the N-terminal, NLRs either have a pyrin domain (PYD), a caspase recruitment 
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domain (CARD), or a baculovirus inhibitory repeat domain (BIR). An exception is 
NLRX1, which does not contain the three similar domains. However, it can still fold in 
a similar way[68]. The N-terminus domain is assumed to conduct homotypic 
interactions, such as PYD-PYD or CARD-CARD. The function of BIR domain is 
unclear. There are at least 23 known members of the NLR family, which can be 
subdivided into 3 subgroups depending on N- terminus structure: NLRC family 
(contain CARD domain), NLRP (contain pyrin domain), and the rest NLRs including 
CARD-containing activation domain of the class II transactivator(CIITA), 
ICE-protease activating factor(IPAF) and NAIP which has the BIR domain (Figure 1.8) 
[69]. The NLRs with pyrin domain or BIR domain cannot induce transcriptional factor 
of inflammatory cytokines such as NF-κB. However, they are involved in 
inflammasome formation and induce caspase-1 activation[13]. 
 
Figure 1.8 The schematic diagram of NLR family members (Meylan, Tschopp et al. 2006) 
NOD1 and NOD2 are the first reported NLRs members[70]. Both NOD1 and NOD2 
recruit serine/theronine kinase receptor-interacting protein (RIP2) which results in the 
activation of IκB, and finally induces NF-κB activation [71, 72]. However, recent 
research indicates that the NLRP subfamily plays a key role in forming inflammasome. 
The common feature of NALP is that they contain N-terminus PYD domain which is 
used to recruit PYD domain of apoptosis-associated speck like protein (ASC) [73]. 
Then ASC can recruit caspase-1 through CARD-CARD homophilic interaction. Thus, 
oligomerization of NLRP is thought to bring the caspases together and generate a 
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macrocomplex called the inflammasome [74]. Activation of caspase-1 catalyzes the 
cleavage of pro-IL-1β/IL-18 to mature IL-1β/IL-18 which is released into the 
extracellular space. In turn, they can activate IL-RI and IL-18R signalling pathways 
[69]. Regarding the inflammasome induced-maturation of IL-1β and IL-18, early 
research addresses that pre-priming of TLRs isrequired [75, 76]. In whole, these 
investigations imply that TLRs, IL-1R and NLRs have tight interaction with each other 
in terms of orchestrating innate immunity (See figure 1.9) 
 
Figure 1.9 The cross talk among TLRs, IL-1RI and inflammasome (Netea and Veerdonk et al, 
2008 ). Several control mechanisms have evolved to modulate the production and activation of IL-1β: 
① transcription of IL-1β mRNA when cells were activated by TLR ligands. ② translation to pro- 
IL-1β. ③ processing of the 31kDa inactive IL-1β precursor into the bioactive 17kDa IL-1β by cleavage 
of Caspase-1 and 17kDa IL-1β is released to the extracellular space. ④ potassium efflux also triggers 
the IL-1β maturation and release. ⑤ the extracellular 17kDa IL-1β directly binds to IL-1R and induces 
the transcription of IL-1β. However, this step is controled by IL-1 receptor antagonist (IL-Ra) and Type 
II decoy receptors (IL-1RII). ⑥ Blockade of the interaction of bioactive IL-1β with the singnalling type 
I IL-1R/interleukin 1 receptor accessory protein (IL-1RAcP) complex. 
1.3 The TIR-domain containing adaptor protein in TLR signalling 
pathways 
To date, five TIR domain containing adaptor proteins have been found. They are the 
myeloid differentiation primary response gene 88 (MyD88), MyD88 adaptor-like 
(MAL), TIR-domain-containing adaptor-inducing interferno-β (TRIF), TRIF-related 
adaptor molecular (TRAM) and sterile   and HEAT-Armadillo motifs (SARM) [77]. 
(Figure1.10) 
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Figure 1.10 The schematic diagram of five TIR-domain containing adaptors (O’Neill, Bowie 
2007) 
TLRs are activated by their respective ligands. The TIR domain of TLRs then forms 
homo or heter dimerization and recruits the TIR domain of the adaptor protein to 
initiate downstream signalling. The TIR domain is a ~160 amino acid motif, and 
consists of five β-sheets surrounded by five   helices and connected by flexibly loops 
[78]. Two significant loops are called ‘BB loop’ and ‘DD loop’, which are found in 
each TIR domain [79]. Meanwhile, the TIR domain is divided into three regions, 
named Box 1, 2, 3. Box1 is the signature of the TIR domain; Box 2 contains the‘BB 
loop’ which mostly contains a key proline residue inside; Box 3 is important for 
signalling [21]( see figure1.11). 
 
Figure 1.11 The TIR domain structure of human TLR2 (modified from Xu, Tao et el, 2000) 
Albeit the backbone structure of TIR domain is conserved, the surface properties can be 
unique for each TIR-containing-protein, thus they can guide the specific interaction and 
induce appropriate immune responses [79]. 
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1.3.1 Myd88 dependent signalling pathway 
MyD88 was found and named by searching the induced genes in terms of 
differentiation of M1D+ myeloid precursors in response to IL-6 [80]. It was first found 
to be involved in the IL-1 receptor signalling pathway [81]. Then it was more widely 
investigated in TLR signalling pathway [82, 83]. The generation of MyD88 deficient 
mice demonstrated that MyD88 is essential for TLR2, TL4, TLR5, TLR7 TLR9, IL-1R 
and IL-18R activation to produce pro-inflammatory cytokines [79]. Therefore, those 
receptors signalling pathways were named as MyD88-dependent signalling pathway. 
Only TLR3 and partially TLR4 signalling were not impacted in MyD88 deficient mice. 
This indicates that there may be another adaptor protein that can induce signalling by a 
“ MyD88-independent signalling pathway” (section1.2.4.2). 
It has also been shown that MyD88 is essential for NF-κB, JNK and p38 activation. 
MyD88 is composed of a C terminus TIR domain, an intermediary domain (ID) and an 
N-terminal Death domain (DD). The MyD88 TIR domain directly interacts with TLR5, 
TLR7, TLR8 and TLR9 and its DD domain recruits interleukin-1 receptor associated 
kinase 4 (IRAK4) via homotypic interaction. The IRAK family consists of four 
members: IRAK1, IRAK2, IRAK3 (also called IRAK-M) and IRAK4. More detail 
information will be documented in section 1.4. IRAK4 is the first kinase recruited to 
MyD88, and autophosphorylates and phosphorylates IRAK1 or IRAK2 [84]. These 
interactions are all realized via the DD domain homotypic interaction, and form an 
oligomeric complex named as the Myddosome [85, 86]. IRAK3 plays a negative role 
that arrests the IRAK1 or IRAK2 and IRAK4 dissociating from Myd88 [87]. Then 
IRAK1 or IRAK2 interacts with tumour necrosis-factor- receptor-associated factor6 
(TRAF6). Recently, the experiments indicated that IRAK2 binding to TRAF6 is 
essential to trigger the ubiquitination of TRAF6 [88]. Sequentially, TRAF6 recruits 
transforming-growth-factor-β-activated kinase 1 (TAK1) and TAK 1-binding protein 
2/3 (TAB2/3), further leading to TAK1 activation which directs NF-κB and 
AP-1(ERK1/2 and JNKs)/CREB activation [89]. For NF-κB activation, TAK1 then 
induces the IκB kinase (IKK) complex which contains two catalytic subunits (IKK  or 
IKKβ), and one essential regulatory subunit IKKγ (also called NEMO) activation. The 
complex sequentially phosphorylates the inhibitor subunit IκB [90]. The 
phosphorylated IκB degrades and releases the p65/p50 to translocate into the nucleus 
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and activates NF-κB. Similarly, the IKK complex phosphorylates p105 and induces 
p105 degradation, where the serine/theronine kinase tumour progression locus2 (Tpl2) 
will be activated [91]. Tpl2 can further induce MKK1/MKK2 to phosphorylate singnal 
–regulated kinases ERK1 and ERK2. Meanwhile, TAK1 activates MKK4/7, which 
leads to Jun-N-terminal kinase (JNK) activation. Both JNKs and ERK1/2 direct AP-1 
transcription factor activation. Moreover, TAK1 activates MKK3/6, which induces the 
phosphorylation of p38 [92]. See figure 1.12 
MyD88 is also involved in IFN-  production as well. In terms of TLR7, TLR8 and 
TLR9 activation, the DD of MyD88 interacts with the interferon regulating factor 7 
(IRF7), and activates the IFN-  promoter in pDCs. The ubiquitin ligase activity of 
TRAF6 is required for further IRF7 activation [93]. After this, a complex 
encompassing IRAK1, IRAK4, MyD88, TRAF6 and IRF7 was detected and IRAK1 
was essential for IRF7 phosphorylation [94]. MyD88 also takes part in the IRF1, IRF5 
and IFN-γ signalling pathways. IRF1 is required for several genes related to TLRs. 
IRF5 is vital for the production of  pro-inflammatory and type I IFN in response to the 
activation of all TLRs [95]. Strikingly, IFN-γ is required to induce IRF1 
activation.[79]. 
 
Figure 1.12 The MyD88 dependent signalling pathway (O’Neill and Bowie, 2007) 
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TLR2 and TLR4 activation also need MyD88. However, this is different from TLR5, 7, 
8, 9, which directly interact with MyD88 via the TIR domain. TLR2 and TLR4 need 
another TIR domain containing adaptor protein called MAL or TIRAP to bridge the 
interaction between TLR2/4 and MyD88 [96]. Similar to MyD88, no evidence has been 
found to support that MAL participates in the IRF3 signalling pathway. Then it was 
thought to be a component in the MyD88 signalling pathway. Except for possessing a 
TIR domain in the C terminus, MAL encompasses a phosphatidylinositol-4, 
5-bisphosphate (PtdIns(4,5)P2) in the N-terminus which orientates MAL anchoring to 
the plasma membrane[97]. From the perspective of the protein structure, the 
electrostatic surface of the TIR domain of MAL is negative, while the TIR domain of 
MyD88 and TLR4 are positive. Therefore, TLR4 prefers to interact with MAL first [98]. 
Moreover, MAL has a TRAF6 binding motif, and may be involved directly in the 
interaction with TRAF6 and further activation of NF-κB and MAPKs [99]. This is the 
only finding that represents a unique MAL signalling pathway. Additionally, MAL is 
phosphorylated by Bruton’s tyrosine kinase (Btk) and Btk is further involved in TLR2 
and TLR4 signalling to activate NF-κB signalling [100]. Meanwhile, the suppressor of 
cytokine signalling-1 (SOCS-1) recognizes proline (P), glutamine (E), serine(S), 
threosine (T) rich region, also called PEST domain of MAL, and leads to the 
degradation of MAL via ubiquitination. Several epidemiological studies indicate that 
MAL coordinates the immune response of TLR4/2 activation in an appropriate way 
[101, 102]. Current research finds that MAL was cleaved by caspase-1 which is 
required for MAL to activate NF-κB [103] (See figure1.13). 
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Figure 1.13 The Mal dependent signalling pathway 
1.3.2 The TIRF dependent signalling pathway 
In view of challenging MyD88/MAL deficient mice with different TLR ligands, only 
TLR3 and partially TLR4 signalling were not affected. Therefore, there must be 
another adaptor in charge of this signalling pathway. Hence, TRIF was identified by 
searching for TIR domain protein in the human genome [104]. One year later, another 
independent group also found TRIF by a yeast two-hybrid screen with TLR3 [105]. 
TIRF is very important to activate the IFN-β promoter. Stimulating TRIF-deficient 
mice demonstrated that IFN-β production and IRF3 activation were reduced, and the 
pro-inflammatory cytokine production was only reduced in TLR4 signalling pathway. 
However, no impact on TLR2, TLR7 and TLR9 in macrophage was found [106]. It was 
confirmed that the activation of NF-κB was abolished when challenging double 
knock-out MyD88 and TRIF cells with LPS. Furthermore, no genes were induced in 
double knockout cells which were stimulated with LPS. Therefore, this indicates that 
Myd88 and TRIF are complementary in terms of theTLR4 signalling pathway [107]. It 
was known that TRIF has a TIR domain in C terminus, while the TRAF6 binding motif 
is located in the N-terminus of TRIF. It indicates that TRAF6 can directly interact with 
TRIF and induce NF-κB. However, more research is needed to confirm this proposal 
[108, 109]. Moreover, the receptor-interacting protein homotypic interaction motif 
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(RHIM) was shown in the C-terminus of TRIF, and is involved in NF-κB activation as 
well [110]. The N-terminus of TRIF was shown to interact with TRAF family member 
associated NF-B activator (TANK) -binding kinase 1 (TBK1), which is a vital upstream 
kinase for IRF3 activation. 
TLR3 directly interacts with TRIF. However, TLR4 needs another bridge protein called 
TRAM (also known as TICAM2), which is only involved in the TLR4 signalling 
pathway. Two biochemical modifications highlight the role of TRAM. Similar to MAL, 
the N-terminus of TRAM undergoes myristolyation, and thus can anchor TRAM to the 
plasma membrane [111]. Phosphorylation of TRAM at serine residue in position 16 is 
essential to activate the downstream signalling to release TRAM-TRIF from the 
membrane [112].  
SARM was the last TIR domain containing adaptor protein found to be involved in 
TLR signalling pathway. It also participates in TRIF signalling pathway. In contrast to 
the other four members in TLRs signalling pathway, it interacts directly with TIRF and 
blocks TRIF signalling with no impact on MyD88-dependent signalling pathway [113] 
(See figure 1.14). 
 
Figure 1.14 The TRIF dependent signalling pathway (O’Neill and Bowie, 2007) 
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1.4 The IRAK family 
Interleukine -1receptor-associated kinases (IRAKs) are a family of serine and theronine 
kinases which are located intracellularly. The IRAK family consists of four members, 
IRAK1, IRAK2, IRAK3 (also called IRAK-M) and IRAK4. The IRAK activity was 
first described in 1994 in T cells responding to IL-1R stimulation [114]. Then the first 
family member IRAK1 was cloned in 1996. IRAK1 shares high similarity with Pelle a 
downstream serine/theronine kinase in Drosophila which acts in the Toll signalling 
pathway to induce the activation of Dorsal (equivalent to human NF-κB). Therefore, it 
was assumed that IRAK1 should be the downstream kinase of TLRs to activate of 
NF-κB [115]. IRAK1, IRAK2 and IRAK4 are expressed ubiquitously, whereas IRAK3 
was only found in marcophages and monocytes upon stimulation [116]. All IRAKs 
share a similar arrangement of their functional domains (Figure1.15). They contain an 
N-terminal death domain (DD), a ProST domain (proline, serine and threonine rich 
domain), a conserved kinase domain (KD) and a C-terminal domain (except for IRAK4, 
which lacks the C-terminal) [117]. The DD interacts with the DD of MyD88 or with the 
DD of other IRAKs in a multimeric way to induce downstream signalling [118]. First, 
upon activation, MyD88 recruits IRAK4 via DD domains homotypic interaction. Then 
IRAK4 recruits IRAK2 by homotypic DD interactions to then form a multimeric 
complex called the Myddosome [85, 86]. The ProST region is rich in prolines, serines 
and threonines, and important for post-translation modifications, such as 
phosphorylation and ubiquitination [119, 120]. The KD of the IRAK family has an 
activation loop which is important for the kinase activity. Each IRAK encompasses an 
invariant lysine docked in the ATP binding pocket. Moreover, they also possess a 
tyrosine gatekeeper residue in the center of the ATP binding site. This tyrosine proves 
that the IRAK family is an unique serine/threonine kinase family [121, 122]. IRAK1 
and IRAK4 contain an aspartate residue at the position 340aa and 311aa respectively. 
Thus, those two IRAKs are proposed to be active kinases. However, the alignment 
reveals that IRAK2 encompasses an asparagine residue at position 335aa instead of an 
aspartate. Moreover, IRAK3 has a serine at position 293 aa. Therefore, initially both of 
these kinases were thought to be pseudo kinases. The C-terminal domain of IRAKs 
contains the TRAF6 binding motif which is important to bind TRAF6. There are three 
TRAF6 binding motifs in IRAK1, two in IRAK2 and one in IRAK3 [123]. The IRAK 
family members are not only involved into NF-κB activation, but also play a role in 
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MAP kinase and IRF signalling pathways as described in section 1.2.4.1. The specific 
function of each IRAK will be presented in the following sections. 
 
Figure 1.15 The schematic diagram of IRAK family members (Flannery and Bowie, 2010) 
1.4.1 IRAK1 
IRAK1 was the first IRAK family member to be identified as a downstream kinase in 
the IL-1R signalling pathway.The IRAK1 gene was mapped to chromosome Xq28, and 
encodes for a protein with 712 amino acids and a molecular weight of around 80 kDa. 
It has three splice variants (IRAK1a, b, c) in humans. In this dissertation, IRAK1 refers 
to IRAK1a (712aa). Except for the general domains that all IRAKs possess, IRAK1 
contains a nuclear localization sequence (504-508aa) and a nuclear exit sequence 
(518-526aa) [124]. It was shown that IRAK1 translocates to the nucleus after the 
activation of TLRs in an over-expression system [125]. Thr66 in the DD domain of 
IRAK1 is pivotal to induce NF-κB activation. Although a mutation of this residue still 
retains the interaction with IRAK2 or IRAK-M, it cannot induce NF-κB activation but 
several studies argue that IRAK1 can undergo phosphorylation, ubiquitination and 
sumoylation [119, 126, 127]. Therefore, it is proposed that IRAK1 is tightly regulated 
and may play various roles in multiple signalling pathways. 
IRAK1 undergoes phosphorylation in vitro by several steps. The first phosphorylation 
occurs at Thr209 which results in a conformational change in the kinase domain, and 
sequentially induces Thr387 phosphorylation as a secondary phosphorylation, which 
further leads to full enzymatic activity. Thr387 is also proposed to be the 
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phosphorylation site for IRAK4 [121]. Sequentially, several autophosphorylations 
occur in the ProST domain which permit IRAK1 to disassociate from MyD88 and to 
further trigger NF-κB activation [119]. The auto-phosphorylation may contribute to 
IRAK1 ubiquitination, which includes both K48-linked polyubiquitination leading to 
protein degradation [127] and K63-linked polyubiquitination leading to protein 
interaction and signal transduction [128]. It was assumed that pellino or TRAF6, which 
both belong to the E3 ligase family, can cause IRAK1 ubiquitination. Intriguingly, it 
was shown that IRAK1 also undergoes sumoylation through LPS stimulation. The 
sumoylated IRAK1 translocates into the nucleus and triggers STAT3 avtivation and 
selected gene expression [129]. Hence, the various modifications of IRAK1 generate 
more functions of IRAK1. 
IRAK1 deficient macrophage cells demonstrate that NF-κB/p38/JNK activation was 
partially influenced in response to IL-1/LPS stimulation [130, 131]. Recently, it was 
claimed that IFN-  was totally abolished in response to TLR7/TLR9 ligands activation 
in IRAK1-deficient plasmacytoid DCs (pDCs). However, the NF-κB/MAP kinase 
activity was maintained at normal levels. Thus, IRAK1 may play a crucial role in type I 
IFN production. Strikingly, IRAK1 directly phosphorylates IRF7 [94]. In addition, it 
was shown that IRAK1 is essential for activation of IRF5 in human and mouse cells 
[132, 133]. Moreover, IRAK1 can directly interact with TRAF3 which is vital to induce 
type I IFN [134]. Intriguingly, IRAK1 is also involved in STAT1/STAT3 activation [129, 
134, 135]. Conclusively, IRAK1 has diverse role in innate immunity.      
1.4.2 IRAK2 
IRAK2 was initially found by expressed sequence tag (EST) database search for 
homologs of IRAK1 in 1997 [136]. It was mapped to chromosome 3 at position 
3q25.3-3q24.1. The length of the IRAK2 protein is 625aa and the molecular weight is 
around ~65 kDa. Compared to IRAK1 or IRAK4, which contain an aspartate in kinase 
domain, IRAK2 contains an asparagine. Upon over-expression, only full length IRAK2 
can activate NF-κB, whereas the DD or central kinase domain plays a dominat-negative 
role in the signalling pathway. Thus, the integrity of IRAK2 is essential for its function 
[136]. Interestingly, the residue lysine 237 was thought as an intrinsic kinase of the 
IRAK2. Reconstitution of K237A into Irak2 knockout marocphages dimished the 
production of TNF-α and IL-6 [137]. Originally, it was assumed that IRAK2 has a 
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redundant role with IRAK1. The important role of IRAK2 was only discovered by 
Vaccina Virus (VAVC) induced NF-κB activation. It was shown that A52 (an important 
component of virus virulence) interacts with IRAK2, not IRAK1, then blocks the 
activation of NF-κB through TLR2, 3, 4, 5, 7/8, 9. Interestingly, it was claimed that 
IRAK2 is important for HEK293T which stably expresses TLR3 and is stimulated with 
polyI:C in terms of NF-κB activation, whereas IRAK1 was not involved in the TLR3 
activation [138]. Subsequently, it was shown that over-expression of IRAK2 in 
HEK293T cells results in the interaction with TRAF6 and induces TRAF6 
polyubiquitiantion, whereas over-expression of IRAK1 does not. Moreover, it was 
shown that IRAK2 triggers TRAF6 ubiquitination in IRAK1 deficient cells. All 
aforementioned results indicate that IRAK2 possesses a predominant role in NF-κB 
activation. 
It is worth noting that only one isoform of IRAK2 is found in human. However, there 
are four splice variants in mice (Irak2a, Irak2b, Irak2c and Irak2d) [139]. Both of them 
have 13 exons(Human IRAK2 and Irak2a ). The sequence identity of IRAK2 between 
human and mice is around 65%. Figure 1.16 shows the schematic diagram of human 
IRAK2 and murine Irak2. 
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Figure 1.16 Schematic diagram of human and murine IRAK2.(modified from Hardy and O’Neill, 
2004) Functional structure of human IRAK2 (a) and murine Irak2 (b).Extons(numbered black boxes) 
are shown on the genomic sequence with start and stop codons marked by asterisks(*) and 
cartes(^),individually. 5’-UTR and 3’UTR are presented with white box. The human IRAK2 consists of 
death domain (gray box), the ProST domain, the kinase domain (black box) and the C-terminal domain. 
Numbers above the bar indicate the amino acid start and stop points of each putative domain. (C) 
Alternative splicing pattern at the 5’-end of murine IRAK2 leads to the generation of four IRAK2 
isoforms. Irak2a compose all exons; Irak2b and Irak2d lack the exon3 and exon 2 respectively. Irak2d 
misses 10aa in the C-terminal additionally. Irak2c generated by deletion exon1, 2, 3 while it encompass 
its own 5’-UTR in the exon 4’(intron 3). Start codon used by each isoform are indicated nu asterisks. 
Irak2a utilizes all exons, which is most similar to human IRAK2. Irak2b and Irak2d are 
generated by deleting exon3 and exon2 respectively. Additionally, Irak2d lack 10 
amino acids in the C-terminus. Irak2c is generated by deleting exon 1, 2, 3, while it has 
its own specific 5’-UTR in exon 4’ and its start codon ATG lies in exon 4.  
Alignement of human IRAK2 and murine Irak2 amino acid (figure 1.17) indicates that 
they are conserved. Particularly, the death domain and kinase domain are well 
conserved, whereas the ProST domain and C-terminal display a lower identity. 
Comparing the whole genomic region of human IRAK2 and murine Irak2, it 
demonstrated that the coding sequences were generally well conserved while there is no 
identity in non-coding sequence. It indicates that human IRAK2 and murine Irak2 
might be regulated differently. Thus, caution should be taken when extrapolating date 
from mice to human in the IRAK2 research. 
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Figure 1.17 Protein sequence alignments of human and murine IRAK2. (Regions of amino acid 
identity between human IRAK2 and mouse Irak2 are shaded) 
Irak2 deficient mice were generated in 2008 by Kawagoe, which four splice variants 
of Irak2 were knocked out. In comparison with IRAK1 deficient mice, Irak2 deficient 
mice were highly resistant to LPS and CpG induced septic shock. Moreover, similar to 
the IRAK1 function in the early time points of a TLR stimulation, IRAK2 is more 
important in sustaining the NF-κB at later time points and MAPK activation at early 
time point [137, 140]. 
As mentioned above, there are four splice variants in mice. Irak2a and Irak2c are active, 
whereas Irak2c and Irak2d are negative in terms of NF-κB activation. Strikingly, one 
study compared the inbred mice C57BL/6J with wild derived mice strain MOLF/Ei in 
terms of splice variants of Irak2. In classical inbred mice C57BL/6J the Irak2c splice 
variant was expressed highly in early response to TLR stimulation and inhibited the 
functions of Irak2a. Along with the stimulation being longer, Irak2c expression levels 
were found to decrease, whereas the expression of Irak2a would become stronger and 
show positive immune responses. Interestingly, there was a natural mutation in the 
promoter of Irak2c in MOLF/Ei, which resulted in significantly less expression of 
Irak2c to inhibit the isoform of Irak2a. Using siRNA to knock down Irak2a in the mice, 
the results show that NF-κB and MAPK activation are abolished, indicating that Irak2a 
is indispensable for NF-κB and MAPK activation. Moreover, it also indicates that 
wild-derived murine Irak2 has many similarities with human IRAK2.  
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1.4.3 IRAK3 
IRAK3 was found by EST search as well. The human IRAK3 gene is mapped to 
chromosome 12 at position 12q14.1-12q15. It encodes for a protein with 596 amino 
acids and a molecular weight 68 kDa. Northern blot analysis showed that IRAK3 
transcripts are predominantly present in peripheral blood lymphocytes. Human IRAK3 
and murine IRAK3 share 71% sequence similarity.  
Compared to IRAK1 and 4, which contain aspartate residue in the kinase domain, 
IRAK3 contains a serine residue. Thus, IRAK3 was thought to be a negative regulator 
in the TLR signalling pathway. Initial experiments displayed that over-expression of 
IRAK3 in HEK293T cells induced NF-κB activation. Moreover, IRAK3 can restore 
NF-κB activation in IRAK1 deficient cells [141]. However, IRAK3 knock out 
macrophages revealed that NF-κB activation was enhanced in those cells which were 
stimulated by Salmonella typhimurium [87]. The hypothesis is that IRAK3 prevents 
IRAK1/4 from dissociating from the activated MyD88 complex by building next to the 
IRAK2 layer of the ternary complex [86].  
Phenotypically, IRAK3-/- mice develop severe osteoporosis, which is related to the 
accelerated differentiation of osteoclasts (increase half-life and activation) [142]. 
Additional studies reveal that IRAK3 plays a more critical role in alternative NF-κB 
signalling pathway which depends on the activation of NF-κB inducing kinase (NIK) 
and subsequent phosphorylation of p100[143]. IRAK3 expression levels are also 
increased in deactivated macrophages which are incubated with tumour cells, whereas 
IRAK1 expression decreased [144].  
All abovementioned evidences indicate that IRAK3 serves as a negative regulator in the 
TLR signalling pathway. Strikingly, one recent study showed that IRAK3 was able to 
interact with MyD88-IRAK4 to form IRAK3 Myddosome and to mediate the 
MEKK3-dependent TAK1-independent NF-κB activation. This IRAK3 dependent 
pathway is essential for the second wave of TLR7-induced NF-κB activation in the 
absence of IRAK1/IRAK2, which is uncoupled from post-translational regulation 
[145]. 
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1.4.4 IRAK4 
IRAK4 is the latest IRAK family member to be identified. Human IRAK4 is the closest 
homolog to the Drosophilla Pelle. It was mapped to the chromosome 12 at position 
12p11.22. The IRAK4 protein is composed of 460 amino acids resulting in a molecular 
weight of 52 kDa. Human IRAK4 shares 87% similarity with murine IRAK4 [146]. 
Challenging IRAK4-deficient mice with different TLR ligands, showed that NF-κB 
activation was severely affected. As an IRAK family member, IRAK4 is also involved 
in the IL-1R signalling pathway. NF-κB, JNK and p38 activation were severely affected 
by stimulating IRAK4 deficient macrophages with IL-1 [146].  
It was shown that the interaction of DD of IRAK4 with DD of MyD88 is vital for 
downstream activation. This experiment indicates that IRAK4 was the primary kinase 
that is recruited to MyD88 and that is essential for NF-κB activation [147]. Meanwhile, 
the Myddosome structure confirmed this as well. 6 DDs of MyD88 assembled as a first 
layer, then 4 DDs of IRAK4 docked into the Myd88 upper surface and formed the 
second layer, followed by 4 DDs of IRAK2 sitting on the top of the second layer. This 
large oligomeric complex was assumed to interact with IRAK1 or IRAK3[86].  
However, whether the kinase activity of IRAK4 is vital for NF-κB and MAPK 
activation is still not fully understood. The in vivo assay of the IRAK4 knock in mice 
revealed that the IRAK4 kinase activity is essential for resistance to TLR-induced 
shock [148, 149]. However, the macrophages from those mice demonstrate that the 
kinase activity is dispensable for the activation of NF-κB when challenging the cells 
with agonists for IL-1, TLR2, TLR4 and TLR7 [150, 151]. It is interesting to note that 
MAPK activation is more dependent on IRAK4 than NF-κB in IRAK4 inactivity 
knock-in mice [151].  
Intriguingly, human IRAK4 deficient fibroblast cells reconstituted with kinase dead 
IRAK4 was able to fulfil the NF-κB and JNK activation in response to IL-1 stimulation 
[152]. Moreover, Capucine Picard et al revealed that IRAK4 deficiency in patients 
resulted in a recurrent pyogenic bacterial infection in childhood. While no impaired 
function was found in viral infection[153]. In this context one should be cautious that 
in applying these results to the human system as there may be differences between 
human and mouse IRAKs. In conclusion, much effort was done on the mice 
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experiments. However, there are differences between mouse IRAKs and human IRAKs. 
In table 1.2, these differences are listed.  
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Table 1.2 knockout/knockdown studies showing the effect of absence of IRAKs on IL-1/TLR signalling 
Name Species Phenotype in vivo Effect on NF-κB activation Effect on MAPK Effect on IRF activation 
IRAK1 
Knockout 
Mice 
Partially resistant to 
LPS-induced spetic shock 
Partial impairment for 
IL-1/TLR4 
Impairment for IL-1/TLR4. No 
impairment of TLR2 induced 
ERK and JNK 
Effect on TLR7/9 
induced IFN 
 
Human related to SLE(mutation) No impatiment of IL-1 N/D N/D 
IRAK2 
Knockout 
Mice 
Mice completely resistant 
to LPS and CpG induced 
septic shock 
Impairment of late 
TLR2/TLR7 activation.  
No impairment of TLR4 
Impairment of late TLR2 
activation 
N/D 
 
Human 
Silence IRAK2 
N/D 
Impairment of early TLR4 
and TLR7 
Reduced phosphorylation of p38 
Reduced IRF3 signalling 
in HEK293-TLR3 cells 
IRAK3 
Knockout 
Mice 
Reduced survial upon 
viral infection 
Enhanced activation of 
TLR4 and TLR9 
Enhanced activation TLR4 and 
TLR9. Enhanced TLR2-induced 
p38. No effect on TLR2-induced 
ERK and JNK 
N/D 
 
Human N/D 
Enhanced activation of 
TLR4 
N/D N/D 
IRAK4 
Knockout 
Mice 
Mice completely resistant 
to LPS and CpG induced 
septic shock 
Impairment of IL-1 and 
MyD88-dependent TLR  
No effect on TLR3 
Impairment of TLR4 induced 
JNK              Impairment 
of IL-1 induced p38 
Effect on TLR7/8/9 
induced IFN 
 
Human 
Recurrent pyogenic 
infection, limited to 
certain kinds of bacteria.  
IRAK4 deficient patiants 
Impairment of 
TLR2,4,5,7,8,9.No 
impatiment of IL-1 
No effect on TLR3 and TLR4 
induced p38 and JNK 
Required for TLR7/8/9 
induced IFN. No effect 
on TLR3 and TLR4 
induced IRF3 
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1.5 The death fold superfamily for homotypic interaction  
1.5.1 Overview on the death fold superfamily 
Signal transduction pathways of inflammation and cell apoptosis depend to a large 
extent on proteins containing homotypic interaction motifs. Those motifs belong to the 
death fold family. The well known Death Domain (DD) together with the structurally 
homologous Death Effector Domains (DEDs), CAspase Recruitment Domains 
(CARDs) and the PYrin Domains (PYDs) belong to the death domain superfamily. 
There are 215 proteins in humans that are predicted to have this structure. They are 
involved in controlling signaling transduction of inflammation, apoptosis or cell death 
via homotypic interaction. The structural hallmark of the superfamily is the so called 
death fold which consists of six antiparallel  -helices which arrange into a Greek key 
topology that folds into two 3-helix bundles. All of the death folds form a hydropobic 
core. Furthermore, each member encompasses a specific array of homotypic interaction 
partners that in principle do not cross interaction with another subfamily [154] (See 
Figure 1.18). 
 
Figure 1.18 Tertiary structures of the different death-fold subfamilies (Kersse and Verspurten et 
al 2011) 
The reason that death folds form oligomeric complexes is that this can generate three 
distinct types of asymmetric interactions. The type I interaction consists of helices1 and 
4 (patch Ia) of one death-fold domain interacting with helices 2 and 3(patch Ib) of 
another death-fold domain. Type II interaction is formed from helices4 and the loop 
between helices 4 and 5 (Patch IIa) of one death-fold domain, which interact with the 
loop between helices 5 and 6 (Patch IIb) of another death fold domain. Type III 
interaction is formed from helices 3 (Patch IIIa) of one death-fold domain, which 
interacts with the loop connecting helices 1 and 2 and the loop connecting helices 3 and 
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4 (Patch IIIb) of another death-fold domain. There is no overlapping between the six 
patches which are generated by the death fold, suggesting that each patch can interact 
with the other six patches twice by pairwise interaction [154] (Figure1.19).  
 
 
Figure 1.19 DD mediates three interaction types through six interaction patches.( Kersse and 
Verspurten et al 2011) 
1.5.2 Myddosome structure 
The Myddosome structure was first proposed by Dr. Precious G. Motshwene in 2009. 
In his research he displayed a large oligomeric complex which contained 7/8 death 
domains (DDs) of MyD88 and 4 DDs IRAK4 [85]. In 2010, Su-Chang Lin reported the 
crystal structure of a Myddsome complex which is consisted of a 
MyD88-IRAK4-IRAK2 death domain complex. This complex composed of 6 DD 
MyD88, 4 DD IRAK4 and 4 DD IRAK2, and results in a left-handed helical oligomer 
[86] (Figure1.20A). The Myddosome structure contains three types of interaction. Type 
I and II interaction connect the different layers, while type III interaction mediates the 
connection within one layer. 
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Figure 1.20 The schematic diagram of Myddosome structuer (modified from  George, 
Motshwene et al, 2011)  
It is worthwhile to notice that the Myddosome structure assembly is tightly controlled. 
It is a sequential process, since the charge and shape on each layer on bottom and top is 
different. It determines that the top surface of MyD88 can only recruit IRAK4; 
sequentially the bottom of IRAK2 can only fit the top surface of IRAK4. This dynamic 
assembly indicates that IRAK4 is first recruited to MyD88, and can autophosphorylate 
and phosphorylate IRAK2. Then the phosphorylated IRAK2 is released, and 
furthermore induces the NF-κB activation. This structural arrangement was also 
confirmed in vivo by our lab Julie George and her colleagues [155]. Meanwhile, the 
hypofunctional polymorphisms MyD88 S34Y and R98C provided adequate 
information for designing therapeutic drugs in the future [154]. 
1.6 Ubiquitination in TLR signalling pathway 
1.6.1 Overview on ubiquitination 
Like most signalling pathways, the function of phosphorylation in TLR signalling 
pathway has been very well described. To date, more and more investigations have 
been done on ubiquitination, and ubiquitination was found to play an important role in 
adjusting and regulating in TLR signalling pathway. Ubiquitination is one type of 
post-translation modifications, in which ubiquitin, a highly conserved polypeptide of 
76 amino acids, is covalently attached to other proteins through the enzymes E1, E2 
and E3. In principle, ubiquitin binds the target protein via binding motifs. However, the 
binding affinity is low which provides for more flexible and dynamic regulation in the 
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cells. A protein can be modified on one lysine residue by a single ubiquitination 
(monoubiquitination), and it can direct DNA repair, vesicle sorting or receptor 
internalization [156]. Alternatively, multiple ubiquitination can be added with 
different K48 or K63 and this named polyubiquitiantion. They are two major 
non-linear polyubiquitination modifications. The lysine 48 (K48) linked 
polyubiquitination with at least four ubiquitins, usually guides the targeted protein for 
degradation via 26S protrasome. The lysine 63(K63)-linked polyubiquitination which 
is mostly involved in singnal transduction events [157]. In some cases, multiple lysine 
residues on one protein can be modified by polyubiquitin chain. 
1.6.2 Ubiquitination in the MyD88 dependent signalling pathway 
Activation of TLRs by pathogens results in the recruitment of IRAK4 to MyD88. 
Sequentially, IRAK4 interacts with IRAK1 which was shown to undergo lys-63 linked 
polyubiquitination after IL-1 and LPS stimulation. IRAK1 lys-63 polyubiquitination 
orientates IRAK1 interaction with NEMO which activates the transcription factor 
NF-κB. It was assumed that pellino serves as an E3 ubiquitin ligase in assembling 
polyubiquitin chains on IRAK1 [158]. Interestingly, IRAK1 can phosphorylate pellino 
and trigger pellino to undergo lys-48 polyubiquitination for degradation [159]. 
Following IRAK1/IRAK2 activation, TRAF6 a RING-domain ubiquitin E3 ligase is 
recuited. The interaction of IRAK2 with TRAF6 is hypothesized to turn on TRAF6 
lys-63 polyubiquitination via TRAF6 oligomerization. The lys-63 polyubiquitin chain 
of TRAF6 can be identified by the TAK1 complex which further leads to TAK1 
complex activation. Sequentially, MAPK and JNK are activated. Meanwhile, 
polyubiquitin chain can be recognized by NEMO which can be polyubitquitined at 
lys-285. It was found that lys-285 polyubiquitination is required for NF-κB activation. 
Binding of the TRAF6 Lys-63 polyubiquitin chain to TAK1 and IKK complex results 
in IKKβ phosphorylation, and in turn induces IκB degradation via lys-48 polyubiquitin 
chain. The IκB degradation releases p65 to enter into the nucleus, and to further 
activate NF-κB [160] ( See figure1.21). 
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Figure1.21 Ubiquitination in MyD88 dependent signalling pathway (Jiang and Chen 2011) 
1.6.3 The ubiquitination communication in the TLR signalling pathway. 
Additionally, ubiquitination also occurs in TRIF signalling pathway. Similar to TRAF6, 
which is an E3 ligase, TRAF3 undergoes lys-63 polyubiquitination after TLR4 has been 
translocated from the plasma membrane to the endosome. The lys-63 polyubiquitinated 
TRAF3 directs the activation of TBK1 and IKKε and leads to IRF3 phosphorylation 
upon stimulation of TLR4. Another protein, the receptor-interacting protein1 (RIP1) is 
recruited to TRIF and modified on lys-63 polyubiquitin via pellino 1 [161]. Lys-48 and 
lys-63 polyubiquitinations collaborate with each other. For instance, following the 
activation of MyD88 triggered by TLR4 ligands, several ubiquitin E3 ligases are 
recruited together. TRAF6 induced its own lys-63 polyubiquitination and activates 
cellular inhibitor of apopotosis protein1 (cIAP1) and cIAP 2, both of which also belong 
to the E3 ligase family. Those two proteins then trigger lys-48 polyubiquitination in 
TRAF3, and finally enhance NF-κB and MAPK activation. However, when TLR4 is 
translocated to the endosome, cIAP1 and cIAP 2 cannot be recruited to TRAF6 
anymore. Then TRAF3 is directly modified on lys63 for polyubiquitination, and further 
more triggers TBK1 activation and induces type I IFN production [162] (See 
Figure1.22). 
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Figure1.22 The ubiquitination communication in TLR signalling pathway ( Jiang and Chen 2011) 
As a counter of ubiquitination, deubiquitination exists in cells as well. A20 and CYLD 
are two of the best known deubiquitination enzymes inhibiting NF-κB activation. The 
ubiquitination is not only involved in innate immunity, but also adaptive immunity. 
There are still a lots of unknowns factors in this field and future research is needed to 
investigate on it.     
1.7 The relationship between TLR signalling pathway genetic variants 
and diseases. 
Although plenty of research has been done on immunity, most of the immunological 
knowledge we have gained is based on mice or cell line experiments. How accurate and 
reliable is these information and can we apply it to human immunity? Human genetic 
studies are an effective approach to precisely define the role of molecules in nature 
[163]. The crucial element of the innate defence are the germline encoded receptors 
named Toll-like receptors which are composed of conserved motifs that can detect 
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various pathogen-associated molecular patterns and activate the production of 
inflammatory cytokines. More than 10 years effort in this field have identified that two 
classical TLR/IL-1R signalling pathways, a MyD88 dependent signalling pathway, and 
a the MyD88 independent signalling pathway, which is employed by TLR3 and partial 
TLR4 signalling pathways. Meanwhile, deficiencies in those two signalling pathways 
in humans being have been described. MyD88-IRAK4 deficiency leads to greater 
susceptibility for pyogenic bacteria [164], and TLR3-Unc93b-TRAF3 deficiency leads 
to higher susceptibility for herpes simplex encephalitis (HSE) [35]. 
1.7.1 The MyD88-IRAK4 deficiency 
The knowledge on primary immunodeficiencies (PID) was considerably expanded ever 
since Bruton worked on the X-linked agammaglobulinemia in 1952 [165]. In 2001, 
single genetic hypomorphic mutations in NEMO (IKKγ) were found to be related to 
X-linked recessive anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) 
[166]. Subsequently, a hypermorphic mutation in IκB  was discovered to be related to 
autosomal dominant EDA-ID [167]. NF-κB activation was impaired in both mutations 
and those patients were susceptible to invasive pneumococcal disease which paved the 
way for studying the inborn errors of IRAK4 and MyD88. IRAK4 deficiency was 
discovered in 2003 in three unrelated children who were susceptible to pyogenic 
bacteria infection. Until now, 28 IRAK4 (homozygous or heterozygous) deficient 
patients were found to harbour a variety of mutations, which all abolished the IRAK4 
protein expression as being proved by western blot. Mostly, the kinase domain of 
IRAK4 was affected [153]. These patients presented with a life-threatening without 
treatment of antibiotics or intensive care but narrow and transient predisposition to 
infection during the first 10 years of life, which was mostly restricted to pyogenic 
bacterial diseases, particularly invasive pneumococcal disease IPD [168]. Consistent 
with IRAK4 deficiencies, MyD88 deficiencies were discovered in 2008. Nine children 
presented with invasive pyogenic bacterial diseases but did not have any IRAK4 
deficiency. Instead, they had three different autosomal recessive mutations of MyD88, 
including one deletion (Glu52) and two missense mutations (L93P and R98C) [169]. 
These three mutations all impaired the interaction of MyD88 with IRAK4 in the 
context of the Myddosome formation [155, 169]. Similar to IRAK4-deficient patients, 
MyD88-deficient children are only threatened by pyogenic bacterial infection in early 
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infancy, although one needs to be caution to extrapolate from 9 subjects. However, 
they have normal resistance to other microbes and display an improving clinical status 
with age. This may indicate that the shaped adaptive immunity which develops 
throughout childhood compensates at later age for the defects in the innate immunity. 
It is interesting to notice that the mortality rate of MyD88 or IRAK4 deficient patients 
is 30-40% in children. This calculation is already taking into account the prophylaxis 
treatment, including intensive care and antibiotic up-taken. The natural course of such 
mutations is most likely to be fully lethal.  
Recently, a somatic mutation in MyD88 (L256P) was shown to relate to chronic 
lymphocytic leukemia (2.9% occurrence) and diffuse large B cell lypmphoma (29% 
occurence). It was assumed that this TIR domain mutation constitutively activates the 
production of various pro-inflammatory cytokines, which is pivotal for the tumour cells 
to survive [170, 171]. Meanwhile, it provides an opportunity of treatment for those 
patients or hyperinfection related diseases with IRAK4 inhibitors to block the 
constitutively activated signalling in malignant cells.          
1.7.2 The TLR3-UNC93B1-TRIF-TRAF3 deficiency 
TLR3 7, 8, and TLR9 are jointly defined as nucleic acid sensing PRRs, which are 
important to produce type I IFN to fight against viruses. Except for TLR3, 7, 8 and 9 are 
all dependent on MyD88 signalling pathway. Both TLR3 and the RIG-I like receptor 
(RLR) families can detect dsRNA. However, till now, no genetic deficiency in the RLR 
family has been discovered. A deficiency of the TLR3-IFN signalling pathway in 
response to viruses is cause by autosomal recessive mutation in UNC93B1, which was 
first described in 2006 [172]. UNC93B1 is an endoplasmic protein with 12 
membrane-spanning domains, and which is involved in TLR3, TLR7 and the TLR9 
signalling. It functions as a transporting protein for the nucleotide sensing TLRs, to 
transport them from the ER to endolysosomes, where they localize and recognize their 
ligands. In addition, UNC93B1 assists TLRs in identifying pathogens and inducing 
signal transduction. The clinical syndrome of those patients presents recurrent herpes 
simplex encephalitis (HSE).  Following that, two French children from 
non-consanguineous families with recurrent HSE were detected with autosomal 
dominant TLR3 deficiency in 2007 [35]. Continually, autosomal dominant mutations in 
TRAF3 [173] and autosomal recessive or dominant mutations of TRIF [174] were 
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recently found by two groups. All of those patients displayed a similar clinical 
syndrome with UNC93B1 deficient patients. The HSE also mainly occurred in early 
childhood, in patients under the age of 6 years, following a first infection by herpes 
simplex virus type1. Strikingly, the TLR3-UNC93B1-TRIF-TRAF3 deficient patients 
are only susceptible to HSE without susceptibility by other viruses. Furthermore 
research is required to elucidate the mechanism of TLR3-UNC93B1-TRIF-TRAF3 
deficiency. 
1.7.3 TLR signalling pathway polymorphisms. 
Soon after the discovery of TLRs, a body of research has shed light on the genetic 
variations of TLRs. The most popular genetic variation characterized in research is the 
non-synonymous single nucleotide polymorphism. This means one base change alters 
the genetic triplet code, which further induces changes in the amino acid residue of the 
encoded protein. Finally, the change in the amino acid sequence might have some 
impact on the function of the protein due to potential changes in the electric charge and 
structure of the protein. The first genetic variation discovered in TLRs were the 
polymorphisms in TLR4 (D299G and T399I). It was reported that those two 
polymorphisms decrease the interaction of TLR4 with LPS, and to thus increase the 
susceptibility to sepsis [175, 176].  Then, the polymorphism R753Q in TLR2 was 
found to impair TLR2 dependent signalling and was shown to be associated with the 
susceptibility to tuberculosis [177], and to protect from the development of late-stage 
lyme disease [178]. R392X, one interesting polymorphism in TLR5, results in a stop 
codon in position 392, and thus generates a total defect of TLR5 to recognize flagellin. 
However, the frequency of this mutation is approximately 10% in the European 
population and 23% in other populations. The epidemiological studies imply that this 
mutation increases the susceptibility of Legionnaire’s disease [179], but has no relation 
with typhoid fever caused by Salmonella typhimurium [180]. Strikingly, this mutation 
can reduce the susceptibility of systemic lupus erythematosus [181] and Crohn’s 
disease [182]. Regarding the TIR domain containing adaptor MAL, one 
non-synonymous polymorphism was presented as S180L. Initially, it was shown to be 
associated with decreasing the susceptibility of tuberculosis. However, meta-analysis 
did not provide any evidence that MAL S180L is involved in protecting patients from 
tuberculosis [101, 102]. D96N was another one polymorphism which was found in 
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lymphoma patients. However, case control study indicates that no relationship is linked 
between lymphoma and the D96N genetic variants [183]. In contrast to the complete 
deficiency in TLR signalling pathway, those polymorphisms in the TLR family lack 
replications and functional studies. Moreover, the epidemiological studies have 
limitations in size and location. Therefore, the results must be interpreted with caution. 
Now, it is possible to conduct genome-wide association studies or whole genome/whole 
exome sequencing, and many more mutations and polymorphisms are expected to be 
identified in association studies, as exemplified for the somatic MyD88 in B cell 
malignancies (L256P). Simililary, TLR7 and TLR8 were recently identified to be 
associated with celiac disease which involved an abnormal intestinal immune response 
to dietary gluten [184]. 
Because IRAK1 was the first member described in the IRAK family, many SNP studies 
were carried out on IRAK1. The variants F196S and S532L were in complete linkage 
disequilibrium that carries the 196F/532S genetic variation with low radical bone 
mineral density [185]. Later on, IRAK1 was shown to be associated with C-reactive 
protein in a diabetes heart disease study [186] and sepsis [187]. Interestingly, IRAK1 
was also involved in the pathogenesis of rheumatoid arthritis [188] and systemic lupus 
erythenatisus(SLE) [135] . Meanwhile, genetic variants in IRAK3 were also reported to 
be associated with asthma [189]. However, those studies are also limited in size and 
population, the OR value is not significant enough and solid functional studies are 
lacking. It is worthwhile to apply new sequencing methods and to perform functional 
studies to present more convincing results of valuable genetic variance in the IRAK 
family.       
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1.8 Aim of Ph.D. project 
The aim of this study was to functionally and epidemiologically characterize the causal 
relationship between non-synonymous single nucleotide polymorphisms of IRAK2 and 
certain kinds of diseases. The function of IRAK2 in the TLR/IL-1R signalling pathway 
was so far investigated by many researchers, indicating that within the IRAK protein 
family, IRAK2 fulfils similar functions like IRAK1, but more in response to activation 
of NF-κB at late time points. Furthermore, in the published research IRAK2 was mainly 
studied in mouse cell lines or mouse models, not taking into account of different splice 
variants of IRAK2 that exist in humans and mice. The precise role of IRAK2 in humans 
therefore remains enigmatic. Moreover, no reports are published that address the 
relationship between genetic variants of IRAK2 and the susceptibility to certain kind of 
diseases. Therefore, this work focused on the in-depth molecular studies on IRAK2 
SNPs and their clinical epidemiological relevance. Furthermore, dysfunctional SNPs of 
IRAK2 served as a probe to decipher the signalling properties of IRAK2 in human 
system.  
First, experimental studies of IRAK2 were established by comparing the signalling 
properties of IRAK2 with IRAK1 and 3 in an in vitro assay. Meanwhile, the SNPs of 
IRAK1 and 3 were chosen as well. Then functionally interesting SNPs of IRAK1, 2 and 
3 were screened for interesting phenotype by in vitro assays in a human cell system. 
Plasmids encoding for polymorphisms of IRAK2 were overexpressed into the human 
cell system and their impact on the activation of the transcription factor NF-κB and the 
production of pro-inflammation cytokines were measured. Based on this information, 
the SNPs of interest were selected and the mechanistic molecular biology studies were 
conducted to understand how these variants alter the signalling functions of IRAK2 WT. 
Thus, these variants served as probes to gain further insight into the IRAK2-NF-κB 
signalling pathway. The research included studies for protein-protein interaction, 
downstream partner protein activation and post-translational modifications. Moreover, 
the impact of IRAK2 variants on the TLR signalling pathway was further investigated 
in reconstituted IRAK2 knockout murine macrophages.  
Meanwhile, the SNPs of interest were analysed in epidemiological studies to discover 
the relationship between these IRAK2 SNPs and the progression and prognosis of 
certain kinds of diseases. 
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2.1 Molecular Biological Methods 
2.1.1 Generation of ds-oligonucleotide sequences. 
Oligonucleotides sequences were designed using the vector NTI, Geneious software 
(Biomatters) or online primer design systems provided Agilent Technologies. The 
synthesis was done by MWG Biotech or Biomers Biotech. Double stranded 
oligonucleotides were generated by first mixing equimolar amount of two 
complementary single-stranded molecules in distiled H2O and denaturing the mixture 
for 5min at 95°C. Then the sample was slowly cooled down by 0.3°C per second to 
30°C. The hybridized double-stranded oligonucleotides were checked via running 3% 
agarose gel. For ligation purposes, 20nmol of double-stranded oligonucleotides were 
phosphorylated by 14U T4-polybnucleotide kinase (PNK, NEB), the reaction contained 
additionally 50mM of adenosine triphosphate (ATP) with an adequate amount of 
10×PNK buffer (NEB). The mixture was incubated at 37°C for 1hour. The PNK 
activity was stopped by adding 50mM EDTA and incubating the reaction at 68°C for 
10min. 
2.1.2 Polymerase chain reaction (PCR) 
PCR methods were majorly used for site-directed mutagenesis and for cloning gene 
constructs into plasmids; for each purpose different protocols were used (see table 2.1 
and 2.2). All PCR reactions were prepared with 4-100ng of DNA template, 0.2pmol of 
the forward and 0.2pmol of the reverse primers, 0.2mM deoxyribonucleotide 
triphosphates (dNTPs), 2mM MgSO4 and 2U of the thermostable Pfu or Vent 
polymerase in a reaction volume of 20-50μl containing the appropriate amount of the 
reaction buffer. The cloning enzymes were purchased from NEB, the enzymes for 
mutagenesis reactions were provided with the QuickChange site-directed Mutagenesis 
kit from Agilent Techologies. The PCR reactions were run on a MJ Research Thermo 
Cycler or a PEQ lab cycler, which were programmed according to the parameters listed 
below (Table2.1 and Table 2.2)  
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Table 2.1 PCR cloning program 
Program Steps Cycles Temperature(°C) Time Application 
Initial Denaturation 1 
95 1min 
 
95 1min 
 
Pre-amplification 
(optional) 
5 
50-60 45s -annealing a short tag 
-cloning a new constructs 
with restriction sites  
72 1min/1000bp 
95 1min 
Amplification 30 
50-65 45s 
 
72 1min/1000bp 
 
Extension 1 72 10min 
 
Storage 1 4 Infiniti 
 
 
Table 2.2 Site-directed mutagenesis 
Program step Cycles Temperature(°C ) Time 
Initial denaturation 1 
95 1min 
95 1min 
Amplification 18 
60 45s 
68 1min/1000bp 
68 10min 
Storage 1 4 Infiniti 
 
2.1.3 Quantitative real-time polymerase chain reaction 
The quantitative Real-time Polymerase Chain Reaction (qPCR) is an improvement of a 
standard PCR. The difference between a standard PCR and qPCR is that the amplified 
DNA is measured according to the reaction in progresses in real time. This method was 
applied to quantify the mRNA expression of certain genes when stimulating cells with 
TLR ligands. In order to compare the gene expression levels, total RNA was extracted 
from cells. In the case of macrophages, 1-1.5×10
5
 per well cells were seeded into 
24-well plates, and treated with specific ligands. The RNA was then extracted by using 
the RNeasy mini kit (Qiagen). Each well was treated with 350μl of the provided RLT 
buffer, which was supplemented with 1% of bete-mercaptoethnaol. The subsequent 
steps for RNA isolation were conducted according to the protocol of the manufacture. 
In order to avoid DNA contamninations, the isolated RNA was digested using the 
Ambion DNA-free kit (Life Techonologies). The genomic DNA was eliminated by 
adding 1μl of rDNase I to 1400ng of RNA mixed in the provided buffer conditions. The 
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reaction was incubated at 37°C in a thermocycler block for 30min. The DNase enzyme 
was subsequently removed by adding 2.5μl of the DNase inactivation reagent followed 
by incubation at room temperature for 2 min, meanwhile flipping the reaction every 
other second. The microtube was centrifuged for 1mintue at maximum speed in order to 
precipitate the genomic DNA. Then 20μl of the supernatant, the contained the RNA was 
transferred to a new microtube. The purified mRNA with this reaction was transcribed 
to cDNA using the Hight Capacity RNA to cDNA kit (Life Technologies). 1μl of the 
reverse transcriptase (RT) was added to 9μl of the purified RNA diluted in the 
appropriate amount of the provided transcription buffer. The reaction was heated at a 
thermocycler at 95°C for 1min, and then incubated at 37°C for 1hour, followed by a 
final inactivation period of 5 minutes at 95°C. A potential contamination of the purified 
RNA with genomic DNA was assessed by a ‘RT-minus’ control in which the 
transcriptase and the transcription buffer were replaced with distilled H2O. 
The mRNA of interest was quantified by applying a Tagman probe-based real time PCR. 
The qPCR experiments were done at a Applied Biosystem 7500 faster real time PCR 
system (Life Technologies). Gene-specific primers were purchased from Life 
Technologies (see appendix), and the qPCR reactions were conducted according to the 
protocol provided by the company. The quantified mRNA level of the TATA-binding 
protein (TBP) served as a reference and was used for normalization purpose.  
2.1.4 Plasmids and DNA purification 
Plasmids which were bought from companies were first transformed and then 
propagated in the type of bacteria that is suitable for the respective plasmid construct. 
After an overnight growth on the agar plates, several colonies were picked up and 
inoculated into 3-5ml LB medium (mini prep) or into 50ml-200ml LB medium (medi 
prep) that was supplemented with the required antibiotics. The cultures were 
maintained for 16 hours culture at 37°C. Then the DNA was extracted from the bacteria 
using the Promega high yield kits for mini and medi prep.  
A PCR-clean up kit or Gel- extraction kit (Qiagen) was used to purify DNA fragments 
of PCR products 
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2.1.5 Agarose gel electrophorsis 
Agarose gels were prepared with agarose (Roth) at 0.7-3% solutions, dissolved in 
sodium borate buffer (Brody and Kern 2004) containing 0.004% ethidium bromide 
(AppliChem), which intercalates into the double-stranded DNA helix. The agarose 
solution was heated and then cast into a chamber with a comb (PEQ Lab), which 
created the loading pocket. When cooling down, the solution polymerized to a gel. The 
DNA samples were diluted in 10×loading dye (NEB) and loaded into the gel. The DNA 
fragments were horizontally separated insodium borate buffer at 100-150V in sodium 
borate buffer. The 2-log DNA ladder (NEB) was used as a DNA marker. The DNA 
fragments agarose gels were visualized and documented with a UV-transilluminator 
(Pharmacia Biotech).  
2.1.6 Restriction digestion 
Restriction digests were either done to generat complementary sticky ends of DNA 
products for DNA ligation (cloning) or to checking the correct insertion of a gene in a 
plasmid. 2-5 μg of the vector was digested with 5-10U of the repective restriction 
enzyme(Fermentas Fast digest enzymes) in a 10×FastDigest buffer (Fermentas) by 
incubating the reaction at 37°C for 1hour. The digest was further analysed by agarose 
gel electrophoresis. In cases where the cleaved DNA was needed for cloning, the 
fragment of interest was purified by a gel extraction kit (Qiagen). In selected case, 
restriction enzymes were purchased from NEB; the reaction was set up according to the 
directions of the manufactures. 
2.1.7 Ligation 
DNA fragments were ligated into a plasmid backbone by applying choosing a 
molecular ratio of backbone plasmid and gene of insertion of either 1:3, 1:4 or 1:1, 
depending on the length of the insert. The total ligation volume was kept at as 20μl, 
containing 1μl T4-ligase (Roche), and the required amount of gene insert and plasmid 
backbone, in buffer conditions provided by Roche. The reaction was performed at 16°C 
overnight or at room temperature for 2-4 hours. In certain cases, the backbone needed 
be dephosphorylated to avoid self-recirculation. For this aim, 1μg of the digested 
plasmid backbone was incubated with 2.5μl of the Antarctic phosphatise (NEB) in the 
buffer recommended by the manufacturer. 10μl of the ligation reaction was transformed 
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to required competent cells (DH5α or DB3.1). The new cloning constructs were further 
analysed by restriction enzyme digestion and correct insertion of the gene was 
confirmed by Sanger sequencing (GATC Biotech).  
2.1.8 Plasmids transformation 
Plasmids transformations were performed with 100ng of DNA and 20-100μl of 
competent bacteria (E.coli DH5α, DB3.1 (containing CcdB resistant gene) or 
XL-blue/Gold).  Usually, DH5α were used for plasmid transformations. DB 3.1 
bacterial cells were used for propagating plasmids that encoded for the CcdB gene. 
CcdB is a lethal gene that targets the DNA gyrase and thus inhibits the bacteria growth. 
DB3.1 competent bacteria have a specific mutation in the gyrase, which make them 
resistant to CcdB. In the case where the plasmids were generated by mutagenesis, 1μl of 
the PCR product was transformed to XL-Gold bacteria to obtain higher transformation 
efficiencies. The transformed bacteria were incubated on ice for 30min in 
14ml polypropylene round-bottom tubes (BD) before applying a heat-shock in a water 
bath at 42°C for 45s. The tubes were placed back on ice for 2min and 200μl of 
pre-warmed S.O.C or NZY+ medium was added to cultivate the transformed bacteria 
for 1 hour at 37°C. 200μl of the bacterial suspension was plated on agar plates 
containing the required selective antibiotics. 
2.1.9 Gateway® cloning: LR cloning 
Gateway recombination cloning technology (Life technology) is a system with which 
allows the shuffling of genes from one plasmid to another by making use of specific 
recombination sites. The gene of interest was cloned to the pENTR1A entry clone (Life 
Technologies) which has attL1 and attL2 recombination sites. The gene of insert was 
shuttled into a destination clone which has attR1 and attR2 sites and additionally 
encoded for protein tags, see figure 2.1. In general, the reaction was prepared with 25ng 
of the entry clone, 75ng of the destination vector, 1μl of the LR clonase II Enzyme Mix 
(Invitrogen), and adjusted to a total volume of 5μl with TE buffer (pH=8.0). The 
reaction was incubated at room temperature (25°C) for 1hour, and then stopped by 
adding 0.5μl of proteinase K at 37°C for 10min, 1μl of the reaction was transformed to 
DH5a bacteria. The colonies, which grew in the presence of the respective antibiotic, 
were picked and further cultivated for plasmid isolations. In order to confirm that the 
gene of interest was inserted into the destination vector, the plasmids were digested 
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with BsrGI (Fermentas with Tango buffer), which cuts at the att recombination sites. 
The correct size of the insertion was confirmed by agarose gel electrophoresis. 
 
Figure 2.1 The Schematic diagram for LR reactions (Life Technologies) 
 
2.1.10 Plasmid constructs and cloning stragtegies 
2.1.10.1 Generation of Gateway compatible full length of human IRAK2  
The IRAK2-encoding plasmid (NCBI accession No. AAC50954)  was bought from 
Imagenes (IRCMP5012D0935D); the vector backbone was P4-Topo backbone. Due to 
the lack of proper antibodies that specifically recognize IRAK2 proteins, the IRAK2 
IRAK2 gene was cloned to a pENTR1A (Life Technologies), which facilitates the 
transfer of the IRAK2 gene to Gateway compatible destination vectors encoding 
in-frame for an N- or C-terminal Strep-HA or Flag. For this purpose, forward and 
reverse primers were designed to generate a Gateway entry clone of IRAK2: the 
forward primer contained a BamHI restriction site; the Reverse Primer 1 contained a 
NotI restriction site and did not encode for a stop codon to allow for the adding of 
C-terminal tag. Alternatively, the reverse primer 2 also contained a NotI restriction site 
as well and encoded for a stop codon in order to generate plasmids with N-terminal tag. 
Certain mutations were generated on the IRAK2 pENTR1A construct by site-directed 
mutagenesis. All primers are listed in the Appendix. 
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2.1.10.2 Generation of Gateway compatible human IRAK2 death domain 
constructs 
An IRAK2 death domain (IRAK2DD) construct was generated according to the amino 
acid sequence that was elucidated in the Myddosome structure (Lin et el. 2010) which 
includes the first 122 amino acids of IRAK2. The forward primer and reverse primers 
used are listed in the appendix. The Subsequent steps were the same as the ones applied 
to generate the IRAK2 for full length entry plasimds. Additionally, IRAK1DD and 
IRAK3DD constructs were generated according to the same procedures (see the 
appendix). The sequence of all the Gateway compatible plasmids encoding for the 
death domain encoding was confirmed by DNA sequencing. 
2.1.10.3 Generation of IRAK2 strep-HA pcDNA
TM
5/FRT construct 
The Strep-HA pcDNA
TM
5/FRT construct is a Gateway compatible destination vector 
and allows for the introduction of a N- or C- terminal comprising Strep and HA double 
tags. The plasmids were obtained from Dr. Andreas Pichlmair (CeMM, Vienna, 
Austria). In general, overexpression of a gene of interested based on this expression 
vector can be detected via the HA tag and purified via Strep tag. Additionally, the vector 
possesses two more special characteristic which are the Flp recognition target (FRT) 
site fused with a hygromycin resistant gene and a tetracycline-regulated, hybrid human 
cytomegalovirus (CMV)/TetO2 promoter cloned upstream to the gene of interest. The 
FRT site allows for the stable integration of the gene of interest, when co-transfecting 
the respective plasmid and the pOG44 plasmid (encoding a Flp recombinase) into 
Flp-In HEK293T-Rex cell line is a host cell line allowing for the stable intergration of 
the gene of interest into its genome via the FRT recombination site. The host cell line is 
equipped with a FRT site due to the stable integration of the pFRT/lac-zeo plasmid 
which has a single FRT site under the control of the SV40 early promoter. Mover, this 
plasmid encodes for a lacZ-Zeocin gene which makes the cells resistant to zeocin. 
Furthermore, the Flp-In HEK293T-Rex cells constitutively express the Tet repressor 
which is under control of the CMV promoter and fused to the blasticidin resistant gene. 
Usually, the Tet-repressor gene is independent from FRT sites. The Tet repressor 
normally binds to the TetO2 promoter and thus represses the transcription of the gene of 
interest. However, tetracycline can counteract the funcitions of the Tet repressor and 
avctivates the TetO2 promoter to induce the transcription of the gene of interest (see 
figure 2.2)  
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The IRAK2 gene that was cloned to the pENTR1A plasmid can be easily shuttled into 
the Strep-HA pcDNA
TM
5/FRT destination vector. The correct insertion was confirmed 
by BsrGI digestion and the protein expression was analysed by immunoblotting for the 
HA tag detection. The same vector was also used to when cloning all IRAK2 mutants, 
the IRAK1 and IRAK3 genes, and when constructing all the IRAKDD constructs.     
 
Figure 2.2 The diagram of generation of Flp-In stable cell line (Life Technology) 
2.1.10.4 Generation of the IRAK and TRAF6 constructs for LUMIER assay 
In order to perform high throughput protein-protein interaction screening, the LUMIER 
method was applied [190]. The one protein was tagged with Protein-A (Gateway 
destination vector, pT-Rex-DEST30 encoding for proteinA), the other protein 
interaction partner was tagged with the Renilla luciferase (Gateway destination vector 
pcDNA3nt-renilla or pT-Rex-DEST30 ct-Renilla). The destination vectors were 
obtained from the Core facility of Genomics and Proteomics, German Cancer Research 
Center(Dr. Manfred Kögl, DKFZ). Gateway LR reactions were done to generate IRAK 
and TRAF6 constructs for LUMIER assays. See Appendix.  
2.1.10.5 Generation of Flag-tagged TRAF6 gene constructs 
Gateway compatible plasmids encoding for human TRAF6 were bought from the Core 
facility of Genomics and Proteomics, German Cancer Research Centre (Dr. Manfred 
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Kögl, DKFZ). In order to conduct the co-immunoprecipitations, TRAF6 was 
introduced into a N-terminal or C-terminal Flag-tagged Gateway-compatible 
expression vectors (from Dr. Stefan Pusch, Department of Pathology, University of 
Heidelberg, Germany). The expression of the protein fused to the tags was confirmed 
by immunoblot analysis. 
2.1.10.6 Generation of IRAK2 wild-type and mutants constructs for retroviral 
transduction 
A retroviral vector is an infectious virus used to introduce a non-viral gene into mitotic 
cells in vivo or in vitro. The advantage of this vector is that it has higher transduction 
efficiencies than lipofectamine or calcium phosphate and can allow for the stable 
integration the gene of interest into the genome of the cell. pMXs-IP-puro vector 
(received from Dr. Kevin Michael Dennehy, Department of Virology, University of 
Tübingen) is a retroviral transduction vectors. The gene of interest flanked at the 5’ and 
3’ end by long term repeat (LTR). The vector was transfected in to a packaging cell line 
(Phoenix ampho(provided by Dr. Kevin Michael Dennehy ) or Phoenix eco(provided 
by Dr. Markus Feuerer).Since the vector contains the packaging sequence ψ, the RNA 
is recognized by capsid proteins encoded by the packaging cell line and packed into 
viral particles that are released into supernatant. The cultured supernatant is harvested 
after 48hours post-transfection, and applied to the cell-line of interest to generate stable 
cell lines. Cells that were successfully infected and integrated the genes of interest were 
selected by adding 10μg/ml puromycin. This is due to the fact that the pMXs-IP-puro 
vector has an internal ribosomal entry site (IRES) that allows for the expression the 
puromycin resistance gene, which makes stably transfected cell lines resistant to 
puromycin selection. Figure 2.3 shows schematic structure of the pMXs-IP-IRES-puro 
vector containing a N-terminal HA tagged human IRAK2.   
 
Figure 2.3 The schematic structure of pMXs-IP retroviral vector  
2.1.11 Cultivation and cryo-preservation of transformed bacteria cells 
Transformed bacteria were cultured in LB medium, which contained the required 
concentration of the antibiotics, and incubated at a shaker at 200rpm for 16 hours, 37°C. 
Glycerol stocks were prepared by using 500μl bacteria of the baterial suspension and 
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adding 150μl 100% glycerol. The bacterial glycerol stocks were shock-frozen in liquid 
nitrogen and stored at -80°C. 
2.2 Biochemical Methods 
2.2.1 Protein quantification 
Protein concentrations of cell lysate were determined with the bicinchoninic acid assay 
(BCA) (Thermo Fisher Scientific). The assay is based on a colormertric technique, in 
which the total protein concentration is quantified by a color change of the sample 
solution from green to purple. Bicinchoninic acid, sodium salt, is a stable, 
water-soluble compound capable of forming an intense purple complex with cuprous 
ion (Cu
1+
) in an alkaline environment. This reagent forms the basis of an analytical 
method capable of monitoring cuprous ion produced in the reaction of protein with 
alkaline Cu
2+
 (biuret reaction). The colour produced from this reaction is stable and 
increases in a proportional fashion over a broad range of increasing protein 
concentrations [191]. Bovine serum albumin (BSA) served as a standard protein 
solution that was diluted with the required lysis buffer to concentrations ranging from 
0.125mg/ml to 2mg/ml. The protein concentrations were determined in a 96 flat-bottom 
microplate, in which 200μl working reagent was mixed with 25μl of the protein sample, 
followed by an incubating at 37°C for 30min. The working reagent was made from 
solution A and solution B, mixed in a 50:1 ratio. In cases where the protein lysate 
exceeded the absorption range, samples were diluted in a 1:2 ratio with lysis buffer or 
H2O. Each sample was measured in duplicates. The concentration was determined at a 
wavelength of 562nm with a 96 well plate reader (BMG labtech)  
2.2.2 SDS-polyacrylamid electrophoresis 
The Sodium–Dodecyl-Sulfate-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) was 
performed with the Invitrogen X cell Surelock Mini Cell chamber system. Protein 
samples were diluted with the 4×NuPAGE LDS (Invitrogen) and 10×Sample reducing 
buffer (Invitrogen) and denatured at 90°C for 10min. 
The protein separation was carried out with pre-casted gels. Proteins with a molecular 
weight ranging from 10kDa to 140kDa were separated on Bis-Tris 4-12% gradient gels 
with MES or MOPS running buffer. . The gel was run for 70 mins at175V. Proteins with 
larger molecular weight were run on Tris-Acetate 3-8% gradient gels with Tris-Acetate 
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running buffer. Similarly, the separation was carried out for 70 mins at 150V. 4μl of a 
prestained protein marker (PageRuler, Fermentas) was loaded on each gel and served as 
a reference for the molecular weight.  
2.2.3 Immunoblot analysis 
The immunoblot analysis was carried out after SDS-PAGE. It was performed within an 
X-cell Surelock Mini chamber (Invitrogen). The transfer buffer(Invitrogen) was  
prepared with 20% methanol (Roth), Whatman filter papers and the nitocellular 
membrane were preincubated in the transfer buffer to enhance the transfer efficiency. 
The proteins were transfered to a nitrocellulose membrane with either 0.45μm or 
0.25μm pore size; depending on the protein size. The transfer was conducted at 30V, for 
1-2 hours (depending on the protein size). The transfer efficiency was confirmed by the 
transfer of the pre-stained protein marker. Then, the nitrocellulose membrane was 
blocked for 30-60 min in a 3% skimmed milk or 5% BSA diluted in PBS with 
0.5%Tween or in TBS with 0.1%Tween buffer. The membrane was incubated overnight 
at 4°C with respective primary antibody, which was diluted in the desired blocking 
buffer.  The membranes were washed 3×5min with the respective washing buffer 
(PBS-0.5% Tween orTBS-0.1% Tween) before adding the secondary antibody diluted 
in the respective blocking buffer. The membranes were incubated for 1.5-2 hours at 
room temperature with secondary antibody that is conjugated to the horseradish 
peroxidise (HRP). The membranes were again washed 3×5min with the required buffer. 
Meanwhile, the enhanced chemical luminescence (ECL, Thermo fisher scientific) 
solution was prepared. The membranes were incubated with the ECL solution for at 
least 2 min, and then exposed to photographic films (GE health care). When dectecing 
another protein on the same membrane, the membrane was incubated with stripping 
buffer (Thermo Fisher Scientific) for 15min at room temperature. In order to confirm 
secondary antibody was stripped off, the membrane were incubated with ECL solution 
for 2min, and exposed for 3min to X-ray film. If no signal was detected after 
developing, the membranes were re-incubated with the blocking buffer, followed by the 
incubation with the respective primary and secondary antibodies. The stripping and 
re-incubation of the membranes with other antibodies was only done in cases, whether 
the respective secondary antibodies were produced from different species; this helped 
in controlling cross-reactivity of the antibodies. 
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2.2.4 Two-dimensional gel electrophoresis 
The two-dimensional gel electrophoresis can be used to detect post-translational 
modifications of a protein. All experiments were carried out with a GE IPGphore 
Electrophoresis machine. Immunoprecipitated protein samples were resuspended in 
13μl lysis buffer (7M urea, 2M thiourea, 4% CHAPS, IPG buffer 3-10 2%, + protease 
inhibitor cocktail) and incubated for 30min at room temperature shaking at 400 rpm. 
Then 117 μl of rehydration buffer (7M urea, 2M thiourea, 2% CHAPS, IPG buffer 3-10 
0.5%, 40mM DTT) was added, and the samples were evenly distributed on 7cm strip 
ceramic holders (GE Healthcare). The IPG strips covered the pH range from 3 to 10 
(GE Healthcare). The strips were covered with 600 μl pure oil (GE Healthcare) and 
closed with a plastic lid. The protein samples were absorbed overnight to the agarose 
strip at 30V. Before conducting the iso-electrophoretic focusing, small rectangular 
whatman paper pieces (3mm×10mm) were moisturized and placed between the agarose 
strip and the anode or cathode to increase the conductivity.The samples were separated 
and focused by first maintaining 300V for 1 hour (step-n-hold), then applying a 
gradient increase to 1000V with 30min, followed by another increase to 5000V within 
1.5 hours, and keeping the voltage constant at 5000V for 36min (step-n-hold). Each 
strip acquired in total 7000-8000 Vhs. The agarose strips were taken out from the strip 
holders and washed briefly with distilled H2O. The proteins were loaded on the strips in 
2.5ml of 1% DTT which was diluted in 1×LDS buffer (Invitrogen). Then the strips 
were incubated for 15min with 2.5ml of 2.5% iodoacetamide which were diluted in 
LDS buffer. This step helped alkylating thiol groups and thus preventing reoxidation 
during electrophoresis, which may create artefacts in the saparation. The strips were 
adjusted to fit in the pocket of the IPG zoom precast Bis-Tris 4-12% gel (Invitrogen). 
and the position was fixed with 0.5% 1×MES agarose buffer. The separation was 
carried out with the MES buffer, was first applying 100V for 5min, and then increasing 
the voltage to 200V for 45min. The separated spots were identified by immunoblot 
analysis as described in section 2.2.3 
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2.3 Cell Biological Assay 
2.3.1 Cell lines and cultivation 
The following cell lines were used as in this thesis: HEK293T cells ( obtained from Dr. 
Alexander Dalpke, Department of Medical Microbiology and Hygiene, University of 
Heidelberg, Germany), HEK293 Flp-In T-Rex cell line(from Dr. Andreas Pichlmair, 
CeMM,Vienna, Austria), IRAK2 knock out macrophage cells(from Dr. Katherine A. 
Fitzgerald, Division of Infection Disease and Immunology, Department of Medicine, 
University of Massachusetts Medical School, Worcester, MA, USA ), Phoenix ampho 
cells (from Dr. Kevin Dennehy, Institute of Medical Virology, University of Tübingen, 
Germany) . 
HEK293T, Phoenix ampho and Flp-In HEK293 T-Rex cell lines were cultured in 
Dulbecco’s Modified Eagles Medium (DMEM Sigma), and supplemented with 10% 
FCS (Biowestern), 100u penicillin/streptomycin (Invitrogen), and 100u glutamine 
(Invitrogen). The Flp-In HEK293T-Rex cell line needed additionally the antibiotics, 
blasticidin (15µg/ml, Invitrogen) and zeocin (100µg/ml, Invitrogen) to maintain the 
Tetracycline repressor and FRT site. In cases when the Flp-In HEK293T-Rex cell line 
was used for stable transfections, zeocin was replaced with hygromycin (100µg/ml, 
Invitrogen) to select the interested stable cell line. 
IRAK2 knock out macrophage cells were cultured in DMEM, supplemented with 10% 
FCS, 10 µg/ml ciprofloxacin, and 100u glutamine.  IRAK2 reconstituetions were 
conducted in these cells via retrovial transductions (see 2.3.9). Throughout the infection 
period cells were maintained under security level 2 conditions (S2 lab). 10 μg/ml of 
puromycin was added when selecting for cells that stably intergrated the gene of 
interest.  
All cell lines were cultivated at 37°C in an incubator adjusted to 5% CO2. 
2.3.2 Transfection of plasmids to mammalian cell lines 
2.3.2.1 Calcium phosphate transfection 
Calcium phosphate was taken as a transient transfection reagent for HEK293T cells, 
and generally applied for signalling and gene expression assays in HEK293T cells. 
2×HBS (50mM HEPES pH 7.05±0.05, 10 mM KCl, 12 mM Dextrose, 280 mM NaCl, 
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1.5 mM Na2HPO4) and 2M CaCl2 were prepared for transfection. According to the 
set-up of the experiment, different transfection mixes were required, as shown in 
Table2.3. 
Table2.3   The calcium phosphate transfection method 
Format 24 wells plates/each well 6cm dishes 10cm dishes 
Cell number 7.5×10
4
 7.0×10
5
 1.5×10
6
 
Aim Dual Luciferase Assay WB blot Co-IP 
Plasmids for gene of interest (100ng/μl) 1μl 25μl 40μl 
EGFP (100ng/μl) 1μl 5μl 10μl 
NF-κB firefly reporter (100ng/μl)  1μl 0 0 
Renilla luciferase (100ng/μl)  0.1μl 0 0 
CaCl2 (2M) 1.2μl 22μl 61μl 
H2O 5.7μl 308μl 389μl 
2xHBS 10μl 360μl 500μl 
Total volume 20μl 720μl 1000μl 
 
The transfection mixture was added drop-wise into the wells. Then the plates were 
shaken slowly side to side or forward and backward to evenly distribute the transfection 
mixture. In general, the efficiency of transfection was over 90%. 
2.3.2.2 Lipofectamine 2000 (Invitrogen) transfection 
Lipofectamine 2000 (Invitrogen) was taken as a transient transfection method for 
LUMIER assays as described below. The efficiency of transfection was around 
70-80%. 
Table 2.4 Lipofectamine 2000 (Invitrogen) transfection method 
Format 96 wells plates/each well 
Aim LUMIER assay 
Gene of interest 1(10ng/μl) 2μl 
Gene of interest 2(10ng/μl) 2μl 
Optimem 6μl 
Lipofectamine mix 6μl 
Incubating for 20min at room temperature before adding to cells 
Lipofectamine mix: 12.6μl lipofectamine 2000 + 1200μl optimem / plate 
Incubating 5min before adding to DNA mixture 
 
2.3.2.4 X-treme GENE HP transfection 
The X-treme GENE HP transfection method was used to perform retroviral 
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transductions. 2μg retroviral plasmid encoding the gene of interest was mixed with 
OptiMEM (Life Technologies) to reach a total volume of 100μl. Then 6μl of the 
X-treme gene transfection solution (Roche Applied Science) was added into the 
OptiMEM-DNA mixture: the ratio of gene and X-treme gene transfection solution was 
1:3. The transfection mixture was mixed by pipetting up and down for several times and 
incubating the solution at room temperature for 20min. The DNA-transfection mixture 
was added to the cells and the plates were shaken side to side to ensure an even 
distribution of the transfection mixture. 
2.3.3 Stable transfections of Flp-In™ 293T-REx™ cell lines 
Flp-In™ 293T-Rex cells were used to generate a cell line stably expressing IRAK2-HA, 
700000 Flp-In™ 293T-Rex cells were seeded into a 6cm dish in 5ml DMEM medium 
that did not contain any selective antibiotics. 0.2μg of the pcDNA5TM/FRT plasmid 
encoding for IRAK2-HA and 1.8μg pOG44 (ratio: 1:9) were co-transfected into 
Flp-In™ 293T-Rex cells by calcium phosphate method. The transfection mix was 
added to the Flp-In
TM
 HEK293T-Rex cells;
 
additionally, GFP encoding plasmids were 
transfected to a separate dish to assess the transfection efficiency. After two days, the 
cells were trypsinized and transferred from the 6cm dish to a 10cm dish, keeping the 
cells in 10ml of DMEM.  Blasticidin (15μg/ml) and hygromycin (100μg/ml) were 
added two days later (Invitrogen) and the selection medium was replenished every 3-4 
days. After two weeks, the cellular foci were formed, indicating a successful stable 
integration of the gene of interest into the Flp-In™ 293T-Rex cells. Due to the fact that 
this cell line only contained one FRT site for recombination, the cellular colonies all 
shared the exact same site for the integration of the gene (this was analysed beforehand 
in the lab). In order to confirm that IRAK2-HA is expressed cells were treated with 
1μg/ml of tetracycline for at least 2 hours. Subsequently, an immunoblot analysis of the 
cell lysate was conducted to probe the expression of IRAK2-HA.  
2.3.4 Gene expression analysis 
All the expression plasmids generated in this thesis were analysed for the correct 
expression of respective cloned genes. HEK293T cells were seeded into 24 well plates 
with 75000 cells per well. 100ng of the gene encoding plasmids were transfected and 
after 48 hours the cells were lysed with 60μl RIPA lysis buffer (pH=6.9) freshly 
supplemented with protease and phosphatise inhibitors (Roche). In some cases, 
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HEK293T cells were seeded into 6 well plates, with 700000 cells per well. 2.5 µg of 
gene encoding plasmids and 0.5µg EGFP encoding plasmids were co-transfected into 
each well. After 48 hours, the medium was removed and 250μl of the lysis buffer was 
added.  
The cell lysis was conducted for 15min, keeping the cell culture dishes/plates on ice. 
The cellular lysates were then collected in 1.5ml tubes and centrifuged at 13000rpm for 
10min at 4°C to pellet the cellular debris. The supernatant with the lysed proteins was 
transferred to a new 1.5ml tube. In order to compare the protein expression levels, the 
BCA assay was carried out (see 2.2.1). The protein concentrations were adjusted to 
similar values with the lysis buffer. The samples were separated by SDS-PAGE to then 
probe for the protein of interest in a subsequent immunoblt assay (see 2.2.3) 
2.3.5 Dual luciferase assay 
In order to analyse if certain proteins can induce signalling pathways, Dual Luciferase 
Assays (Promega) was performed to check for the activation of transcription factors. 
This work focused on the activation of NF-κB, IRF3 and AP-1 transcription factors 
using firefly luciferase reporter plasmids. The plasmid constructs contained the 
promoter binding motifs of the respective transcription factors that were cloned 
upstream to the firefly luciferase gene. Therefore, signalling activities were analysed by 
detecting the luminescence of firefly. Different transcription factor encoding plasmids 
were tagged with firefly (Photinus pyralis (Strategene)) luciferase reporter. 
Additionally, a Renilla (Renilla reniformi or sea pansy) luciferase reporter vector with 
constitutive expression served as a transfection control were used for Dual Luciferase 
Assa.. The firefly luciferase reporter gene was measured by adding luciferase Assay 
Reagent II to generate a luminescent signal lasting at least one minute. After 
quantifying the firefly luminescence, this reaction is quenched, and the Renilla 
luciferase reaction is initiated simultaneously by adding Stop & Go reagent to the same 
sample. Both reporters yield linear assays with attomole (<10
-18
) sensitivities and no 
endogenous activity in the experimental host cells.  
Usually, Dual Luciferase Assay was conducted in HEK293T cells. 75000 HEK293T 
cells per well were seeded in 24 well plates. Transfection was conducted after 2-4 hours 
of seeding. The transfection mixture is listed in table 2.3. DNA plasmids (including 
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EGFP, NF-κB firefly luciferase reporter, and Renilla luciferase reporter) 
concentrations were adjusted to 100ng/μl. EGFP was taken as a control of transfection 
efficiency; Renilla luicferase reporter plasmid was taken as a relative expression 
control. Cells were lysed with passive lysis buffer (Promega) after 48 hours’ 
transfection. 60μl passive lysis buffer was added into each well, and plates were 
shaken at 1000rpm for 15min at the room temperature. Then samples were frozen at 
-80°C for 15min and thawed at the room temperature in order to extract all proteins 
from the cells into the lysate. To separate debris, lysed samples were centrifuged at 
2500rpm for 10min. Luminometric measurements were carried out in 96 well white 
plates (Nunc) by analyzing 10μl of the cell lysate. The measurements were performed 
with a luminometer (Fluostar (BMG Labtech)). 50μl of the firefly luciferase substrate 
(beetle luciferin, promega) and 50μl of the Renilla luciferase substrate (coelenterazine, 
Promega) were sequentially injected to the sample. The luminescence signals were 
captured at every 0.5 seconds during a time window of 10s, and expressed as relative 
light units. The relative activity of firefly luciferase reporter was normalized to the 
signals of the renilla luciferase reporter. The measurements were conducted in 
triplicates, and presented as mean value ± standard deviations.  
2.3.6 LUMIER 
Luminescence-based mammalian interactome is an automated high throughput 
technology designed for the systematic mapping of dynamic protein-protein interaction 
networks in mammalian cells [190]. It can display the relative interaction intensity of 
interacted proteins. In this method one protein of interest is fused to a Protein-A tag, 
which is then co-transfected with the other protein of interest that has a Renilla 
luciferase tag. The protein complex is purified from the cellular lysates by 
immunoprecipiation with IgG Dynabeads M-280 (Invitrogen) which detects the 
Protein-A tagged protein. The interaction intensity is then detected by conducting a 
Renilla luciferase enzymatic assay. The method described here was optimized by 
Dr.  Manfred Kögl (DKFZ). 10000 HEK293T cells were seeded per well into 96 well 
plates and cultivated in 100μl growth medium. 2-4 hours after seeding, 20ng of the 
plasmids encoding for the Renilla fused protein (one protein of intereste) and 20ng of 
expression plasmids for the Protein A-tagged protein partner were co-transfected by 
Lipofectamine 2000 (Invitrogen). Fos (Renilla-tagged) and Jun (Protein A-tagged) 
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were set up as a positive interaction control for each experiment [190]. Meanwhile, a 
negative control was set up by co-transfecting the empty vector plasmids which only 
encoded for the Renilla luciferase and the Protein A-tag. Each condition was done in 
triplicates. The cells were lysed 48 hours after transfection with 10μl lysis buffer 2 
which was supplemented with fresh Proteinase inhibitor cocktail (Roche), Phos-stop 
(Roche), DTT (1M), Benzonase 0.0125 U/μl and 1% of IgG Dynabeads M-280 
(Invitrogen). The samples were lysed for 15 minutes on ice. Triton-X100 may interfere 
with the luciferase measurement. Therefore, 100μl of PBS was added to the lysate, and 
10μl of the diluted suspension were again diluted in 90μl PBS. These diluted samples 
were used to measure for the raw Renilla luciferase activity within the cellular lysate. 
The remaining amount of the cellular lysate was subjected to a magnetic plate washer 
(Tecan) to perform the immunoprecipitation of the Protein A -tagged protein and to 
remove unbound Renilla-tagged proteins. The immunoprecipiates were then analysed 
for their Renilla activity to quantify the amount of interaction between the Protein A 
and Renilla-tagged proteins. The substrate for the Renilla luciferase was prepared by 
adding 18μl of co-elenterazine (P.J.K) into 15 ml of Renilla assay buffer (see appendix). 
The final concentration of coelenterazine was kept at 2.5μM. The renilla activity was 
detected at a platereader (Infinity 200, Tecan) which automatically added 70μl of the 
renilla luciferase substrate to the well and measured the enzymatic luciferase activity in 
a time window of one second (see figure 2.4). The protein interaction intensity was 
calculated according to the following ratio [190], which was modified by Dr. Manfred 
Kögl . 
                      
                                
                            
                                          
                                      
 
The whole experimental procedures see the figure below: 
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Figure 2.4 The schematic diagram of the LUMIER procedure 
2.3.7 ELISA 
Enzyme-Linked Immunosorbent Assay was used to detect for the induction of 
pro-inflammatory cytokines on a protein level. In order to confirm that different SNPs 
can alter the NF-κB activation on a protein level, IL-8 production in HEK293T cells 
and TNF-  production in macrophages were measured by ELISA. In the cellular 
system of HEK293T, human IL-8 was taken as readout. Supernatants were collected 48 
hours after transfecting certain expression plasmids into HEK293T cells and the 
concentration of IL-8 was detected (Biolegend). For the reconstituted IRAK2 knockout 
macrophages, mouse TNF-α (Biolegend) was taken as readout for NF-κB activation 
when stimulating the cells with different TLR ligands. In both conditions, 96 well 
plates were pre-coated either with IL-8 or TNF-α monoclonal antibodies overnight at 
4°C. According to the protocol which was provided by the company, the plates was 
blocked with 1× assay buffer for 1 hour, then 100μl of the cell culture supernatant 
(according to the different sensitivity and ability of various kit, dilutions of the samples 
were required) and 100μl of a standard human recombinant IL-8 dilution series 
(ranging from 15.6 to 1000pg/ml) or of mouse recombinant TNF-α (concentrations 
from 7.8 to 500 pg/ml) were added into each well of a 96 well plate, respectively. Each 
sample was analysed in triplicates or at least duplicates and the samples were incubated 
at room temperature for 2 hours. Then 100μl of biotinylated anti-human IL-8 or 
anti-mouse TNF-α detection antibody were added into each well and the samples were 
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again incubated at room temperature for 1 hour. Finally, 100μl of avidin-HRP was 
added to each well and incubated at room temperature for another 30 minutes. 
Sequentially, TMB substrate was added and the colorimetric reaction was stopped by 
adding the provided stop solution. The concentrations of IL-8 or TNF-α were measured 
at the wave length of 450 nm on a 96 well plate-reader (Fluostar, BMG). In order to 
substract any background noise of the plates, the plates were again measured at 570nm 
and the respective values were substracted from the readings at 450nm. 
2.3.8 Immunoprecipitation 
Immunoprecipitation is a method in which a protein of interest is precipitated by using a 
specific antibody. The advantage of this method is that the protein of interest can be 
isolated from the whole cell lysate and be concentrated on modified agarose beads. It 
was applied in this thesis to detect protein-protein interactions. In the case of IRAK2 
and TRAF6 interactions, 1.5 million HEK293T cells were seeded into 10 cm dishes, 
and 4 μg of each gene encoding plasmids and 1μg of EGFP encoding plasmids were 
co-transfected into HEK293T cells with the calcium phosphate transfection method. 
The efficiency of transfection was assessed with the fluorescent microscope after 48 
hours of transfection. Usually, the transfection efficiency reached up to 90%. The 
culture medium was then removed and the cells were washed with 3 ml of cold PBS. 
The cells were lysed with 850μl of the respective lysis buffer by incubating the dishes 
on ice for 15min. The celluare lysates were transferred into a 1.5ml tube and incubated 
for additional 30min on ice to thoroughly lyse the cells. Meanwhile centrifuge was 
pre-cooled to 4°C, and the cell debris was then separated from the lysate by 
centrifuging the samples at 13000g for 10 minutes. The supernatant was transferred to a 
new 1.5ml tube. In cases where the expression levels of each sample were needed to be 
compared, a BCA assay was conducted as well (see 2.2.1). 800μl of the lysate was 
applied for immunoprecitations. When precipitated HA-tagged proteins, 1.5μl of an 
 -HA mouse antibody was added to the lysate. In the case of TRAF6 ubiquitination 
assays, 4μl of a TRAF6 monoclonal antibody (Santa Cruz) was added to the lysate. The 
samples were rotated end-to-end for one hour at 4°C. Then 30μl of an A/G agarose bead 
slurry (Thermo Fisher Scientific) was added to the samples and rotated end-to-end for 
additional two hours at 4°C. In order to get rid of unbound proteins, agarose beads were 
washed three times with cold lysis buffer. In the case of TRAF6 ubiquitiantion assays, 
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IAA and proteinase inhibitor and phos-stop were freshly added. The samples were 
centrifuged at 6000 g for 2 minutes, which precipitated the agarose beads bound to the 
protein interaction complex. The washing buffer was carefully removed from the pellet, 
and the samples were again washed for another 2 times. If no further studies were 
performed on the same day, the samples were kept at -20°C. For SDS PAGE analysis, 
the samples were treated with 14μl of 4×LDS buffer (Invitrogen, NuPAGE) with 3μl of 
a sample reducing agent (Invitrogen NuPAGE) and heated at 90°C for 10 minutes. This 
procedure helped in releasing the protein complex from the agarose beads, Then 
SDS-PAGE was carried out and the proteins of interest were detected by immunoblot 
analysis. 
2.3.9 Retroviral transduction 
Retroviral transduction was used to introduce N-terminal HA tagged human IRAK2 
into murine IRAK2 KO macrophages. N-terminal HA tagged IRAK2 was introduced 
into the pMXs-IP retroviral vector which is based on the Moloney Murine Leukemia 
Virus (MMLV), whose LTR is the most commonly used for retroviral vectors, and is 
expressed in almost all cell types (see 2.1.9.6) The viral stocks were generated by 
transfecting pMXs-IP-puro plasmids which contained the N-terminal HA tagged 
IRAK2 into the Phoenix ampho cells, which is a packaging cell line.  
On the first day, 5×10
5
 Phoenix ampho cells per well were seeded into a 6 well plate 
with 3 ml growth medium; two wells of Phoenix ampho cells were prepared for each 
transduction condition.  
On the second day, 2μg of the plasmid carrying the gene of interest was transfected into 
each well with the X-treme gene HP transfection reagent. The ratio of the plasmid and 
the transfection reagent was 1: 3 (1μg plamid and 3μl X-treme gene HP).  
On the third day, 3×10
5
 of the mouse IRAK2 knockout macrophages were seeded per 
well into a separate 6-well plate and were maintained in 2ml growth medium; one well 
was prepared for each transduction condition.  
On the fourth day, virues were harvested from the Phoenix ampho cells. The viruses 
were released into the supernatant and contained the gene of interest. Since two wells 
were prepared for one transduction condition, the supernatant (containing the viruses) 
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of both wells were pooled and passed through a 0.45 micro-m filter to remove cellular 
debris. The volume of viral stock was approximately 5ml. Polybrene (Sigma, 
hexadimethrine bromide) was added into the viral stock to reach a final concentration 
of 8μg/ml. Polybrene is used to enhance the efficiency of transduction by neutralizing 
the charge repulsion between virions and sialic acid on the cell surface. The culture 
medium of the macrophages was removed from the IRAK2 knock out macrophages and 
replaced by the viral stock medium. The centrifuge was pre-warmed to 32°C and the 
plates containing the IRAK2 knockout macrophages with the viral medium were 
centrifuged down at 2000 rpm for 2 hours. Then the plates were placed back into the 
incubator.  
In order to avoid that polybrene may inhibit the growth of the cells; the viral 
supernatant was replaced with growth medium after 6 hours of infection. In the case 
that the infected cells are in suspension, they can be counted on the same day of 
infection and directly be resuspended into the viral supernatant. 
2.4 Infection of reconstituted macrophages with Influenza A 
The Influenza A strain WT PR8 and △ NS1 were obtained from Prof. Dr. Oliver Plantz 
(Interfaculty of Cell biology Department of Immunology, University of Tübingen, 
Germany). The following protocol was applied to infect macrophages with the 
Influenza A strain. 
Day 1: Seeding of 1.5×10
5
 macrophages per well into 24 well plates with 500μl culture 
medium.  
Day 2: The growth medium was removed and the cells were washed with 1 ml PBS, 
since FCS affects the infection efficiency. Meanwhile, “infection PBS” (PBS with 
trypsin) and “infection medium” (DMEM without FCS, supplemented with trypsin and 
BSA) were prepared. Viruses were diluted in the ‘infection PBS’ solution to the 
required concentrations (MOI of 1, 10 or 100), added to the cells and incubated at 37°C 
for 30 min in the S2 incubator. Then the “infection PBS” solution containing viral 
media was replaced with 500μl of the “infection medium” and then incubated at the 
37°C in the incubator. After required amount of time, RNA was harvested according to 
the protocol (RNeasy kit, Qiagen) (see 2.1.3). 
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2.5 Infection of reconstituted macrophages with Salmonella 
typhimurium 
Salmonella typhimurium (strain LT2) was a gift from Dr. Samuel Wager (Department of 
Medical Microbiology and Hygiene, University hospital of Tübingen). The following 
protocol was applied to infect macrophages with Salmonella typhimurium. 
On the first day, Salmonella typhimurium was inoculated in 5ml LB medium and kept at 
37°C for overnight (at least 16 hours). Meanwhile, 1.5×10
5
 of the reconstituted 
macrophages were seeded into each well of a 24 well plate with 500 μl of culture 
medium.  
On the second day, Salmonella typhimurium were cultured again by inoculating 
overnight culture into 5ml of fresh LB medium at 1:10 dilution, and cultivating the 
suspension for another 2-3 hours at 37°C. Then the OD value of Salmonella 
typhimurium was measured at 600 nm. An OD value of 0.9 corresponds to 
approximately 1.0×109 Salmonella typhimurium in 1ml LB medium. Then Salmonella 
typhimurium were diluted with in HBSS in a 1:10 ratio (see Appendix) which inhibited 
the growth of Salmonella typhimurium. The cultural medium of the reconstituted 
macrophages was removed and washed once with 500μl HBSS. In the case of 
macrophage infections, a MOI of 1 or 10 was chosen. HBSS containing the required 
amount of Salmonella typhimurium were added into each well and incubated at 37°C 
for 30 min in the S2 incubator. At the same time, the infection medium (DMEM 
supplemented with FCS and spectinomycin 50ng/ml-100ng/ml) was prepared. The 
HBSS containing Salmonella typhimurium was replaced by 500μl of the infection 
medium which kills all of the extracellular Salmonella typhimurium. RNA was 
harvested according to the required experimental conditions (see 2.1.3).     
2.6 Computational methods. 
2.6.1 Homology modelling of IRAK2 kinase domain. 
The structural homology model of the IRAK2 kinase domain was done by Dr. Andriy 
Kubarenko to gain further insights into the three dimensional location of the amino acid 
residues of interest. The structure of the kinase domain of IRAK2 was generated 
according to IRAK4 KD structure which is available at the PDB databank (PDB code 
2NRU). Protein structure images were generated with the PyMOL software.  
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2.6.2 Software tools and web-based browsers 
The DNA sequences were aligned and checked by vector NTI Advanced (Invitrogen) or 
Geneious software (www.geneious.com). Additionally, the Geneious software was 
used to generate plasmid maps for the expression plasmids and to design the cloning 
primers. Furthermore, Geneious was used to analyse protein sequences and to perfom 
protein sequence alignments. Site-directed mutagenesis primers were designed by the 
website which is provided by Agilent. The qPCR primers were directly designed and 
purchased from Life Technology. Figures were done with Prism or Adobe Illustrator. 
2.6.3 Statistic analysis 
Statistical analysises were mainly done in Excel using the student t-test; two-way 
ANOVA was done in Stata. The epidemiological data analysis was done with SPSS 
20.0 (SPSS, Chicago, Illinois, USA) or SAS (SAS Institute Inc., Cary, NC, USA). 
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3.1 Part I: IRAK2 played a central role in the TLR signalling 
pathway. 
3.1.1 Introduction 
The aim of part I was to decipher the role of IRAK2 in the TLR signalling pathway. The 
IRAK family consists of four members: IRAK1, IRAK2, IRAK3 and IRAK4. IRAK4 
is essential for TLR/IL-1R-mediated signal transduction [192]. IRAK4 deficient mice 
are shown to be resistant to LPS- induced shock [146]. In humans, IRAK4 deficiency 
leads to recurrent infections with pyogenic bacteria, especially Streptococcus 
pneumonia [164]. In contrast, IRAK3 is shown to inhibit the production of 
pro-inflammatory cytokines and block the formation of the IRAK1-TRAF6 complex 
[87]. Furthermore, IRAK1-deficient mice are resistant to LPS inoculation. Moreover, 
IRAK1 is essential for the production of TLR7/9-induced type I interferons [94]. 
However, IRAK1-deficient cells are still able to produce cytokines after TLR or IL-1R 
stimulation [130]. It was therefore assumed that other IRAK family members should be 
able to participate the production of pro-inflammatory cytokines. Macrophages derived 
from IRAK2 deficient mice showed reduced TNF-α production upon stimulation with 
multiple TLR ligands, with the exception of TLR3 [137]. Particularly, IRAK2 appears 
to be essential for sustaining TLR-mediated expression of pro-inflammatory cytokines 
at late time points [137]. However, siRNA silenced IRAK2 human PBMC severely 
reduced the TNF-α production when stimulating with TLR4 or TLR7 ligands within 30 
minutes [193]. Moreover, another study showed that IRAK2 has no impact on early or 
late TLR4-induced NF-κB activation [140]. Based on these controversial arguments, 
we would like to clarify the role of IRAK2 in TLR signalling pathway. 
3.1.2 IRAK2 can only induce NF-κB activation in HEK293 cells 
It was shown that overexpression of human IRAK2 in HEK293T cells induced NF-κB 
activation. Moreover, IRAK2 is essential for the activation of IRF3 in stably transfected 
TLR3-HEK293T cells [88]. However, overexpression human IRAK2 in HEK293T 
cells cannot drive the activation of IRF3 [88].  In order to confirm the IRAK2 
construct and further elucidate the role of IRAK2 in pro-inflammatory signalling 
pathways, dual luciferase assays were carried out with a NF-κB luciferase reporter, a 
ISG56 luciferase reporter (IRF3 activation indicator), and an AP-1 luciferase reporter 
(MAP kinase signalling pathway) See figure3.1. 
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HA-tagged human IRAK2 plasmids were introduced into pcDNA5/FRT/TO based 
expression plasmid and transfected to HEK293 cells to first analyse for the induction of 
NF-κB. Fig. 3.1 A shows that overexpression of IRAK2 strongly induced NF-κB 
activation, which confirmed that the IRAK2 construct is correct and the transfection 
was efficient. 
Additionally, either HA-tagged IRAK1 or IRAK2 or IRAK3 was transfected to the 
cells to check and compare for the IRF3 activation. The transfection of TRIF expression 
plasmids served as a positive control for IRF3 activation (figure 3.1 B). Whereas TRIF 
induced high level of ISG promoter activation, neither IRAK2 nor IRAK1 nor IRAK3 
overexpression resulted in any IRF3 activation in HEK293T cells. This observation is 
consistent with the results obtained in another lab [88] 
Subsequently, the induction of the MAPK pathway was investigated for which 
transfections of MyD88 expression plasmids served as positive control for AP-1 
activation. However, neither IRAK2 nor MyD88 could induce AP-1 activation (Figure 
3.1 C). This might due to defects in the AP-1 reporter construct or this system cannot 
work out in HEK293T cells. 
 
Figure 3.1 IRAK2 overexpression results in NF-κB activation, but not MAPK or IRF3 signaling 
in HEK293T cells. (A) Transfection of 100ng of IRAK2-HA encoding plasmids and 100ng of NF-κ B 
luciferase reporter plasmids into HEK293T cells, (B) Co-transfection of 100ng IRAK encoding 
plasmids with ISG56 luciferase reporter plasmids. (C): Transfection of 100ng of IRAK2-HA encoding 
plasmids and 100ng of AP-1 luciferase reporter plasmids. The measurements were conducted 48 hours 
post-transfection in Fluro star (BMG Labtech). Experiments were repeated three times. 
Based on the results shown above, the NF-κB reporter assay was used for further 
experiments to serve as a read-out for functionally characterizing IRAK2 and genetic 
variants of IRAK2 proteins in HEK293T cells. However, in order to decipher the 
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complex role of IRAK2 in the TLR/IL-1R signalling pathway, subsequent experiments 
focused on the reconstitution of IRAK2 knockout macrophages. 
3.1.3 IRAK2 rescued the pro-inflammatory cytokines production in macrophages  
IRAK2 has been shown to be involved in TLR2, TLR3, TLR4, TLR7/8, and TLR9 
signalling to sustain NF-κB activation at late time points [137]. Thus, the following 
experiments focused on investigating the role of IRAK2 upon stimulation with different 
TLR ligands.  
Mouse Irak2 knockout macrophage cells were kindly provided by Dr. Katherine A. 
Fitzgerald (Division of Infectious Diseases and Immunology, University of 
Massachusetts Medical School, Worcester, USA). The advantage of murine 
macrophages is that they can directly test the TLR ligand activation. However, these 
macrophage cells are not easily transfected by calcium phosphate and lipofectamine. 
Retroviral transduction is a method which can easily introduce a gene of interest into 
mitotic cells. Human IRAK2 has around 65% identity with murine Irak2. Moreover, the 
death domain (for oligomerization) and kinase domain of murine and human IRAK2 
are well conserved. We assumed that human IRAK2 possibly can rescue the signalling 
properties in TLRs signalling pathways. This method is also conducted by Dr. Nagpal 
who investigated defected mutants in MyD88 [194] and Mal [195]. 
The retroviral transduction vector pMXs-IP-puro was kindly provided by Dr. Kevin 
Micheal Dennehy. The schematic structure was described in section 2.1.9.6. The human 
N-terminal-HA tagged IRAK2 WT was introduced into pMXs-IP-puro via pacI and 
NotI restriction enzyme respectively and the successful retroviral transduction was 
selected by 10μg puromycin and confirmed by immunoblot assay (as described in 
section 2.1.9.6 and 2.3.9). Figure 3.2 A shows that HA-tagged human IRAK2 was 
expressed in the KO macrophages.  
TNF-  is one of several pro-inflammatory cytokines which is produced and secreted 
when NF-κB is activated. Therefore, mock treated and IRAK2-HA reconstituted KO 
cells were stimulated with different TLRs ligands, and the amount of TNF-  production 
was measured by ELISA (see Figure 3.2). Stimulations of TLR2 (Pam2CSK4), TLR4 
(LPS) and TLR7 (R848) resulted in moderate levels of TNF-  secretion in mock 
treated cells, which was strongly enhanced in IRAK2 reconstituted cells (Figure 3.2 B). 
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This observation is consistent with the data generated by Sinead Flannery in human 
PBMCs (Trinity College, University of Dublin, Ireland). However, TLR3 (Poly I: C), 
TLR5 (Flagellin) and TLR9 (CpG) ligands only slightly increased TNF-  secretion 
(Figure 3.2 C). Additionally, PMA and ionomycin was added to the cells; it is known 
that this treatment results in the activation of the protein kinase C (PKC) and in the 
subsequent production of pro-inflammatory cytokines. This condition therefore served 
as a positive control for TNF-  secretion. Interestingly, upon stimulation with PMA and 
ionomycin, reconstituted macrophages resulted in a 3-fold higher production of TNF-  
in comparison to mock treated cells; this may, indicate that IRAK2 is also involved in 
PKC activation. 
Conclusively, IRAK2 is demonstrated be important for TLR2, TLR4 and TLR7 
induced TNF-α production in macrophages. 
 
Figure 3.2 IRAK2 rescues TNF-α production in IRAK2 KO macrophages stimulated with TLR2, 
TLR4 and TLR7 ligands. (A) Cell lysates of human N-HA IRAK2 reconstituted macrophages or 
mock reconstituted macrophages were harvested and probed with anti-HA (rabbit) monoclonal 
antibody. (B) and (C): The 25000 cells were seeded stimulated overnight with the indicated TLR 
ligands. The amount of TNF-α in the culture supernatants was analyzed by ELISA. Stimulations with 
Pams2CSK4 (1μg/ml), PolyI:C (10μg/ml), LPS (0.05μg/ml), Flagellin (50μg/ml), R848 (1μg/ml) CpG 
(2.5mM) and PAM (10μg/ml)+ Ionomycin (1mM) The results are reported as a mean of triplicates ±
S.D. The graph is a representative of three independent experiments. 
In order to investigate the role of IRAK2 in the context of pathogenic infections, mock 
treated and IRAK2 reconstituted macrophages were treated with influenza A (PR8 
strain) and Salmonella typhimurium (strain LT2). The cellular response to these 
infectious agents was quantified by the mRNA levels for Tnf-a, Il-6, Il-1β, Ifn-β and 
Ccl5. The infection with influenza A did not induce any changes in the induction of 
pro-inflammatory cytokines and type I interferons (data was not shown). However, 
reconstituted macrophages resulted in enhanced mRNA levels for Il-1β and Il-6 upon 
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stimulation by Salmonella typhimurium (Figure 3.3) The significant induction of Tnf-a, 
Ccl5 or Ifn-β was not observed in this experimental set up.  
 
Figure 3.3 IRAK2 is critical for the pro-inflammatory response against Salmonella typhimurium.   
1.5×106 cells of mock treated and IRAK2-HA reconstituted macrophages were challenged for 3 hours 
with (A) 1 MOI and (B) 10 MOI of Salmonella typhimurium. The mRNA levels of Ifn-β, Ccl-5, Il-6, 
Il-1β and Tnf-α were determined and normalized to the unstimulated conditions. Mean+SEM. of three 
independent experiments is shown.  
3.1.4 IRAK2 enhanced the phosphorylation of p38, p65, ERK and Akt  
Previous experiments showed that the reconstitution of human IRAK2 into murine 
IRAK2 knockout macrophages can rescue the production of several pro-inflammatory 
cytokines. In order to confirm that this also involved the activation of the respective 
signalling pathways, further experiments analysed the phosphorylation of p38, p65 and 
Akt, which is a preliminary test. 
Akt, also known as protein kinase B (PKB), is a serine/threonine-specific protein kinase 
that plays a key role in multiple cellular processes such as metabolism, apoptosis, cell 
proliferation, transcription and cell migration. IRAK1 was required for IL-1β induced 
phosphorylation of the PKB signalling pathway [196]. Recently, unpublished data of 
Isabelle Bekeredjian-Ding (Institute of Microbiology, Immunology and Parasitology, 
University of Bonn, Germany) showed that IRAK4 interacted with Akt to crosslink the 
TLR with the PKB signalling pathway. Additionally, it is well known that pathogenic 
infections have an impact on the cellular metabolism. Therefore, Akt was included into 
our preliminary investigation as well. 
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The stimulation of reconstituted macrophages with Pam2CSK4, LPS and R848 
demonstrated that p38 and p65 were phosphorylated even in the absence of IRAK2 at 
low level (mock treated control). However, the phosphorylation intensity was enhanced 
in macrophages which were reconstituted with IRAK2. Interestingly, phosphorylation 
of Akt only occurred in macrophages which were reconstituted with human IRAK2. 
This might indicate that IRAK2 possibly interact with IRAK4 and then involved in the 
PKB signalling pathway (Figure 3.4).  
 
Figure 3.4 IRAK2 enhanced the activation of NF-κ B and MAP kinases signalling pathways and 
triggered the phosphorylation of Akt upon TLR stimulation. Mock and WT cells were treated with 
the indicated ligands for 30 min. Cell lysate were analysed on SDS-PAGE and by immunoblot assay to 
probe for phosphor-Akt, -p65, -p38 and –ERK, respectively. Phospho Akt experiment was repeated 
twice. The densitometry was analysed with Image J. 
If the total amount of Akt, p65, p38 and ERK are kept at same level, then we can 
assume that IRAK2 plays an important role to boost the induction of the NF-κB and 
MAP kinase signalling pathways. Furthermore, IRAK2 appears to play a unique and 
critical role in the activation of Akt. Therefore, as kinases are involved in various 
signalling pathways, further experiments focused on understanding the post-translation 
modifications in IRAK2. 
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3.1.5 Post-translational modifications in IRAK2 
Post-translational modifications are essential for proteins undergoing signal 
transduction and protein-protein interaction. Previous research demonstrated that 
IRAK1 undergoes several post-translation mofications, including phosphorylation, 
polyubiquitiantiaon and sumoylation[124]. Phosphorylated IRAK1 disassociates from 
MyD88, and induces TRAF6 activation. The polyubiquitination results in the 
degradation of IRAK1 through the 26S proteasome. Sumoylated IRAK1 translocates 
into the nucleus and induces Stat3 activation [124]. Regarding IRAK2, which is a 
serine and threonine kinase and has the similar functional structure with IRAK1, we 
assume that IRAK2 might undergo certain kinds of post-translation modifications as 
well. IRAK2 may undergo auto-phosphorylation or become phosphorylated by other 
kinases like IRAK4; these events would both cause phosphorylations on serine or 
threonine residues in IRAK2. However, this was not well characterized within current 
research. Therefore the subsequent experiments aimed to discover the pattern of 
post-translational modifications of IRAK2.  
Two-dimensional (2D) gel electrophoresis is a method which is generally applied for 
separating the whole cellular proteome according to two properties of proteins: the 
isoelectric point (IP) and the molecular weight. The first separation was conducted 
according to the different IPs .Then the second separation was performed by another 
property (molecular weight) in a direction 90 degree based on the first separation. 
Additionally, 2D gel electrophoresis also detects the post-translation modifications 
within one protein if conducted with immunoblot. 2D gel electrophoresis was chosen as 
a substantial and cost-effective method to get an overview of post-translation 
modifications in IRAK2. Phosphorylations would usually shift the isoelectric point of 
the protein to a more acidic pH range. Moreover, ubiquitination would usually increase 
the protein weight. Thus different spots will be observed in the blot if the protein 
undergoes phosphorylation or ubiquitination.  
In order to enhance the detection of post-translational modifications in IRAK2, 
HA-tagged IRAK2 WT was over-expressed into HEK293T cells. The HA-tagged 
IRAK2 were isolated and enriched by HA-immuno-precipitation. Then the enriched 
protein samples were used for 2D separation pH (3-10), followed by immunoblot 
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analysis. Additionally, the cells were transfected with an empty vector control to probe 
for unspecific spots (Figure 3.5 C).  
HA-tagged IRAK2 is predicted to have an isoelectric point of around 5.4. According to 
the literature, phosphorylation would usually shift the isoelectric point of the protein to 
a more acidic pH value. The 2D gel showed that IRAK2 mainly had isoelectric species 
in the range from pH 3 to 7 (Figure 3.5 A and D Box1). A few spots were even found to 
be beyond this range, but appear to be unspecific, since these are also detected in the 
empty vector control. Some studies indicate that IRAK family members are special 
serine/threonine kinase with additional tyrosine phosphorylation activity [121]. In 
order to analyse if IRAK2 has phosphorylations on tyrosine residues, the immunoblots 
were probed with a  -phospho-tyrosine antibody. However, no specific spots were 
detected (data not shown). 
In order to further elucidate if IRAK2 modifications in the pH range of 3-7 are due to 
auto-phosphorylation, 2D separations were conducted with the HA-tagged IRAK2 
mutant K237A. It is well known that the K237A mutation abolishes IRAK2 kinase 
functions[137]. In comparison to WT IRAK2, K237A resulted in marginal but not 
strong differences in the modification profile (Figure 3.5 A, B and D Box1). However, 
the high amount of acidic isoelectric species complicates a decent separation of the 
individual spots. The isoelectric focusing was conducted for the pH range of 3-10. 
Alternatively, separations of overexpressed HA tagged IRAK2 on a pH range from 4-7 
would help in further distinguishing the profile of mutant K273A from WT IRAK2. 
Based on the results shown here, one may conclude that the large amount of IRAK2 
WT modifications in the pH range 3-7 are not due to auto-phosphorylation events, and 
may rather imply that IRAK2 becomes modified by upstream kinases like IRAK4. 
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Figure 3.5 Profile of post-translational modifications in IRAK2. 4 μg of expression plasmids 
encoding for HA-tagged IRAK2 WT, K237A or EV were transfected into HEK293T cells. After 48 
hours, immunoprecipitations were done with an α-HA mouse monoclonal antibody. The samples were 
subjected to IEF, followed by SDS-PAGE on a 4-12% Bis-Tris gel. The immunoblot analysis was then 
done with a α-HA rabbit monoclonal antibody showing the profile for (A) IRAK2-HA WT, (B) 
IRAK2-HA K273A and (C) the EV control. (D) Comparison of the profile of EV (green), WT IRAK2 
HA (blue) and mutant K237A (red) quantified by Image J and the figure D was generated by Microsoft 
excel. Box1 shows the shift of phostphorylation sites. Box2 shows the shift of MW.   
The calculated molecular weight of IRAK2 HA is 70 kDa. Several separated spots were 
identified for IRAK2 WT, ranging from 15 kDa to 140 kDa. It seems as if IRAK2 
undergoes a certain amount of degradation. The experiments were repeated at least 3 
times, showing the same result. Of note, the immunoblot analysis probed for an HA-tag 
that was fused to the C-terminal part of IRAK2. Any sort of degradation may therefore 
first occur at the N-terminal end of IRAK2. In order to further investigate this notion, 
the same experiment was performed for N-terminal HA-tagged IRAK2. In turn, the 
degraded spots disappeared (data not shown). This may be indicative for a mechanism 
in which IRAK2 degradation is starting at the N-terminal end of the protein.  
Moreover, as one of the most well-known post-translational modifications, 
ubiquitination shifts the molecular weight of a protein to higher positions. IRAK2 WT 
does show several separated spots in the higher molecular weight range of 
approximately 140kDa (Figure 3.5 A and D Box2). Compared to IRAK2 WT, the 
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mutant K237A showed a similar pattern of separation. However, IRAK2 K237A did not 
show any higher molecular weight modifications, implicating an absence of 
poly-ubiquitination (Figure 3.5 B and D Box2). 
Having noticed that IRAK2 is likely to be phosphorylated, to further elucidate 
post-translational modifications and identity precise phosphorylation sites in IRAK2, a 
HEK293 cell line stably expressing strep-HA-tagged IRAK2 was generated. The 
expression of IRAK2 was induced by adding tetracycline. IRAK2 was purified by strep 
tag, followed by phospho enrichment (Done by Daniel Backes, a master student 
supervised by me). Then the enriched samples were used for mass spectrometry 
analysis which was conducted at the proteomics centre of Tübingen University, 
Germany. Most of IRAK2-specific peptide fragments were identified. Only one 
phosphorylation site was found in IRAK2 and the position is determined at serine 144 
which locates in the proline, serine and threonine rich region in IRAK2. (Figure 3.6) 
Possibly due to the low yield, some additionally phosphorylation sites were not 
detected. Higher amount purification of IRAK2 was performed which confirmed that 
the phosphorylation site is S144. 
 
Figure 3.6 The novel phosphorylation site in IRAK2 
In conclusion, in agreement with 2D gel analysis, one novel phosphorylation site was 
found in IRAK2. However, there might be additional phosphorylation sites and other 
post-translational modifications in IRAK2. To address those questions, higher 
quantities of purified IRAK2 are required. Future studies will also have to investigate 
the properties of S144 phosphorylation in signal transduction. 
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3.1.6 Discussion 
3.1.6.1 IRAK2 plays a central role in the TLR signalling pathway 
First, it is known that IRAK2 plays a role in the production of pro-inflammatory 
cytokines up on multiple TLR ligands stimulations [137]. So far, IRAK2 functions 
were mainly elucidated by applying TLR-ligands as stimuli on IRAK2 deficient 
macrophages or reconstituted macrophages. Similarly, this thesis investigated the 
functional properties of IRAK2 in a murine cell system of reconstituted IRAK2 
macrophages. It revealed that the agonists of TLR2, TLR4 and TLR7 induced a high 
amount of TNF-α production in a IRAK2 dependent manner. This is consistent with the 
fact that IRAK2 deficient macrophages had decreased TNF-α production which was 
observed in primary IRAK2 deficient macrophages upon stimulation with MALP-2, 
LPS and R848[137, 140]. Moreover, reduced TNF-α production was detected in human 
PBMCs which were knocked down IRAK2 and were stimulated with TLR4 and TLR7 
agonists [193].  
However, in this thesis the reconstituted IRAK2 macrophages did not elevate TNF-α 
production upon activation of TLR9 agonist. This result stands in contrast to the 
published data in which IRAK2 deficient mice are displayed to be resistant to 
TLR9-mediated septic shock[137]. Moreover, in the same study, the IRAK2 deficient 
peritoneal macrophages demonstrated decreased IL-6 and TNF-α production upon CpG 
stimulation. Therefore, it rules out that the discrepancy may be caused by differences in 
different cell types, but may rather human IRAK2 have different specificity.   
Although IRAK2 did not impact on TLR3-induced production of pro-inflammatory 
cytokines in murine macrophages, it is shown to be critical for polyI:C induced NF-κB 
activation in a HEK293T cell system that stably expressed TLR3[88]. Furthermore, in 
the same study co-immunoprecipitation assays showed that over-expression TLR3 in 
HEK293T cells results in an interaction with IRAK2 even in the absence of polyI:C 
stimulation [88]. Moreover, the poxvirus protein A52 specifically targets IRAK2 to 
inhibit NF-κB activation in all TLRs signalling pathways, which was functionally 
characterized in both to human and mouse cells [88, 197]. Altogether, these results 
therefore endorse the fact that IRAK2 is involved in TLR3 induced NF-κB activation. 
The discrepancy of IRAK2 function in TLR3 might be causes by different cell type and 
different species.  
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Conclusively, the data in this work and the current literature emphasize IRAK2 as a 
central component in the TLR signalling pathway. The functional studies reveal 
differences with regard to their response to various TLR ligands. This may be affected 
by the cell type, which was used for experiments (see Table 3.1).  IRAK2 is expressed 
universally and may therefore play distinct roles in different cell types. When 
considering all the experimental set ups, IRAK2 is found to be involved in the 
signalling pathways elicited by all the receptors of the TLR family, to integrate the 
signal in response to various pathogenic compounds. The impact on the respective 
pathway may alter between different cell types. 
Table 3.1 reported the dependency of IRAK2 in various TLRs 
Cell Type Receptors Readout IRAK2 dependency 
IRAK2 deficient 
macrophages 
TLR2,4,7,8,9 TNF-α partially decreased [137, 140] 
TLR2, IL-6 absolutely diminished [137] 
TLR4,7,8, 9 IL-6 partially decreased [137, 140] 
TLR4, TLR7 chemokines partially decreased [140] 
Human PBMC 
silenced IRAK2 
TLR4, TLR7 IL-8 decreased to basal level[193] 
TLR4, TLR7 TNF-α decreased to basal level[193] 
HEK293T 
silenced IRAK2 
TLR3, 4, 7 
NF-κB 
activation 
partially decreased [88] 
Human IRAK2 
reconstituted mouse 
Irak2 KO 
macrophages (our 
experiments) 
TLR2,4,7 
TNF-α 
(protein level) 
Strongly enhanced 
TLR2,4,7 
IL-6,IL-1β 
(mRNA level) 
Strongly enhanced 
 
Second, another controversial point is the functional involvement of IRAK2 at late time 
of NF-κB/MAP kinase activation as proposed by Kawagoe et al, 2008. IRAK2 deficient 
macrophages were generated and challenged with the TLR2 ligand MALP-2. In 
comparison to WT macrophages, experiments on IRAK2 deficient cells revealed that 
the activation of the NF-κB and MAP kinase signalling pathway was only impacted at 
later time points. This led to the notion that IRAK1 may be involved at early time points 
of the signalling pathway, whereas IRAK2 is essential in sustaining the response at late 
time points [137].  
However, the IRAK2 deficient macrophages were generated by Xiaoxia Li 
(Department of Immunology, Lerner Research Institute, Cleveland clinic, USA), 30 
minutes of LPS stimulation showed an impaired activation of MAP kinases-mediated 
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signalling [140]. Moreover, silencing the expression of IRAK2 in human PBMCs 
reduced the phosphorylation of p38 upon already after 20minutes of stimulation with 
TLR4/TLR7 agonists [193]. Also this thesis showed IRAK2 reconstituted macrophages 
enhanced the Pam2CSK4, LPS and R848-mediated NF-κB and MAP kinases activation 
within 30minutes. Interestingly, macrophages derived from the wild-derived mouse 
strain MOLF/Ei presented a quicker and higher production of IL-6 and phosphorylation 
of p105 and p38 in comparison to the classical inbred strain C57BL/6J [198]. The 
reason for these differences is a deletion in the promoter of the inhibitor Irak2c splice 
isoform found in MOLF/Ei mice, which leads to an increased ratio of pro to 
anti-inflammatory IRAK2 isoforms. Conclusively, the hypothesis that IRAK2 may 
only be involved in later time points requires further investigation. The initial 
observation of Kawagoe stands in contrast to the subsequent findings published in the 
literature (See Table 3.2). The current work rather agrees with the view that IRAK2 
mediates an immediate response to TLR agonists 
Table 3.2 The dependency of IRAK2 at early or later time point of NF-κB activation 
Cell Type Signalling Pathway 
Early time 
Point 
Later Time 
Point/ after 
4hours 
Macrophages 
 
NF-κB Yes[140] Yes[137] 
MAP kinase Yes[140] Yes[137] 
IRF3 N.D. No[137] 
Human PBMC 
 
NF-κB Yes[193] N.D. 
MAP kinase Yes[193] N.D. 
HEK293T 
 
NF-κB N.D. Yes[88] 
MAP kinase N.D. Yes[88] 
IRF3 N.D. Yes[88] 
IRAK2 reconstituted 
macrophages 
(our experiments) 
NF-κB Yes Yes   
MAP kinase Yes N.D. 
IRF3 N.D. N.D. 
 
3.1.6.2 What are the functions of human IRAK2 vs mouse IRAK2 
As known, only one splice variant of IRAK2 exist in humans while four splice variants 
of IRAK2 are in mice, namely Irak2a, Irak2b, Irak2c and Irak2d. Moreover, IRAK2 
function in mice appears to be more complicated: Irak2a and Irak2b are positive 
regulators of the NF-κB activation, while Irak2c and Irak2d are negative regulators 
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[139]. Additionally, Irak2a, b and d share the same start codon in exon 1, whereas the 
negative regulator Irak2c encompasses its own start codon in exon 4(see section 1.4.2). 
Therefore, caution is required when using the IRAK2 deficient mice as a research 
model to draw experimental conclusion on the functions of human IRAK2. 
Furthermore, the genetic background of the knock mice is needed to be considered in 
detail. For instance, Kawagoe (Osaka University) generated the Irak2 deficient mice by 
replacing exon 4, 5, and 6 of Irak2 with a neomycin-resistance cassette in the 
embryonic stem cells. This method might abrogate all of the four isoforms of IRAK2. 
However, the IRAK2 deficient mice that generated by Xiaoxia Li (Department of 
Immunology, Lerner Research Institute, Cleveland clinic, USA), have replaced 5’ 
regulatory region, exon1, and 2.1kb of intron 1 replaced with a neomycin resistance 
gene. In this approach, Irak2c may still be expressed. It is unclear if endogenous murine 
Irack2c could inhibit human IRAK2 when reconstituting into IRAK2 deficient cells. 
See figure3.7 
 
Figure 3.7 Structure of generating IRAK2 deficient mice. (A): the generating way from Kawagoe, 
replaced exon 4, 5, 6 with a neomycin-resistance cassette (adoptred from Kawagoe et al. 2008). (B): 
the way of Li generated IRAK2 deficient mice, replaced 5’ regulatory region, exon1, and 2.1kb of 
intron 1 with a neomycin resistance gene (adopted from Wan et al. 2009). 
Moreover, the protein sequence identity of human and mouse IRAK2 is only around 
65%. The degree of conservation is high in the known functional domains, such as the 
DD and the KD (see the section 1.4.2). However, a lot of differences exist in the 
non-coding region and in the ProST domain of IRAK2. These regions are poorly 
characterized in IRAK2 and they might cause some differences in the response to 
pathogens. In order to better understand the functions of human IRAK2, a human cell 
system may be more adequate for this research purpose, albeit it is more difficult to 
manipulate. Using siRNA or shRNA techniques may help us to down-regulate IRAK2 
protein expression in different cell types and this may help to characterize IRAK2 
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functions in detail. Alternatively, all from carries with hypo or hyperfunctional IRAK2 
alleles could serve as probe to study human IRAK2. See part III. 
3.1.6.3 IRAK2 plays an important role in the anti-infection response to 
Salmonella typhimurium  
Aforementioned, most IRAK2 functions were elucidated by applying TLR-ligands as 
stimuli on IRAK2 deficient macrophages or reconstituted macrophages. However, in 
our living world, many pathogens express agonists of more than one PRR, and the 
immune system must integrate signalling through multiple PRRs to specify the correct 
cytokine response [199]. What is the role of IRAK2 when the organism encounters the 
invasion of a pathogen? No pathogenic infection on reconstituted IRAK KO 
macrophages was conducted before to analyse for the production of pro-inflammatory 
cytokines and interferons.  
Our experiments showed that the mRNA expression levels of Il-6 and Il-1β were 
obviously enhanced upon infection with Salmonella typhimurium. The mRNA level of 
Tnf-α was enhanced as well but not significantly. As known, Salmonella typhimurium is 
an intracellular parasite of macrophages [200] and has several PAMPs, such as LPS, 
lipoproteins and flagellin, which are recognized by TLR4, TLR2 and TLR5 
respectively [201]. The infection with this pathogen is known to trigger the production 
of pro-inflammatory cytokines such as IL-1β and IL-6 [201]. Hence, upon infection of 
Salmonella, mRNA expression of Il-1β and Il-6 was observed, which indicated IRAK2 
plays a role in regulating Il-6 and Il-1β production in mRNA level at even early time 
points. This experiment emphasizes the role of IRAK2 as a central regulator 
downstream of the TLR signalling pathway. Especially when encountering a pathogen 
like Salmonella typhimurium, that express a variety of pathogenic patterns, IRAK2 
seems to be indispensable for induction of a pro-inflammatory response, which needs to 
be verified in infection models. 
However, no significant mRNA level of pro-inflammatory cytokines were observed 
when treating the macrophages with Influenza A. This may be due to the fact that 
different strains of Influenza A are known to have different specificities in infecting 
murine macrophages. The strain used in this thesis was the Influenza A PR8. It was 
shown that strain A/PR/8/34(PR8: H1N1) infects macrophages poorly, while the strain 
BJ×109 infects macrophages very efficiently [202]. However, PR8 has much stronger 
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abilities to infect epithelial cells [202], and which may therefore be suitable for 
investigating the role of IRAK2 in epithelial cells. 
This thesis emphasizes future experiments on the involvement of IRAK2 in certain 
disease models with careful consideration of the species and the cell type that is 
investigate, as well as the type of pathogen that is used for the study. Regarding the 
preliminary observation from Salmonella typhimurium infections in macrophages, it is 
worthwhile to further decipher the role of IRAK2 in Salmonella infected disease.    
3.1.6.4 The role of IRAK2 in addition to the conventional TLR pathway 
Surprisingly, reconstituted IRAK2 macrophages recovered for the phosphorylation of 
Akt (also called Protein kinase B (PKB)) when stimulating with Pam2CSK4, LPS and 
R848. The Akt signalling pathway is mainly involved in cell proliferation, metabolism, 
migration and metastasis. Akt becomes activated by sequential phosphorylating at 
T308 and S473 which were accomplished by PDK1 (Phosphoinositide-dependent 
kinase 1) and mTORC2 respectively [203]. 
Studies on PI3-K knockout mice support the idea that PI-3K negatively regulates TLR 
activation [204]. Moreover, primary macrophages derived from mice with conditional 
knockout of PDK1 in myeloid lineages have elevated levels of TNF-  and IL-6 mRNA. 
While immediate TLR4 activation is intact, these PDK1 deficient macrophages 
revealed prolonged ubiquitination of TRAF6 upon LPS stimulation. This indicated that 
PDK-1 may have a negative feedback on NF-κB activation in macrophages [205]. 
Interestingly, alignment of TIR domains of TLR2, 3, and 5 reveals that they all 
endowed a conserved YXXM which presents a potential PI3-K binding site [206]. 
Furthermore, it has been discovered that the TIR containing adaptor protein Mal 
directly interacts with PI3-K subunit p85  which drives phosphorylation of Akt [207]. 
Moreover, it was shown that Mal could further interact with IRAK2 upon TLR4 
stimulation [208], which might indicate IRAK2 also involved into the Akt signalling 
pathway. Strikingly, it was shown that PI3-K directly bound to the cytoplasmic domain 
of IL-1R (Try-E-X-Met) upon phosphorylation of Try479 in IRAK1 [209]. However, A 
similar experiment was done in IRAK1 deficient cells which revealed that IRAK1 is 
required for PI-3K/Akt signalling [196]. Intriguingly, co-immunoprecipitation assay 
demonstrated that IRAK2 interacts with Akt, which depends on the phosphorylation 
status of Akt. The activation of Akt decreases the binding of IRAK2 quickly. Moreover, 
 89 
a kinase defective mutant of Akt impairs IRAK2 and MyD88 dependent NF-κB 
activation which indicates that Akt may facilitate IRAK2 induced NF-κB activation 
[210]. It therefore seems as if activated PI3-K regulates TLR signalling in both positive 
and negative ways. PI3-K is believed to be a gate-keeper to control excessive innate 
immune responses and is proposed as an early event in TLR signalling[206]. 
Furthermore, a global, quantitative and kinetic analysis of the phophoproteome of 
primary macrophages was conducted to investigate kinase cascades triggered by the 
TLR4 ligand LPS on system level. The macrophages were cultured in stable isotope 
labelled amino acids (SILAC) to conduct a phosphopeptide enrichment and 
high-resolution mass spectrometry analysis. Surprisingly, the mTOR, ATM/ATR and 
Akt kinases were highlighted as hotspots in other signalling modules. In order to 
confirm that the activation of Akt is related to TLR4 activation, the pharmacological 
inhibitor of Akt was used which led to the elevated of pro-inflammatory cytokines. The 
inhibition of Akt for 15mins strongly enhanced the production of Tnf and CD69 [211]. 
 
Figure3.8 Akt pathway control of pro and anti-inflammatory cytokines production. (a) The 
negative feedback of pro-inflammatory cytokines production. (b) the positive feedback of 
pro-inflammatory cytokines production (modificated from Cahill, Rogers et al. 2011).  
Although our experiment only showed that reconstituted IRAK2 macrophages 
activated the phosphorylation of Akt which need to be further investigate on different 
cell type, especially in certain kind of cancer primary cells. Collectively, the data in this 
thesis and the recent literature described here strongly implicate a crosstalk between the 
TLR and the PI3-K signalling pathway. 
It is conceivable that when the organism faces inflammation, it should concordantly 
rhythm of the whole body. It is known that chronic inflammation might be a factor of 
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cancer. Meanwhile, the Akt signalling pathway determines cell proliferation, survival 
and growth. Interestingly, the deregulation of the Akt pathway is associated with a 
variety of human cancers, and several mouse models with activated Akt pathway 
support the role of Akt in cancer development. However, the precise relationship 
between the kinase of the IRAK family in TLRs signalling pathway and Akt is not clear 
yet. Further investigations are required to precisely determine the physiological setting 
and the molecular components that link these two pathways.  
3.1.6.5 What kind of post-translation modifications occur in IRAK2? 
It had been established that IRAK1 and IRAK4 were the only active kinases from the 
IRAK family; this was assumed because they both share an enzymatically important an 
aspartate residue in the kinase domain. IRAK4 was thought to undergo 
autophosphorylation upon the activation of TLRs. Then IRAK4 phosphorylates the 
residues T209 and T387 in IRAK1, which leads to full enzymatic acticity. Subsequently, 
several autophosphorylations occur in ProST domain of IRAK1. In comparison to 
IRAK1, IRAK2 has an asparagine residue instead of an aspartate residue. Nonetheless, 
IRAK2 has been shown to possess a kinase activity which is dependent on the residue 
K237 and found to be essential for the activation of TLR-NF-κB pathway [137, 212]. 
Whether IRAK2 is autophosphorylated or phosphorylated by other IRAKs had not 
been known yet.  
Our 2D-PAGE displayed several isoelectric species with a molecular weight of around 
70 kDa and additionally, some high molecular weight species were identified. These 
observations imply that phosphorylations and ubiquitinations occur in IRAK2. 
It was assumed that phosphorylation on IRAK2 are accomplished by IRAK1[141]. 
However, the phosphorylation of IRAK2 even occurred in IRAK1
-/Y
 macrophages 
upon MALP-2 stimulation. On the other hand, IRAK4 deficiency was shown abrogated 
the phosphorylation of IRAK2, which suggested that activated IRAK4 phosphorylated 
IRAK2, thereby inducing its enzymatic activity[137]. These results support the view 
that a certain amount of modifications in IRAK2 are accomplished by upstream 
kinases.  
However, the kinase activity of IRAK2 is essential for activation of NF-κB. It was 
shown that co-expression of IRAK1 and IRAK2 leads to the phosphorylation of IRAK2, 
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whereas co-expression of IRAK1 with an IRAK2 construct that carries the KK237AA 
mutation in the ATP-binding pocket failed to induce IRAK2 phosphorylation [141]. 
Additionally, reconstitution of IRAK2-/- macrophages with wild type IRAK2 restored 
the phosphorylation of IRAK2 in response to MALP-2, albeit reconstitution with 
K237A IRAK2 did not, which indicates that the kinase activity of IRAK2 is required 
for IRAK2 phorsphorylation[137]. These studies therefore indicated the possibility that 
the kinase activity of IRAK2 is required for inducing autophosphorylation in IRAK2. 
The results of the 2D-PAGE analysis showed a few, but not pronounced changes in the 
acidic range of the gel, when comparing the IRAK2 WT and kinase-deficient mutant. 
This may therefore suggest that the modifications observed here are not induced by 
auto-catalytic activities, but by IRAK4 or other, so far unknown. 
So far, no evidence existed that described any specific phosphorylation sites in IRAK2. 
One novel phosphorylation site S144 was found via mass spectrometry. This is the first 
study revealing a phosphorylation site in IRAK2. This phosphorylation site is located in 
the ProST domain of IRAK2, which is the linker region between DD and KD and is a 
domain rich in proline, serine and threonine residues. However, the precise functions of 
ProST domain are not clear yet. It was shown that the proline/serine/threonine rich 
region in the class II transactivator (CIITA) is very important for transcriptional 
activities by mediating protein-protein interactions [213, 214]. Interestingly, it was 
revealed that phosphorylation in ProST domain of IRAK1 is very important to induce 
IRAK1 conformation change and disassociate from Myddosome complex and further 
inducing the downstream activation [215]. Similarly, IRAK2 needs to disassociate from 
the Myddosome complex as well, whether the phosphorylation of S144 encompasses 
the same function which needs to be further delineate.  
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3.2 Part II: IRAK2 plays a central role in the Myddosome formation 
3.2.1 Introduction 
The aim of part II was to elucidate the extent role of IRAK2 in the Myddsome structure. 
The crystal structure of Myddosome was proposed by Lin et al in 2010. The multimeric 
macrocomplex consists of death domains of 6×Myd88-4×IRAK4-4×IRAK2 death 
domain complex. The stable crystal structure of Myddosome was generated by 
recombinant expression and purification of the proteins in Escherichia coli. Therefore, 
three questions arise: (1) Can the Myddosome be formed in the mammalian cells? (2) 
Can the FL protein also form multimers? (3) Can IRAK2 further interact with IRAK1 
or IRAK3 (the two remaining members in the IRAK family, whose positions in the 
Myddosome are unclear). This part will address these three questions and will focus on 
the central role of IRAK2 in mediating the interaction between MyD88 and IRAK 
family members 
3.2.2 Results 
3.2.2.1 Gene expression and signalling properties of IRAK2 construct. 
As described in section 2.1.9.3, the human IRAK2 (Imagenes: IRCMP5012D0935D) 
gene encode plasmid was inserted into pENTRI1A backbone. Furthermore, IRAK2 
(full length) FL or DD was introduced into pcDNA5/FRT/TO-based expression 
plasmid to add an N- or C-terminal Strep-HA-tag (T. Bürckstümmer, CeMM, Vienna). 
Additionally, to compare with IRAK1or IRAK3, the FL or DD version of IRAK1 and 
IRAK3 were introduced into pcDNA5/FRT/TO-based expression plasmid as well.  
The gene expression of IRAK1, 2 and 3 FL and DD HA-tagged proteins was detected 
by overexpressing each construct in the mammalian cell line HEK293T. After 48 hours 
of transfection, cell lysates were applied for SDS-PAGE and immunoblot analysis. . 
Figure3.1 confirmed that all of the genes, which are encoded by the plasmids, are 
expressed. The FL IRAK1, 2 and 3 proteins have a similar molecular weight of around 
80kDa, 70 kDa and 70 kDa, respectively, while the DD of IRAK1, 2 and 3 have a 
molecular weight of around 12 kDa.  
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Figure 3.9 IRAK1,2,3 FL and DD genes expression. Cell lysate from overexpressed IRAK1FL (lane 
1), IRAK1DD (lane2), IRAK3FL (lane 3), IRAK3DD (lane4), IRAK2FL (lane5), IRAK2DD (lane6) 
are shown in the immunoblot. Proteins were separated on a 10% Tris-Glycine gel and immunobloted 
with an anti-HA antibody (rabbit). IRAK2FL and DD expression assays were done separately. 
Results showed that the expression level of the IRAK1DD was relatively low. In order 
to confirm the expression of IRAK1DD, SDS-PAGE was conducted for cell debris of 
the lysate as well. It demonstrated that the protein is expressed and mostly retained in 
the cellular debris after lysing the cells under the buffer conditions described in buffer1 
(Data was not shown). Thus, several different lysis buffers (lysis buffer2 and passive 
lysis buffer from Promega) were applied to improve the extraction of the IRAK1DD. 
However, the applied lysis buffers were still not efficient enough to extract all of the 
IRAK1DD proteins. Nonetheless, the IRAK1DD protein expression level was 
comparable to IRAK1FL. 
Since the gene expression level of all proteins constructs seemed to comparable, 
subsequent studies on the signaling properties of each constructs were conducted in 
HEK293T as well. Although HEK293T cells do not express all TLRs, all necessary 
proteins downstream of the receptor are expressed, which facilitates the 
over-expression analysis of IRAKs in terms of NF-κB activation[141]. In order to 
analyze the signaling features of each construct, three different doses for each plasmid 
were transfected into the HEK293T cell line. Additionally, 100ng of NF-κB reporter 
and 10ng of the Renilla-luciferase encoding plasmids were transfected into each 
condition to perform a dual luciferase assay (Figure 3.10 A, B, C.) The measurement 
showed that IRAK1, 2, 3 FL encoding plasmids all induced NF-κB activation in a 
dose-dependent manner. The IRAK1 and IRAK3 DD induced NF-κB activation as well, 
IRAK1DD induced NF-κB activation at the same extent as FL IRAK1. On the other 
hand, IRAK3DD only slightly reduced the activation of NF-κB in comparison to its FL 
protein. Interestingly, IRAK2 DD could not trigger any NF-κB activation.  
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Figure 3.10 NF-κB signaling assay of IRAK1, 2, 3 FL and DD constructs. HEK293TT cells were 
transfected with 100ng NF-κB-luciferase reporter plasmids and 10ng renilla Renilla luciferase 
expressing control plasmids and the indicated amounts of the IRAK encoding plasmids,. (a) IRAK1 FL 
and DD; (b) IRAK2 FL and DD; (c) IRAK3 FL and DD. 
Thus, it indicates that the kinase activity of IRAK2 plays an essential role of NF-κB 
activation.The Myddosome structure suggests that IRAK2 can stably interact with 
IRAK4. Therefore, LUMIER experiments were carried out to test whether the 
Myddosome structure exists in mammalian cell lines. 
 3.2.2.2 IRAK2DD strongly interacts with IRAKs DD 
IRAK1, 2, 3 and 4 FLs and DDs were introduced individually into a 
pT-Rex-Dest30-based expression plasmid containing N- or C-terminal Renilla or 
Protein A tags via LR reaction (see section 2.1.10.4). The genes expression levels were 
confirmed as well (Data was not shown). Since Renilla- and ProteinA-tags are 
relatively high molecular weight fusion tags, the protein function may be affected by 
these fusion constructs. Therefore those constructs were transfected into HEK293T 
cells to perform an NF-κB dual lucifease assay as well. The measurement revealed that 
these fusion proteins were able to induce signaling which was similar to the results 
obtained from HA tagged proteins (Data was not shown). 
Given the fact that the IRAK2DD directly forms the third layer of the Myddosome by 
interacting with the IRAK4DD, the position of IRAK1 and IRAK3 are not known yest. 
Then the LUMIER method was applied to test for the interaction of the IRAK2DD with 
the other IRAKs DDs (IRAK1 and IRAK3) in mammalian cells. The advantage of the 
LUMIER is that it can provide relative interaction intensities for proteins of interest in a 
high throughput assay, which co-immunoprecipitation assay hardly can quantify the 
relative interaction intensity. In order to get an overview of IRAK2 DD interactions 
with MyD88DD and other IRAKs DDs, 20ng of Renilla-tagged IRAK2DD encoding 
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plasmids were co-transfected with 20ng of Protein-A tagged MyD88DD or other IRAK 
DD encoding plasmids into HEK293T cells. The transcription factor subunits Jun and 
Fos are known to strongly interact with each other [190]. Additionally, generally a 
luminescence intensity ratio above 3 is considered a significant interaction [190].  
Thus, Protein-A tagged Jun and Renilla-tagged Fos were co-transfected and served as a 
positive control for a protein interaction. In order to confirm that the LUMIER system 
can assess the interaction properties of the IRAK2DD, IRAK4DD interactions with 
MyD88DD and IRAK2DD were carried out (Figure 3.11A). Figure 3.11.A shows that 
IRAK4DD strongly interacted with MyD88DD and IRAK2DD, implying that a 
Myddosome structure can be formed in HEK293T cells, and that the LUMIER method 
is reliable at capturing Myddosome interactions. It is described that IRAK4DD 
possesses very specific affinities. Regarding the possibility that IRAK2 may associate 
with MyD88 or Mal, IRAKsDDs interactions with MyD88DD were performed as well. 
Figure 3.11 B shows that only MyD88 has a stronger interaction with IRAK4DD. These 
results therefore demonstrate that the formation of the Myddosome structure is of 
highly sequential and specific nature.  
Subsequently, the interaction between IRAK4DD and IRAK1DD/IRAK3DD was 
analysed. However, the interaction intensity between IRK4DD and IRAK1DD or 
IRAK3DD is very weak. Since IRAK2DD forms the third layer of Myddosome, 
subsequent analyses addressed the questions if it can recruit other IRAKs as well. The 
results reveal that IRAK2DD strongly interacted with IRAK4DD. Figure 3.11 C 
Additionally, IRAK2DD interacted with IRAK1DD, IRAK3 DD and its own DD. 
Clearly, IRAK2DD can mediate interaction between Myddosome and IRAK1DDs or 
IRAK3DDs. This means that IRAK1 and IRAK3 were no be directly recruited to 
IRAK4 but via IRAK2 (see section 3.2.2.4). However, the DD of IRAKs naturally does 
not solely exist in the cytosol. Furthermore, experiments on the full-length proteins 
were conducted since kinase domains of IRAKs affect signalling (see figure 3.10 and 
[155] ) and may interfere with the interactions of IRAK2 and the other IRAKs. 
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Figure 3.11 IRAK2DD interacts with all IRAKs DDs. (a) IRAK4D( I4DD) interactions with rest 
IRAKs DDs; Renilla tagged IRAK4DD co-transfected with protein A tagged IRAK1DD(I1DD) or 
IRAK2DD(I2DD) or IRAK3DD(I3DD) or MyD88DD into HEK293T cells; (b) MyD88DD 
interactions with IRAKs DDs; protein tagged MyD88 co-transfected with Renilla-tagged I1DD or 
I2DD or I3DD or I4DD into HEK293TT cells; (c) I2DD interactions with IRAKs DDs. Renilla tagged 
I2DD co-transfected with protein-A tagged I1DD or I2DD or I3DD or I4DD into HEK293TT cells. 
ILUMIER luciferase readout was performed at the TECAN infinity200 48 hours post-transfection. 
Jun-proteinA and Fos-renilla served as positive controls. 
3.2.2.3 Full length IRAK2 interacts with Full length IRAKs. 
According to the procedure described above, 20ng of Renilla-tagged FL IRAK2 and 
Protein-A-tagged FL IRAK1, 2, 3, 4 encoding plasmids were individually 
co-transfected into HEK293T cells. The analysis confirmed that DDs interactions do 
occur. As shown in Figure 3.12, FL IRAK2 still maintained interaction with FL IRAK1, 
IRAK2, IRAK3 and IRAK4(Figure 3.12C). IRAK2 had a high affinity to IRAK4. 
Consistent with the IRAK4 DD interactions, IRAK4 FL preferred to recruit IRAK2 FL 
and MyD88 FL as well. Figure 3.12 A.  
Direct interactions between IRAK2DD and MyD88DD were not detectable when 
overexpressing the respective protein constructs. In order to investigate if the kinase 
domain of IRAK2 may be important for associations with MyD88FL, MyD88FL 
interactions with FL IRAKs were carried out. As expected, MyD88FL interacted with 
IRAK4FL. However, no interactions between IRAK2FL and MyD88FL were detected. 
Figure3.12 B. 
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Figure3.12 IRAK2FL interacts with all FL of IRAKs. (a) HEK293T cells were transfected with 
Renilla tagged IRAK4 either with protein A tagged IRAK1, 2, 3, or MyD88 respectively. (b) 
HEK293T cells were transfected with each Renilla tagged IRAKs together with Protein A tagged 
MyD88. (c) HEK293T cells were transfected with Renilla tagged IRAK2 with protein A tagged each 
IRAKs individually. The luminescence was measured in fluro star. 
All in all, compared with the DDs interaction, the interaction affinities of the full-length 
proteins were lower. Interestingly, IRAK2 interaction with MAL was reported before 
(1997). However, no interaction was found in this experiment. (Data was not shown.).  
3.2.2.4 IRAK2 bridges the interaction between IRAK4 and IRAK1/3. 
It was shown that IRAK4 is the first kinase that is recruited to MyD88 upon activation 
of TLRs. IRAK4 subsequently undergoes autophosphorylation and phosphorylates 
IRAK1. It was assumed that IRAK4 interacts with IRAK1. However, Lin et al. failed to 
generate the crystal structure of MyD88-IRAK4-IRAK1 DDs complex[86] and the 
measurement of LUMIER did not show any interaction between IRAK4 and IRAK1 or 
IRAK3. Due to the fact that IRAK2 interacts with each IRAK, it is conceivable that 
IRAK2 may bridge the interaction between IRAK4 and IRAK1 or IRAK3. Therefore, 
20ng of HA-tagged IRAK2 (or HA-tagged IRAK3 served as a control, HA tag cannot 
be purified by the IgG Dynabeads M-280 (Invitrogen) with either 20ng of Protein-A 
tagged IRAK1 or IRAK3, and 20ng of Renilla-tagged IRAK4 were co-transfected into 
HEK293T cells. After 48hours, the relative interaction intensity was measured and the 
results revealed that IRAK2 increases the interaction between IRAK4 and IRAK1 or 
IRAK3 (Figure 3.13). In order to investigate whether the kinase domain of IRAK2 is 
crucial to mediate the interactions between IRAK4 and IRAK1/IRAK3, FL and DD 
constructs of IRAK2 (control IRAK3) were tested separately. Figure 3.13 A shows that 
the presence of the IRAK2 DD helped in enhancing the interaction between IRAK4DD 
and IRAK1DD and IRAK3DD; the increase of interaction efficiency is 2-3 fold higher 
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than in the empty vector control. This was similarly observed when adding FL IRAK2 
instead of IRAK2DD (see Figure 3.13 B). However, when analysing the situation for 
the FL IRAK proteins, IRAK2FL only induced a marginal increase of an interaction 
between FL IRAK4 and IRAK1/IRAK3 (Fig 3.13 C). The effects were specifically 
observed when co-transfecting IRAK2, but were not detectable when applying IRAK3 
DD or FL constructs. In conclusion, the assays support the notion that IRAK2 plays a 
central role in mediating the interaction between IRAKs 
 
Figure3.13: IRAK2 bridges the interaction between IRAK4 and IRAK1/IRAK3. 
(a,b)Renilla-tagged IRAK4DD and ProteinA tagged IRAK1DD or IRAK3DD were transfected into 
HEK293T cells. (a)Additionally, HA-tagged IRAK2DD or IRAK3DD or empty vector was 
co-transfected for each condition. (b)HA-tagged IRAKFL or IRAK3FL or empty vector was 
co-transfected for each condition. (c) Renilla-tagged IRAK4FL and ProteinA tagged IRAK1FL or 
IRAK3FL were transfected into HEK293T cells. Additionally, HA-tagged IRAKFL or IRAK3FL or 
empty vector was co-transfected for each condition. 
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3.2.3 Discussion 
3.2.3.1 IRAK2 plays a central role in the Myddosome formation. 
The crystal structure of the Myddosome consists of six MyD88, four IRAK4 and four 
IRAK2DDs which form a left-handed helix. It revealed that the assembly of this 
complex follows a hierarchical and sequential process, in which the sequential 
recruitment of each DD increases the stability of the complex [154, 216]. 
Complementarity in charge and shape between the bottom and top surfaces of the DDs 
are involved in the formation of this multimeric assembly. For example, the bottom 
surface of IRAK4 matches well with the top surface of MyD88 both in charge and 
shape complementarity. IRAK2 is only recruited to the complex when IRAK4 is 
present because the bottom surface of IRAK2 matches well with the top surface of 
IRAK4 both in charge and shape complementarity[86]. See figure 3.14.   
 
Figure 3.14 The charge and shape complementarity in MyD88-IRAK4-IRAK2 interaction. 
(Modified from Lin, Lo et al. 2010) 
The results of this thesis show that MyD88 preferentially interacted with IRAK4, and 
that within the IRAK family, IRAK2 preferentially interacted with IRAK4. In 
comparison to all the other DD containing proteins involved in the TLR pathway, 
IRAK4 preferentially interacted with IRAK2 and MyD88. This phenomenon was 
observed for the DD proteins alone, but also in the context of the FL proteins.These 
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results are consistent with the formation of Myddosome structure and endorse the view 
that upon signal activation MyD88 first recruits IRAK4, which then interacts with 
IRAK2.  
According to the current literature, IRAK2 and IRAK1 are described to fulfil redundant 
roles. It is believed that IRAK1 would similarly function downstream of IRAK4 and 
that it may be incorporated into the Myddosome in a way as it has been demonstrated 
for IRAK2 (see figure introduction). This notion is emphasized by finding in which 
IRAK1 lost its phosphorylation in the IRAK4 deficient macrophages [137]. 
Furthermore, IRAK1 was shown to be phosphorylated in the absence of IRAK2 [137]. 
However, in our LUMIER experiments no interaction was observed between IRAK4 
and IRAK1. Opposed to the current view, this data implies that the formation of the 
Myddosome is of a different nature in the case of IRAK1. Co-immunoprecipitatetion 
assays showed that IRAK1 interacted with IRAK4 in macrophages upon stimulation of 
MALP-2 for 1.5 hours but this could be indirect. In the same study, IRAK2 is 
demonstrated to maintain the interaction with IRAK4 for 8 hours[137]. Furthermore, it 
is known that IRAK1 associated with Pin1 which is a prolyl isomerise and catalyses the 
conversion of specific phosphorylated motifs. The activity of Pin1 leads to a 
conformation change in the phosphorylated form of IRAK1, which might be an 
important step for IRAK1 to disassociate from the Myddosome complex [215]. 
However, any association between IRAK2 and Pin1 was not found which might explain 
why IRAK2 keeps its association within the Myddosome complex [215]. All of these 
data indicated that the interaction between IRAK1 and IRAK4 is of transient nature, 
while the interaction between IRAK2 and IRAK4 is stable.  
The functional impact of IRAK3 on the signalling and the formation of the Myddosome 
remain also controversial. IRAK3 was initially described to be a negative regulator in 
TLR-NF-κB signalling pathway [87]. It was shown that IL-12 and IL-8 production 
were increased in the IRAK3 deficient macrophages upon stimulation of multiple TLR 
ligands. However, the overexpression study in HEK293 cells showed that IRAK3 is 
capable of inducing a NF-κB dependent response. This was observed for the FL protein 
but also in the context of the IRAK3DD proteins. The functions discrepancy of IRAK3 
might due to cell type and different species. 
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Figure 3.15 IRAK family involved in the TLR signalling pathway.(modified from Lin, Lo et al. 
2010) A model of the TLR signalling complex that recruits the MyD88–IRAK4–IRAK2 complex with 
proteins drawn to scale. TLRs, cyan and green (PDB code 3FXI for the extracellular domain of TLR4 
and PDB code 2J67 for the TIR domain of TLR10). MD2, yellow and magenta (PDB code 3FXI 
incomplex TLR4). Orange, MyD88–IRAK4–IRAK2complex. Red, IRAK4 kinase domain (PDB 
code2NRU). Blue, IRAK2 kinase domain using that of IRAK4. 
Regarding the Myddosome formation, it is assumed that IRAK3 prevented IRAK2 or 
IRAK1 from dissociating from the Myddosome complex by interacting with 
IRAK2[86]. In fact, interactions between IRAK4 and IRAK3 were not detected in the 
LUMIER experiment, whereas IRAK3 strongly interacted with IRAK2. Interestingly, 
the over-expression of IRAK2 enhanced the interaction between IRAK4 and 
IRAK1/IRAK3. This data supports the view that the whole signalling multimeric 
complex of Myddosome is stabilized and strongly dependent on IRAK2. It is 
conceivable that the observed signalling functions of IRAK3 are an artefact of the 
overexpression of IRAK3, and may be severely reduced when having the other IRAK 
members expressed at similar levels. Unfortunately, the NF-κB activation was not 
measured for conditions in which IRAKs were co-expressed with IRAK3. This kind of 
study might provide us more information about the functions of IRAK3 and may 
further clarify the supposedly negative regulation of IRAK3. Additionally, it is 
conceivable that using siRNA of IRAK3 knockdown endogenous IRAK3 of different 
cell type might help us understand the role of IRAK3.  
In conclusion, these studies imply that the Myddosome formation is subjected to highly 
regulatory mechanisms that determine assembly and disassembly of the complex. 
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Further experimental studies on the cellular formation of the Myddosome are required 
to identify the molecular factors and physiological conditions that determine the 
IRAK1 or IRAK2 dependent Myddosome formation and the involvement of IRAK3.  
3.2.3.2 The IRAK FL proteins adjust for the proper interaction intensity within 
the Myddosome. 
The study on the DD and FL interactions showed that DD interactions are generally 
stronger than FL interactions. However, in comparison to the DD proteins, the FL 
proteins are capable of inducing stronger transduction of the signalling pathway [155]. 
For example, the relative interaction intensity of the MyD88DD-MyD88DD 
homodimer is shown to be 10 fold higher than for MyD88FL proteins. However, the 
same amount of MyD88FL induced stronger activation of NF-κB than MyD88DD 
alone [155].This tendency was similarly observed in the experiments of this thesis. 
Interactions of IRAK4DD with IRAK2DD reached a value of up to 150, whereas 
IRAK4FL and IRAK2 FL interactions only reached a value of 40. Similarly, IRAK2 
interactions with IRAK3 were strongly increased for the DD proteins alone. However, 
the highest induction of the signalling pathway was only observed for IRAK2 FL and 
IRAK3 FL, respectively. The Myddosome structure should represent a flexible 
multimer formation, which allows for the quick assembly and disassembly of the 
complex. The DD domains alone can hold up a strong association of the complex, 
whereas the respective kinase domains disrupt this rigid assembly to thus allow for the 
engagement of activated IRAKs with further downstream signalling components. The 
downstream actions involve for instance the interaction of IRAK2 with TRAF6. 
Additionally, Myddosome interactions are shown to bring the kinase domains and the 
ProST domains of IRAKs into proximity for phosphorylation and activation of IRAKs 
[86, 119]. The phosphorylation in the ProST domain of IRAK1 then facilitates its 
dissociation from MyD88 to further induce IRF7 activation [215].  
In agreement with the study of Lin et al (2010), these data support the model in which 
Myddosome is a sequential assembly of DD containing proteins. In an unstimulated 
case MyD88 and IRAK proteins may be randomly found in the cell (Figure 3.16 A). As 
soon as stimulations occur, MyD88 first activates IRAK4 (Figure 3.16 B), this in turn 
leads to strong complex formation with IRAK2. Then IRAK2 recruited IRAK1 and 
mediated the interaction between IRAK1 and IRAK4, which results in the 
phosphorylation of IRAK1 (Figure3.16 C). Finally, modified IRAK1disassociates from 
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the Myddosome complex and induces the subsequent activation. However, the 
modified IRAK2 still keeps the interaction with IRAK4 to recruit TRAF6 and further 
induce the ubiquitination of TRAF6 (Figure3.16 D). Ultimately, the ubiquitinationed 
TRAF6 further interacted with downstream partner and induce NF-κB activation. 
When IRAK2 cannot be full modified, although it can still interact with TRAF6, the 
ubiquitination level of TRAF6 will be impaired (See section 3.3.2.5).   
 
Figure 3.16 The schematic diagram of sequential assembly and disassembly in Myddosome 
structure. (A) The situation in the absence of any stimulation (B) the homo/oligomerisation of MyD88 
recruits IRAK4 to the assembly by homotypic DD interaction. This induces IRAK4 autophosporylation. 
(C) Autophosphorylated IRAK4 recruits IRAK2 by homotypic DD interactions to induce 
phosphorylation of IRAK2. Then phosphorylated IRAK2 recruited IRAK1 and bridge the interaction 
between IRAK4 and IRAK1. Finally, IRAK1 was fully activated by IRAK4. (D) Activated IRAK1 
dissociate from the complex to transduce further downstream signaling. However, IRAK2 still keeps 
the interaction with IRAK4 and further recruited TRAF6 and induce the ubiquitination level of TRAF6. 
Yellow star indicates the autophosphorylation site. P indicates phosphorylation. 
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3.3 Part III: IRAK2 genetic variants R214G and L392V reduced TLR 
dependent signalling 
3.3.1 Introduction 
The aim of this part was to identify functionally interesting the non-synonymous single 
nucleotide polymorphisms (SNPs) of IRAK1, 2, and 3, by using a HEK based NF-κB 
screening assay. The mechanistic differences between WT and SNPs were investigated 
by biochemical and molecular biological methods. Meanwhile, the functionally 
interesting SNPs were genotyped in clinically relevant epidemiological studies to 
discover the causal relationship between the SNP and certain kinds of diseases. 
According to at least one of the following three criteria, SNPs were chosen for further 
epidemiological and functional studies: 1) The SNP should occur in the human 
population with a verified frequency of at least>0.0005; 2) The SNP should be 
non-synonymous (i.e. affected amino acid) and occur within a functional domain of 
IRAK. 3) The affected amino acid should have a certain degree of conservation within 
the IRAK family. Thus, 3, 12 and 5 SNPs were selected for the research on IRAK1, 
IRAK2 and IRAK3 respectively. The information on the IRAK SNPs was acquired 
from the NCBI SNP database in the year 2009 (See figure 3.17 and Table 3.3). Two 
SNPs of IRAK2 need to be further specified: R498G (rs7513222) was initially listed 
with a frequency of 0.08 in the NCBI SNP database, but it was recently removed for an 
unknown reason; no frequency is reported for L78M (rs11709928), but the degree of 
conservation is very high among the IRAKs family members. Thus, both SNPs were 
still chosen for the study. See figure 3.17 
Additionally, IRAK4 was well investigated and the structure of IRAK4 was published. 
Hence, the SNPs of IRAK4 were not included into our study.  
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Figure 3.17 SNPs in human IRAK1, IRAK2 and IRAK3. (a) Three SNPs of IRAK1 were studied, 
T113I and R194H are located in the ProST domain (white box) and C203S is located in the kinase 
domain (black box). (b) Twelve SNPs of IRAK2 were analysed: R43Q, S47Y and L78M are located in 
the death domain (gray box); I99V is located in the ProST domain (white box); R214G, L358M, L392V, 
D431E and L439V are located in the kinase domain (black box); R498G, E501G and L503I are located 
in the C-terminal TRAF6 binding domain (white box).(c) Five SNPs of IRAK3 were analysed, H57R is 
located in the death domain(gray box); T129R is located in the ProST domain (white box), I171V and 
Y180X are located in the kinase domain(black box). Additionally, the invariant lysine, the ATP 
gatekeeper tyrosine and the TRAF6 binding motif are indicated in each IRAK protein. 
To date, no comprehensive studies were conducted to elucidate how the mechanism of 
genetic variants in IRAK1, 2 and 3 affects the human health. Therefore, molecular 
studies were first performed for selected SNPs in IRAK1, 2 and 3. Furthermore, an 
epidemiological analysis was carried out for the functionally relevant SNPs to then 
identify the causal relationship between genetic variants and certain diseases. 
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Table 3.3 Frequency information of selected non-synonymous SNPs in humanIRAK2. The SNPs information was derived from the NCBI SNP database. The SNPs were 
discovered in the Halotype Map (HapMap) project which focused on an Asian and European population and in an Exome sequencing project (ESP) cohort study which 
focused on the American population. 
Amino 
acid 
change 
rs Number 
Exon 
position 
Codon 
change 
Location in 
protein 
structure 
3D MAF Source Population Evidence 
T113I rs11465829 3 ACC ⇒ ATC ProST No 0.0012 IIPGA-WEISS-MARTINEZ African American/European n/a 
R194H rs11465830 5 CGC ⇒ CAC ProST No 0.0115 ESP_cohort populations American n/a 
C203S rs10127175 6 TGT ⇒ AGT ProST No 0.0157 HapMap/ESP_cohort populations European/ Asian/American Yes 
R43Q rs34945585 2 CGG ⇒ CAG DD Yes 0.0005 ESP_cohort populations American n/a 
S47Y rs11465864 2 TCC ⇒ TAC DD Yes 0.0101 HapMap/ESP_cohort populations European/ Asian/American n/a 
L78M rs11709928 2 CTG ⇒ ATG DD Yes 
 
n/a n/a n/a 
I99V rs55898544 3 ATC ⇒ GTC ProST Yes 0.011 ESP_cohort populations American n/a 
R214G rs35060588 5 CGC ⇒ GGC KD No 0.0408 ESP_cohort populations American n/a 
L358M rs77590560 9 CTG ⇒ ATG KD No 0.0118 ESP_cohort populations American n/a 
L392V rs3844283 9 CTG ⇒ GTG KD No 0.3036 HapMap/ESP_cohort populations European/ Asian/American n/a 
D431E rs708035 11 GAT ⇒ GAA KD No 0.2115 HapMap Asian n/a 
L439V rs11465927 11 CTC ⇒ GTC KD No 0.0156 HapMap/ESP_cohort populations European/ Asian/American n/a 
R498G rs75132222 12 GCT ⇒GGT C-terminus No 0.08 ESP_cohort populations American n/a 
E501G rs12486661 12 GAG ⇒ GGG C-terminus No 0.0014 ESP_cohort populations American n/a 
L503I rs9854688 12 CTC ⇒ ATC C-terminus No 0.0334 HapMap/ESP_cohort populations European/ Asian/American n/a 
H57R rs35239505 2 CAT ⇒CGT DD No 0.009 HapMap Asian/European n/a 
T129R rs76652915 4 ACA ⇒AGA DD No 0.255 HapMap Asian/European n/a 
I171V rs34682166 5 ATT ⇒GTT ProST No 0.191 HapMap Asian/European n/a 
Y180X rs76408141 5 TAC ⇒TAA KD No 0.022 HapMap East Asian CHB+JPT n/a 
S288L rs35574245 8 TCG ⇒TTG KD No 0.087 HapMap Asian/European n/a 
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3.3.2 Results 
3.3.2.1 Functional studies of genetic variants in IRAKs in a HEK293T cell system 
As presented in section 2.1.2 and 2.1.10, the selected SNPs of human IRAK1, 2 and 3 
were introduced into Gateway-compatible plasmid constructs of IRAK1, 2 and 3 as 
mutants by site-directed mutagenesis. Therefore, the non-synonymous variants of 
IRAK proteins are referred to as mutants in this part of results. The IRAK mutants were 
shuttled into a pcDNA5/FRT/TO-based expression plasmid to add an N- or C-terminal 
Strep-HA-tag. 
The gene expression of the IRAK1, 2 and 3 mutants was determined by transfecting the 
respective plasmid into HEK293T cells. 48 hours post-transfection, cell lysates were 
applied to SDS-PAGE and immunoblot analysis. In order to control for loading errors, 
β-tubulin served as a loading control. Additionally, the transfection of the 
pcDNA5/FRT/TO empty vector served as a negative control. See figure 3.18.  
 
Figure 3.18 Gene expression of IRAK mutants. 100ng of IRAK-encoding plasmids were transfected 
into HEK293T cells, cell lysates were harvest after 48 hours of transfection and (A) separated on a 4-12% 
Bis-Tris gradient gel for IRAK1 proteins, or (B) and (C) analysed on a 3-8% Tris-Acetate gel for 
IRAK3(B), 2(C) mutants, respectively.  An immunoblot analysis was performed probing for the HA 
tag with an anti-HA (rabbit, upper panel) or an anti-tubulin (mouse, lower panel) antibody. The 
expression analysis was repeated at least twice for each IRAK mutant. 
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The molecular weight of IRAK1, 2 and 3 is around 80kDa, 70kDa, 70kDa, respectively. 
The analysis confirmed that the expression of all IRAK mutants is at a similar level 
with the respective WT protein. One special case of mutant Y180X of IRAK3, no HA 
tag was observed in immunoblot which indicated the expression of Y180X is correct, 
because the HA tag is added in the C-terminal of this protein and the mutation X 
generated a stop codon at Y180 residue. Thus, the C-terminal HA tag cannot be 
expressed. Then, the subsequent studies then focused on analysing the signalling 
functions of these mutants in terms of NF-κB activation. 
3.3.2.2 Seven SNPs in IRAK2 alter NF-κB activation in HEK293T cells 
As described in section 3.10, over-expression of IRAK1, 2 and 3 proteins in HEK293T 
cells can induce NF-κB activation. Hence, an NF-κB dual luciferase assay was carried 
out to compare the signalling ability of the IRAK mutants with the respective WT 
protein. Figure 3.3.2 displays a dose-dependent induction of NF-κB activation when 
transfecting increasing amounts of the IRAK WT plasmids.  
In Comparison to IRAK1 WT, T113I, R194H and C203S did not show any significant 
differences. Therefore, no further studies were carried to analyse the impact of these 
SNPs in IRAK1 (Figure 3.19 A). 
Similarly, most of the IRAK3 mutants did not show any significant differences in 
comparison to WT protein. However, the nonsense mutants Y180X reduced NF-κB 
activation dramatically (Figure 3.19 B).  Since the stop mutation (X) in Y180 residue 
generated a truncated version of IRAK3 which lacked the kinase domain and 
C-terminal TRAF6 binding domain. The putative invariant lysine residue is located at 
192. Overexpression the mutation K192A cannot induce any NF-κB activation which 
indicates the K192 is critical for the kinase activity of IRAK3 (see in Appendix). Thus, 
the truncated version Y180X is deficient of the invariant lysine which cannot induce 
NF-κB activation consequently. However, the frequency of Y180X is very low in the 
human population, and has only been reported in an Asian cohort study. Hence, no 
further study was performed to investigate on IRAK3 SNPs  
Interestingly, compared to IRAK2 WT, R43Q, R214G, L392V, A498G and L503I 
showed reduced NF-κB activation while S47Y and L78M significantly enhanced 
NF-κB activation. The remaining SNPs maintained approximately the same amount of 
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signalling as quantified for IRAK2 WT. Additionally, K237A and E528A mutants were 
generated and analysed in parallel, as these mutants are known to completely abolished 
NF-κB activation as observed by Sinead Keating in 2007 (Data was shown in the 
Appendix). In conclusion, seven out of twelve SNPs in IRAK2 alter NF-κB activation. 
Hence, further studies focused on these seven SNPs in IRAK2 (see figure 3.19 C).   
 
Figure 3.19 NF-κB activation analysis of SNPs in IRAK1, 2 and 3. Different doses of HA-tagged 
IRAK encoding plasmids, 100ng of theNF-κB firefly reporter plasmids and 10ng of the Renilla reporter 
plasmids were transfected into HEK293T cells. The total DNA amount was kept constant and by 
titrating the required amount of the empty vector into the transfection mixture. The NF-κB reporter 
activity was measured after 48 hours post-transfection. This experiment was repeated at least 3 times. 
The statistical analysis was performed by a Two-Way ANOVA. 
The activation of NF-κB is known to produce several kinds of pro-inflammatory 
cytokines and chemokines such as TNF-α, IL-6 and IL-8. In turn, the production of the 
pro-inflammatory cytokine IL-8 was analysed by ELISA (see figure 3.3.3) The results 
verified that IL-8 was produced in a dose-dependent pattern; based on the increasing 
amounts of IRAK2 encoding plasmids that were transfected into HEK293T cells, 
increasing levels of IL-8 were detected in the cell culture supernatant. Meanwhile, IL-8 
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secretion was reduced for the R43Q, R214G, L392V, R498G and L503I variants, 
whereas two SNPs, S43Y and L78M, enhanced the IL-8 production compared to WT 
IRAK2. All together, the relative levels of IL-8 production were consistent with the 
quantified amount of NF-κB activation. The analysis showed that the R214G and 
L392V mutants reduced the production IL-8 by 30% and 20% respectively. The R43Q 
significantly decreased IL-8 production as well. However, due to the low frequency in 
the population this SNP was not further considered in epidemiological and functional 
studies. On the one hand, it is interesting to understand the molecular mechanisms that 
determine a reduced NF-κB activation; on the other hand regarding the frequency 
distribution of these SNPs, this study also focused on finding carriers of these SNPs for 
further epidemiological research. R214G an L392V occur frequently in the European 
population. Therefore, the following molecular and epidemiological studies focused on 
IRAK2 R214G and L392V. See figure 3.20 
 
Figure 3.20 R214G and L392V reduced IL-8 production. Different amounts of IRAK2 WT and 
mutants encoding plasmids were transfected into HEK293T cell respectively. The cell culture 
supernatant was harvested 48 hours post-transfection and analysed by IL-8 ELISA. The statistical 
analysis was done by the Two-Way ANOVA. 
3.3.2.3 Homology modelling of the IRAK2 kinase domain 
R214G and L392V are located in the kinase domain of IRAK2. As aforementioned, the 
crystal structure of the FL IRAK2 protein is yet unknown. So far, only the crystal 
structure of the IRAK2 death domain was elucidated by X-ray diffraction [86]. Any 
structural information on the IRAK2 kinase domain is not provided. However, the 
crystal structure of the FL IRAK4 was characterized [121]. Thus, adopting the IRAK4 
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kinase domain structure as a template, Dr. Andriy V. Kubarenko in our lab generated a 
homology model of the IRAK2 kinase domain structure to gain further insight on the 
structural properties of the two mutants R214G and L392V (Figure 3.21 A). In this 
model residue R214 is exposed on the surface and faces the ATP loop region, where the 
invariant lysine K237 and the gatekeeper Y286 are located. K237 is assumed to act as a 
critical enzymatic residue in the IRAK2 kinase. R214 coordinates the ATP loop region 
via hydrogen bonds. The change of arginine to glycine at this position might destroy the 
stability of this structure (Figure 3.21 B). In contrast to R214, L392 is buried in the 
proximity of the putative activation loop of IRAK2 (Figure 3.21 C). 
 
Figure 3.21 3D homology model of the IRAK2 kinase domain. Important areas for the kinase 
activity are highlighted: the catalytic residues are in magenta, putative activation loop in pink. R214G 
and L392V are shown in cyan. (B): R214 (G) is exposed on the surface of the catalytic cleft ;( C) 
L392V is buried in the C-loop adjacent to the putative activation loop. Predicted hydrogen bonds are 
shown as yellow dashes. 
Furthermore, to analysis for the conservation degree of R214 and L392 among different 
species, protein sequence alignments were performed with IRAK2 from humans, 
porcine, Macaca mulatta, Bos Taurus, Mus musculus and Rattus norvegicus. 
Interestingly, the alignment reveals that R214 only exits in human IRAK2, while other 
species carry a conserved histidine at this position. In contrast to R214, L392 is highly 
conserved throughout all species, which suggests an important function for this residue 
in signal transduction. See figure 3.22 (A) 
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Figure 3.22 Sequence conservation of R214 and L392. (A)Multiple sequences alignments of IRAK2 
homologus from different species. Hu(human), Po(porcine), Ma(Macaca Mulatta), Bo(Bos Taurus), 
Mu(Mus musculus), Ra(Rattus norvegicus.) sequence alignments were conducted by using Clustal W. 
(B) The protein sequences alignment of IRAK family. 
Alignments of IRAK2 with other members (IRAK1, 3 and 4) of the IRAKs family were 
conducted as well. However, the conservation degree of R214 is very low while L392V 
keeps the high conservation degree (See figure 3.22B). Conclusively, it is shown that 
the L392 is highly conserved among IRAKs and species, which indicates that L392V 
may impact the process of certain kind of diseases which were proven in the part IV. 
3.3.2.4 R214G and L392V maintain the interaction with TRAF6 
In order to further investigate the reason for the dysfunctional behaviour of the two 
mutants in IRAK2, R214G and L392V, following experiments concentrated on 
protein-protein interactions in terms of the NF-κB signalling pathway. The Myddosome 
structure displayed that IRAK2 builds up the fourth layer by hetero-oligomerization 
with IRAK4 and homo-oligomerization with itself [86]. According to part II, the 
LUMIER results revealed that WT IRAK2 can interact with IRAK4 and with itself. 
Additionally, TRAF6 was proposed as downstream protein of IRAK2 to induce NF-κB 
activation. Regarding the impaired signalling activity which was most likely caused by 
changing the interaction intensity with its partner, we applied LUMIER to test the 
interaction between IRAK2 and itself, IRAK4 or TRAF6 (Figure 3.23) As described 
before, IRAK2 R214G and L392V were introduced into a pT-Rex-Dest30-based 
expression plasmid containing N- or C-terminal Renilla or Protein A tags via LR 
reaction respectively. The expression and signaling ability of these constructs was 
confirmed by immunoblot and dual luciferase assay.  
In the context of Renilla or Protein A fusion constructs, both SNPs remain to be 
hypofunctional in terms of NF-κB activation (data not shown). However, the LUMIER 
results revealed that R214G increased the interaction with IRAK2 and IRAK4, while 
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L392V reduced the interaction with IRAK2 and IRAK4. Figure 3.23 B and C 
LUMIER was then applied to assess the interaction of IRAK2 proteins with the 
downstream signaling partner TRAF6. The quantified interaction intensities were not 
as strong as the interactions of IRAK2 with IRAK4. However, in repeated experiments 
R214G showed a decreased the interaction with TRAF6, whereas L392V slightly 
increased the interaction with TRAF6. In comparision to the interaction intensity 
between WT IRAK2 and TRAF6, these differences between R214G and L392V were 
not significant (figure 3.23 D). The LUMIER results therefore indicate that the two 
mutants, R214G and L392V, keep the interaction with TRAF6. In order to confirm the 
assumption that the two SNPs still interacted with TRAF6, co-immunoprecipitation 
were then performed. 
 
Figure 3.23 LUMIER interaction assay for IRAK2 R214G and L392V. (a) Myddosome structure 
demonstrates the interactions between IRAK2 and IRAK4 DDs (Adopted from George, Motshwene et 
al, 2011). (b)-(d): LUMIER experiments: Over-expression of Renilla-tagged IRAK2 WT, R214G or 
L392V IRAK2 and Protein A tagged IRAK4 WT in HEK293T cells. R214G increased the interaction 
intensity with IRAK4 whereas L392V reduces the interaction intensity with IRAK4. (c) 
Over-expression of Renilla-tagged IRAK2WT, R214G or L392V and ProteinA tagged IRAK2 WT into 
HEK293T cells. R214G increased the interaction intensity whereas L392V reduces the interaction 
intensity with IRAK2 (d). Over-expression of Renilla-tagged IRAK2 WT, R214G or L392V and 
ProteinA- tagged TRAF6 WT into HEK293T cells. R214G decreased the interaction intensity whereas 
L392V slightly increased the interaction intensity with TRAF6. Jun-ProteinA and Fos-Renilla served as 
positive control as described before. The experiments were repeated at least three times. The statistical 
analysis was done with a student’s t-test.  
The interaction between IRAK2 and TRAF6 is considered as an essential step to induce 
NF-κB activation [88]. To confirm the results obtained from LUMIER, 
co-immunoprecipitation assays were carried out. Thus, expression constructs encoding 
for Flag-tagged TRAF6 and HA-tagged IRAK2 were co-transfected into HEK293T 
cells. Additionally, HA-tagged IRAK2 K237A and IRAK2DD constructs were applied 
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as controls, because both constructs are known to completely abolish the activation of 
NF-κB, Moreover, a R214G and L392V double mutants was generated to enhance the 
individual effect seen by the mutants.  
Figure 3.24 shows a strong interaction between IRAK2 WT and TRAF6 (lane7) which 
implies that over-expression results into the assembly of these proteins in the absence of 
TLRs stimulation as shown before. However, IRAK2 R214G and L392V were able to 
maintain the interaction with TRAF6; this was similarly observed for the IRAK2 
double mutants (R214G+L392V). These results are therefore consistent with the 
LUMIER results. Interestingly, the kinase dead IRAK2 muatant K237A still retained 
the interaction with TRAF6 (lane 11). IRAK2 DD proteins on the other hand did not 
keep any interaction with TRAF6 (lane 12), indicating that the DD of IRAK2 is not 
sufficient for the interaction with TRAF6. 
 
Figure 3.24 R214G and L392V maintain the interaction with TRAF6. Co-transfection of 
expression plasmids for HA-tagged IRAK2 WT or mutants and Flagged-tagged TRAF6 into HEK293T 
cells. HA-tagged IRAK2 was precipitated by applying a mouse monoclonal  -HA antibody. Cell 
lysates and immunoprecipitated samples were separated on a 4-12% Bis-Tris gradient gel and analysed 
by immunoblot with  -HA and  -Flag rabbit monoclonal antibodies. The experiments were repeated 
twice. 
3.3.2.5 R214G and L392V reduced the ubiquitination level of TRAF6 
TRAF6 is an E3 ligase and its ubiquitination was the precondition to induce NF-κB 
activation. Previous studies revealed that the overexpression of IRAK2 can induce 
TRAF6 ubiquitination which finally triggers NF-κB activation [88]. As previously 
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described, IRAK2 possesses two TRAF6 binding motifs [123]. Particularly, the 
glutamate residue E528 in the first TRAF6 binding motif of IRAK2 is essential to 
trigger TRAF6 ubiquitination [88]. However, the mutation E528A still maintains 
interaction with TRAF6 without inducing TRAF6 ubiquitination [88]. Additionally, 
overexpressing E528A abolished the NF-κB activation in dual luciferase assays [88]. 
Based on that information, the ubiquitination of endougenous TRAF6 was analysed by 
over-expressing HA-tagged IRAK2 WT and mutants in HEK293T cells. Additionally, 
HA-tagged ubiquitin was co-transfected to probe ubiquitination with an anti-HA 
antibody. The IRAK2 E528A protein served as a positive control (See figure 3.25A). 
Strikingly, IRAK2 WT strongly induced TRAF6 ubiquitination whareas R214G and 
L392V both reduced the ubiquitination level of TRAF6. Meanwhile, the positive 
control E528A almost completely abolished the ubiquitination of TRAF6. The results 
may be confounded by the fact that the IRAK2 constructs and ubiquitin both have the 
same HA-tag. Therefore, endogenous ubiquitination assay was analysed when 
overexpressing HA- tagged IRAK2 proteins in HEK293T cells. this experiments was 
perfomed in collaboration by Sinead M. Flannery (School of Biochemistry and 
Immunology, Trinity Biomedical Sciences Institute, Trinity College, Ireland) see figure 
3.25 (B). Overexpression of WT IRAK2 strongly triggered TRAF6 ubiquitination (lane 
1). Compared to WT IRAK2, R214G and L392V reduced the amount of ubiquitination 
on TRAF6; especially L392V almost completely abrogated the ubiquitination of 
TRAF6. 
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Figure 3.25 R214G and L392V reduce the ubiquitination of TRAF6. 4μg of expression plasmids 
encoding for HA-tagged IRAK2 WT or mutants were transfected into HEK293T cells (A) 
Co-transfection with 4μg of plasmids encoding for HA-tagged ubiquitin into HEK293T cells (a). 48 
hours post-transfection, endogenous TRAF6 was immunoprecipitated by applying a rabbit polyclonal 
 -TRAF6 antibody. Cell lysate and immunoprecipitated samples were separated on 4-12% Bis-Tris 
gradient gels and analysed by immunoblot with  -HA rabbit monoclonal antibody to probe for 
ubiquitine or  -TRAF6 mouse monoclonal antibody was used to precipitate TRAF6. (B)Endogenous 
ubiquitination of TRAF6 was detected by applying  -ubiquitine mouse monoclonal antibody. The 
densitometry was analysed by Image J, the relative value is presented according to each leane. The 
experiment was repeated twice. 
3.3.2.6 R214G and L392V change the post-translation modifications pattern of 
IRK2 
According to the results of part I, it is believed that IRAK2 may undergo 
phosphorylation and ubiquitination. The two hypofunctinal mutants, R214G and 
L392V reduced the ubiquitination level of TRAF6. It is conceivable that both mutants 
may alter the post-translational modifications on IRAK2 (e.g. phosphorylation or 
ubiquitination). Hence, 2D gel electrophoresis was performed to analyze the 
differences between mutants and WT IRAK2. In comparison to IRAK2 WT, the two 
mutants maintained the large amount of modifications (See figure3.26)   
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Figure 3.26 Post-translational modifications profiles of IRAK2 WT, R214G and L392V. 4μg of 
expression plasmid encoding for HA-tagged IRAK2WT, R214G, L392V or EV were transfected into 
HEK293T cells. After 48 hours, IRAK2s were immunoprecipitated by applying  -HA mouse 
monoclonal antibody and the samples were subjected to IEF overnight and separated by SDS-PAGE 
via a 4-12% pre-cast Bis-Tirs gel, then continued with immunoblot with  -HA rabbit monoclonal 
antibod. Experiments were repeated twice. 
However, R214G and L392V slightly shift the acidic modifications found for IRAK2 in 
the range of 80kDa (see figure 3.26 A, C, D, E). Additionally, the pattern at high 
molecular weight are absent in IRAK2 R214G and L392V, which has been similarly 
observed for the kinase dead IRAK2 K237A with K237A which abolished NF-κB 
activation (Figure 3.5 D and 3.26 F). Although L392V showed very vagure pattern at 
that position, they are not as strong as WT. these results may imply the higher molecular 
weight species are essential for IRAK2 to induce NF-κB activation. As discussed 
before (see sections 3.2.3), the higher molecular weight range of IRAK2 may implicate 
polyubiquitiantion event. In order to precisely characterize these modifications, mass 
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spectrometry analysis is needed. 
Until now, the functions of IRAK2 WT and mutants were investigated thoroughly in 
HEK293T cells. However, HEK293T cells are not immune cells and the functional 
impact of these mutants may be different in immune cells. Moreover, HEK293T cells 
have endogenous IRAK2 which might interfere with the functional analysis on the 
overexpressed IRAK2 proteins. It is worthwhile to understand the functional properties 
of IRAK2 SNPs in immune cells without the interference of endogenous IRAK2.  
3.3.2.7 Gene expression of reconstituted IRAK2 WT and SNPs stable cell line 
As mentioned before, the retroviral vectors encoding for the IRAK2 mutants were 
generated by site-directed mutagenesis based on the pMXs-IP-puro vactor encoding for 
IRAK2 WT (section 3.1.3). Additionally, the empty vector pMXs-IP-puro was 
introduced into IRAK2 knockout macrophages to serve as a negative control.  
The stable cell lines of IRAK2 WT and mutants were generated as described in section 
2.3.9 The gene expression of IRAK2WT and mutants proteins were confirmed by 
immunoblot analysis with cell lysates (Figure 3.27). The expression levels of 
HA-tagged IRAK2 WT and mutants is comparable in those stable cell lines. No 
unspecific bands are detected in the empty vector control. 
 
Figure 3.27 Expressions of IRAK2 WT and mutants in reconstituted macrophages. IRAK2 
deficient macropahges were infected with an IRES-Puromycin expressing retrovirus MSCV carrying 
HA tagged versions of either wild type IRAK2 or mutant R214G or mutant L392V. The positive cells 
were selected based on puromycin resistance at 10μg/ml. The expression levels of the proteins were 
analysed with an anti-HA monoclonal antibody. Tubulin served as a loading control. 
3.3.2.8 R214G and L392V maintained the production of TNF-α 
In order to investigate whether the mutants impact on TNF-  production in response to 
TLR stimulation, an ELISA was conducted. Since TLR2, TLR4 and TLR7 ligands are 
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the strongest agonists that induce TNF-  production (see the results of Part I), only 
these three ligands were applied to analyse for TNF-  production (Figure 3.28) In 
comparison to the mock control, reconstituted macrophages enhanced the production of 
the TNF- . However, no significant differences were observed between IRAK2 WT 
and mutants after stimulation with Pam2CSK4 (TLR2 ligands), LPS (TLR4) and R848 
(TLR7). This experiment was repeated three times, where the readout indicated certain 
differences between WT and mutants.  These small variations may also be due to 
differences in cell counting and seeding, or the status of the cells such as passage 
number and growth situation. In order to avoid those technical problems, quantitative 
PCR was carried out to screen for the activation of TNF-α and other pro-inflammatory 
cytokines.  
 
Figure 3.28 R214G and L392V do not alter TNF-  production. IRAK2 WT, R214G and L392V 
protein expression was reconstituted in IRAK2 knockout macrophages. 25000 cells were seeded and 
stimulated with Pams2CSK4 (1μg/ml), LPS (0.05μg/ml) and R848 (1μg/ml) for 16 hours and the 
amount of TNF-  was measured by ELISA. The data is presented for one experiment mean ± STD. 
The experiments were repeated three times. 
3.3.2.9 R214G and L392V reduced mRNA expression levels of IL-1β and IL-6 in 
reconstituted macrophages 
It was demonstrated that the recruitment of NF-κB to the Il-6 promoter within 8 hours 
was impaired in Irak2 deficient macrophages when stimulating with the TLR2 for 8 
hours[137]. Thus, it suggested that IRAK2 is involved in Il-6 promoter activation. In 
order to further explore the functional properties of IRAK2, the quantitative PCR was 
carried out to screen for the induced transcription of Tnf-a, Il-1β, Il-6 and Ccl5. TLR2, 
TLR4 and TLR7 stimulations were performed for 3 hours and the mRNA levels of these 
cytokines was quantified by Taqman-probed qPCR (Figure 3.29)   
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After reconstitution, IRAK2 WT and mutants all strongly induced the transcription of 
Tnf- , Ccl5, Il-1β and Il-6 activation upon TLRs stimulation. In general, LPS 
stimulation preferentially induced Il-6, while Pam2CSK4 induced the same amount of 
Il-1β and Il-6. R848 induced the highest amount of Tnf-a and Il-1β. When analysing the 
IRAK2 mutants, no significant difference between WT and mutant IRAK2 proteins was 
observed for the induction of Tnf-  and Ccl5. This result is in agreement with the fact, 
which no differences were observed for the production of TNF-α in the ELISA 
experiment. However, IRAK2 R214G and L392V cells showed reduced mRNA levels 
of Il-1β and Il-6 when stimulating the cells with the selected TLR ligands. However, the 
transcriptional induction was not completely abrogated in these two cases, as the 
quantified levels were still thousand fold higher in comparison to the mock treated 
IRAK2 deficient cells. Although strong reduction of Il-1β and Il-6 mRNA levels are 
observed, statistical significance was not reached in these experiments.  
In order to investigate whether the mutants also impact on the production of 
pro-inflammatory cytokines when challenged with by pathogens, experiments with 
Salmonella typhimurium infections were carried out. However, no difference were 
observed (Data was not shown) due to several reasons. Since it is only a preliminary 
test, further detail investigation are still required. 
Conclusively, IRAK2 R214G and L392V are variants of IRAK2 which reduce the 
production of Il-1β and Il-6 in macrophages upon stimulation wih TLR2, 4 and 7. 
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Figure 3.29 IRAK2 R214G and L392V reduced the transcriptional induction of Il-1β and Il-6.  
The relative mRNA levels in reference to the unstimulated mock induction (cehquered), WT human 
IRAK2 (black), R214G(white) or L392V(grey) reconstituted macrophages. Upon stimulation with 
Pam2CSK4, LPS or R848 for 3 hours, mRNA levels of Tnf-α (A), Ccl5(B), Il-1β(C) and Il-6 (D) were 
determined. Mean+SEM. of combined data of four independent experiments are shown 
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3.3.3 Discussion 
3.3.3.1 R214G and L392V impaired the ubiquitionation of TRAF6  
The results obtained from part III indicated that R214G and L392V are hypofunctional 
SNPs of IRAK2. The reduced NF-κB activation is caused by decreased TRAF6 
ubiquitination.  
First, the LUMIER data particularly revealed that the IRAK2 mutants R214G and 
L392V interfere with the Myddosome assembly. Residue R214G strongly increased the 
interaction with IRAK4 and itself. In contrast to the R214G mutation, IRAK2 L392V 
severely decreased the interaction with IRAK4 and itself. The residues R214 and L392 
are both located in the kinase domain of IRAK2. The data implies that the kinase 
domain appears to participate in the formation of Myddosome. It was proposed that the 
DD of IRAK4 is important to recruit IRAK2 via homotypic interactions, which brings 
the kinase domain of IRAK4 close to the kinase domain of the IRAK2 kinase 
domain[86]. Thus, IRAK2 becomes fully activated by IRAK4 and further recruit and 
interact with TRAF6 and induce the ubiquitination of TRAF6 [13](see figure 3.16).  
How do the two IRAK2 mutants reduce NF-κB activation? R214G appears to have an 
increased affinity with IRAK4 and itself, which means that it was captured in the 
Myddosome and cannot be released from the Myddosome. TRAF6 still can be recruited 
to IRAK2 but it cannot be fully ubiquitinationed due to the less modification in IRAK2, 
which is shown in the 2D gel analysis. Moreover, the co-immunoprecipitation assay 
and LUMIER experiments confirmed that IRAK2 R214G kept the same interaction 
with TRAF6 comparing to IRAK2 WT. Although IRAK2 L392V showed a decreased 
the interaction with IRAK4 which means IRAK2 may not be fully activated and cannot 
further induce TRAF6 ubiquitination. However, the co-immunoprecipitation and 
LUMIER assay showed that IRAK2 L392V kept the same interaction intensity with 
TRAF6 in comparison to WT, which implies that the interaction between IRAK2 and 
TRAF6 could occur by overexpression, but the fully activated IRAK2 is essential for 
the ubiquitination of TRAF6.  
Moreover, the assembly intensity of Myddosome is critical for the activation of IRAK2, 
which might affect the ubiquitination of TRAF6. . This is consistent with the 
overexpression of IRAK2 mutants E528A and K237A in HEK293T cells which 
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abolished the NF-κB activation, but maintained the interaction with TRAF6. E528 is a 
key residue in the first TRAF6 binding motif of IRAK2. The mutation of this residue 
completely abolishes the ubiquitination of TRAF6, while the interaction with TRAF6 is 
retained [88]. The residue K237 is assumed to control the intrinsic kinase activity. Also 
our experiments showed that the overexpression of the IRAK2 K237A mutant in 
HEK293 cells resulted in abrogated NF-κB activation, whereas the interaction with 
TRAF6 was maintained.  
In conclusion, the ubiquitination level of TRAF6 is a key step to induce NF-κB 
activation, which is dependent on the enzymatic activity of IRAK2. In turn, the 
integrity and activation of IRAK2 is very important for the signal transduction of 
NF-κB. 
Additionally, 2D gel analysis showed that the IRAK2 mutants R214G and L392V lost 
modifications in the higher molecular weight range. IRAK4 was thought to act as 
upstream signalling partner of IRAK2, which means that the proper interaction with 
IRAK4 is a critical step to fully activate IRAK2. Although R214G increased the 
interaction with IRAK4 and the mutant L392V rather reduced the interaction; 
nonetheless both of these two SNPs lost the higher molecular weight modifications. 
Additionally, the kinase dead K237A of IRAK2 lost these modifications as well. It is 
conceivable that this modification is pivotal for IRAK2 to induce TRAF6 
ubiquitination. It is therefore necessary to perform the mass spectrometry to analysis on 
these higher molecular weight shifts, which can be done by enrichment of these higher 
molecular weight protein by staining the 2D gel with coomassie and isolate them from 
gel. It may provide hints about post-translation modifications on IRAK2, and further in 
vitro assays might help to understant its impact on the signal transduction. Moreover, a 
crystal structure of FL IRAK2 and the FL Myddosome individually can further explain 
the opposed behaviour of IRAK2 R214G and L392V in terms of IRAK4 interaction. 
Till now, it is not clear whether TRAF6 was first recruited to the complex,  
ubiquitinationed and then released [217] or if fully activated IRAKs dissociate from the 
Myddosome complex to then interact with TRAF6 [218]. Unfortunately, our 
experimental results cannot confirm of these scenarios which one may hold true. It is 
always very complicated to elucidate the precise mechanism underlying cellular 
signalling. Recently, the ubiquitination events in the RIG-signalling pathway were 
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clarified by using biochemical reconstitution experiments combined with biophysical 
techniques. Thus, applying the same method would help us to understand the 
mechanism of Myddosome assembly and how associations with TRAF6 lead to its 
ubiquitination. Additionally, these two hypofunctional mutants can serve as useful 
functional probes for such studies to help us understand the signalling events following 
the Myddosome assembly. 
3.3.3.2 IRAK2 R214G and L392V impaire the transcription of IL-1β and IL-6 
The qPCR results revealed that Tnf-α, Ccl-5, Il-6 and Il-1β were dramatically enhanced 
in human IRAK2 reconstituted macrophages when they were stimulated with the 
ligands of TLR2, 4 and 7. This result is consistent with data obtained from the infection 
of macrophages with Salmonella typhimurium; which resulted in transcriptional 
activation of Tnf-α, Ccl-5, Il-6 and Il-1β, particularly with Il-6 and Il-1β.     
It was shown that the transcription of Il-6 was impaired in IRAK2 deficient 
macrophages upon MALP-2 stimulation [137]. Consistent with this observation, the 
transcriptional activation of Il-6 was massively enhanced when stimulating human 
IRAK2 reconstituted macrophages with TLR2, 4 and 7 ligands. Similarly, the infection 
with Salmonella typhimurium also triggered the transcriptional activation of Il-6 in 
human IRAK2 reconstituted macrophages (see part I). Moreover, in comparison to 
mock reconstituted macrophages, no transcriptional activation of Il-6 was observed. All 
together, these data indicate that IRAK2 is essential for the transcriptional activation of 
Il-6. 
Interestingly, the two hypofunctional mutants of IRAK2, R214G and L392V reduced 
the transcriptional activation of Il-6. However, no significant differences of IL-6 
transcription were shown between IRAK2 WT and mutants, which be explained by the 
large standard deviations of the different measurements. In order to confirm that this 
phenomenon is of statistical significance, an Il-6 RNA blot assay can aid in 
understanding if the two mutants impact on the transcription of Il-6. Alternatively, IL-6 
ELISA assays may further delineate the impact of IRAK2 WT and the two mutants on 
the production of IL-6. Furthermore, it would also be informative to analyse if the 
colorectal cancer patients who carry the IRAK2 SNP alleles, also show impaired levels 
of IL-6, and if this may correlate with a decreased in survival time of these patients. 
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Similar to the transcription of Il-6, the transcriptional activation of Il-1β was massively 
enhanced in the human IRAK2 reconstituted macrophages comparing to the mock 
control. However, only little research was performed to elucidate the role of IRAK2 in 
inducing the transcriptional activation of Il-1β. The research of Wan et al. (2009), 
describes a reduced IL-1β production in IRAK2 deficient macrophages, which were 
stimulated with LPS for 1.5 hours. However, the amount of IL-1β was recovered after 
3hours of stimulation. In this thesis the R214G and L392V reduced the transcriptional 
activation of Il-1β which is similar to the effect on the transcriptional activation of Il-6. 
It is conceivable that IRAK2 may play a critical role in the transcriptional activation of 
Il-1β. However, further research is required to confirm the relation between IRAK2 and 
IL-1β. The mechanism for IL-1β production involve two steps: first, the precursor of 
IL-1β needs to be produced intracellularly by activation of NF-κB, and mature IL-1β is 
generated through proteolytic cleavage by caspase-1; then mature IL-1β is released to 
the supernatant. Second, the extracellular mature IL-1β activates the IL-1R signalling 
pathway to produce more IL-1β. IRAK2 is a kinase of the TLR and IL-1R signalling 
pathways (see figure introduction 1.2.1.2 and figure 1.4), whether it will balance the 
production of IL-1β is unknown. In order to confirm the role of IRAK2 in the 
transcriptional activation IL-1β, the IL-1β RNA blot could help us understand the 
dependency between IL-1β and IRAK2. Additionally, the WB of intracellular precursor 
IL-1β and extracellular mature IL-1β can help us to understand the role of IRAK2 in 
regulating the production of IL-1β on a protein level. 
In contrast to the transcriptional activation of Il-1β and Il-6, the two hypofuncational 
mutants, R214G and L392V did not shown any discernable differences from IRAK2 
WT in terms of transcriptional activation of Tnf-α and Ccl-5, these results is consistent 
with previous research[140]. On the other hand, these data also indicate that IRAK2 is 
not essential for the transcriptional activation of Tnf-α, but it is required to stabilize the 
mRNA level of Tnf-α [140, 193]. In the case of Ccl-5, the transcription activation was 
slightly impaired in those two mutants upon the R848 stimulation which might indicate 
a special role of IRAK2 in TLR7 activation. Furthermore, this result might supported 
the hypothesis that the IRAK2 variants L392V has a reduced HCV auto clearance (See 
part IV 3.4.2.2 and 3.4.3). 
Conclusively, IRAK2 plays an essential role in the production of multiple 
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pro-inflammatory cytokines, particularly for IL-1β and IL-6. IRAK2 might be 
important for the TLR7 induced the production of pro-inflammatory cytokines and 
Ccl-5. IRAK2 appears to play a special of role of regulating IL-1β and IL-6; but how 
would the two genetic variants of IRAK2 impact on the progress or the prognosis of 
diseases?  Therefore, further investigations are required to decipher the role of IRAK2 
in epidemiological studies. 
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3.4 Part IV: Genetic variants in IRAK2 impact on the progress and 
prognosis of infection-related diseases. 
3.4.1 Introduction 
Epidemiological studies can provide us with the information if certain genetic variants 
are related to the susceptibility to certain kind disease. For instance, TLR3 deficiency is 
related with herpes virus encephalitis [35]. IRAK2 also plays a role in protection the 
mice against pathogens [137]. However, little is known about the associations between 
the SNPs of IRAK2 and diseases generally, particularly these two hypofunctional SNPs 
of IRAK2, R214G (rs35060588) and L392V (rs3844283). The two hypofunctional 
genetic variants in IRAK2 occur relatively frequently in the human population: 
rs35060588 (R214G) occurs with 3 and 9 % in Americans and Europeans, respectively, 
but not in Asians or Africans; rs3844283 (L392V) is found with frequencies between 
15 and 44 % in Americans, Europeans, Asians and Africans. Are these carriers 
potentially susceptibile to any infection-related diseases? In order to address this 
question, three epidemiological studies were carried out in collabration to analyse if the 
two hypofuntional genetic variants are related to the following diseases: (1) the survival 
analysis of colorectal cancer patients, (2) HCV clearance, and (3)the development of 
gastritis.  
3.4.2 Results 
3.4.2.1 R214G reduced the survival time of colorectal cancer patients 
The association of the two IRAK2 alleles (R214G and L392V) with colorectal cancer 
(CRC) survival was analyzed in a German progression cohort of colorectal cancer 
(CRC (n=613)). This study was done in collaboration with Dr. Asta Försti (Division of 
Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), 
Germany). No association was observed for rs3844283 (L392V) with the progress of 
CRC, whereas heterozygous carriage of the rs35060588 (R214G) G allele reduced the 
survival time of CRC (HR 1.60 [1.01-2.52], p=0.04, Table 3.4). However, only four 
persons were homozygous for the G allele and none of them died during the study 
period. Therefore, no firm conclusions can be drawn. Nonetheless, heterozygous 
carriage of R214G in CRC patients was associated with an exacerbate progress of CRC. 
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Table 3.4 Frequencies of IRAK2 rs 3844283 and 35060588 with CRC-specific survival. 
rs number Genotype 
CRC-specific survival 
No. at risk No. died (%) HR (95% CI) p value 
rs35060588 CC 524 124 (23.66) 1 
 
(R214G) CG 69 22 (31.88) 1.60 (1.01-2.52) 0.04 
 
GG 4 0 (0.00) - 
 
 
CG+GG 73 22 (30.14) 1.52 (0.96-2.40) 0.07 
rs3844283 CC 196 51 (26.02) 1 
 
(L392V) CG 297 71 (23.91) 0.92 (0.63-1.32) 0.64 
 
GG 111 25 (22.52) 0.80 (0.49-1.32) 0.39 
 
CG+GG 408 96 (23.53) 0.89 (0.63-1.26) 0.49 
 
3.4.2.2 L392V reduced the HCV clearance 
The epidemiological study of the relation between IRAK2 variants and HCV clearance 
was conducted in collaboration with Dr. Janett Fischer (University Hospital Leipzig, 
Division of Gastroenteroly and Hepatology, Leipzig, Germany). The overall 
distribution of these two hypofunctional IRAK2 alleles in a German HCV cohort is 
presented in Table 3.5. No significant difference of genotype frequency was observed 
which was tested with the Hardy-Weinberg equilibrium. For the rs35060588 (R214G) 
variant, the frequency of homozygous genotype GG was below 1%. Therefore, no 
further analysis was conducted. In the German cohort study, 264 (29.5%) patients had 
spontaneous viral clearance. Significant distribution differences in the genotype of the 
IRAK2 rs3844283 (L392V) was observed between spontaneous clearance and chronic 
infection patients. Meanwhile, the known polymorphisms in IL28B rs12979860 and 
rs8099917 were also displayed the significant differences in genotype distribution 
between spontaneous clearance and chronic infection patients (see table 3.5). When 
analyze the relationship between each polymorphism (rs3844283 (OR=0.66, p=0.005), 
rs129798609 (OR=0.23, p=2.9×10
-21
) and rs8099917 (OR=0.25, p=1.4×10
-15
)) with 
chronic infection by univariate analysis method, it shows each polymorphism is a risk 
factor for the progress of a chronic HCV infection (see table 3.6). Additionally, in order 
to rule out the cross-talk between these polymorphisms, multuivariate analysis still 
confirmed that the G allele of IRAK2 rs3844283 is a independent risk factor for chronic 
HCV infection,  since carriage of the IRAK2 rs3844283 G allele reduced the 
possibility to spontaneously clear HCV to 0.68 [0.49-0.93], p=0.015. As reported 
before, the polymorphism of IL28B rs12979860 and rs8099917, were associated with a 
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treatment failure, respectively (Table 3.6). However, no association was observed 
between L392V and the failure of SVR treatment. This cause relationship between 
L392V and chronic HCV infection was confirmed in an independent SWISS HCV 
cohort study as well [219]. 
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Table 3.5 Frequencies of IRAK2 rs3844283 and rs35060588 and IL-28B rs1297860 and rs8099917 
Polymorphism Overall spontaneous clearance chronic infection SVR non-response 
rs35060588  CC 
CG 
GG 
86.2% 
13.5% 
0.3% 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
rs3844283   CC 
CG 
GG 
34.4% 
50.4% 
15.2% 
41.3% 
46.2% 
12.5% 
31.5% 
52.1% 
16.3% 
29.6% 
52.8% 
17.6% 
32.6% 
52.3% 
15.1% 
rs12979860  CC 
CT 
TT 
37.7% 
48.2% 
14.1% 
62.1% 
29.6% 
8.3% 
27.4% 
55.9% 
16.7% 
36.5% 
49.8% 
13.7% 
22.8% 
58.7% 
18.5% 
rs8099917   TT 
TG 
GG 
59.2% 
34.0% 
6.8% 
80.3% 
17.4% 
2.3% 
50.4% 
40.9% 
8.7% 
59.7% 
32.6% 
7.7% 
45.0% 
44.6% 
10.4% 
 
Table 3.6 Association of IRAK2 rs3844283 and Il28B rs12979860 and rs8099917 with the natural course of HCV infection and spontaneous virologic response 
Parameter 
Spontaneous clearance Sustained virologic response (SVR) 
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
OR [95% CI] p-value OR [95% CI] p-value OR [95% CI] p-value OR [95% CI] p-value 
rs3844283 0.66 [0.49-0.88] 0.005 0.68 [0.49-0.93] 0.015  0.469  0.555 
rs12979860 0.23 [0.17-0.31] 2.9x10
-21 
0.35 [0.24-0.51] 5.2x10
-8 
0.52 [0.35-0.75] 0.001 0.30 [0.19-0.49] 7.5x10
-7 
rs8099917 0.25 [0.18-0.35] 1.4x10
-15 
0.50 [0.32-0.76] 0.001 0.55 [0.39-0.78] 0.001 0.39 80.25-0.60] 2.6x10
-5 
sex  0.824  0.216  0.102  0.824 
age  0.625  0.549 0.97 [0.95-0.98] 0.0003 0.95 [0.93-0.97] 2.2x10
-6 
HCV RNA log10 
concentration 
 -  - 0.62 [0.47-0.82] 0.001 0.60 [0.45-0.81] 0.001 
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3.4.2.3 L392V increase the susceptibility of gastritis progressing to gastric cancer 
The analysis of progression of gastritis to gastric cancer, another malignancy in which 
the innate immune system has been investigated in collaboration with Institute for 
Microbiology and Hygiene CCM, Charité-University Medical Center, Germany. This 
progression from gastritis to gastric cancer case control study revealed a significant 
association between IRAK2 rs3855283 (L392V) and gastric cancer. The analysis 
indicated that carriage of rs3855283 G allele and rs3855283GG allele doubled the risk 
of the progression from gastritis to gastric cancer (OR 2.04 [1.25-3.42], p=0.003). 
Concurrent infection of Helicobacter pylori slightly increased the OR value (OR 2.25 
[1.28-4.00], p=0.002). However, the major affect source is the rs3855283. Collectively, 
this suggests that the carriage of rs3855283 G allele will increase the susceptibility of 
gastritis to gastric cancer. The rs3855283GG genotype may therefore be an independent 
prognostic marker for the progression of gastritis to gastric cancer. 
Table 3.7 Frequencies of IRAK2 rs3844283 in gastritis and gastric cancer patients 
Polymorphism 
Gastric 
Cancer 
High Risk 
Gastritis(HRG) 
OR value 
95% CI 
P 
value 
CC 36(27%) 58(43%) 2.04 0.003 
CG 71(53%) 55(40%) (1.225-3.421) 
 
GG 28(21%) 23(17%) CC/CG+GG 
 
Only H.pylori 
positive 
Gastric 
Cancer 
High Risk 
Gastritis(HRG) 
OR value 
95% CI 
P 
value 
CC 28(27%) 54(46%) 2.25 
 
CG 59(57%) 44(37%) (1.282-4.000) 0.002 
GG 16(16%) 20(17%) CC/CG+GG 
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3.4.3 Discussion 
3.4.3.1 Genetic variants in IRAK2 effect on the progress and prognosis of 
infection related diseases 
It is known that IRAK4 or MyD88 deficiency is correlated with recurrent pyogenic 
bacterial infections in early childhood [220]. Recently, it was found that the somatic 
L265P mutation in MyD88 is also highly related with diffuse large B-cell lymphoma 
[171]. However, in comparison to IRAK2, germ-line encoded mutations are relatively 
rare in MyD88 and IRAK4. Here, the hypothesis of a “Common disease, rare variant” 
(CDRV) may apply, in which rare DNA sequence variations, seem to have a high 
penetrance, and therefore seem to dramatically determine the genetic susceptibility to 
common diseases [221]. IRAK4 and MyD88 are highly conserved and 
polymorphisms hardly occur with frequencies of over 1 %. Patients which carry 
deficiencies of IRAK4 or MyD88, are highly susceptible to bacterial infections, and 
early diagnosis, clinical care and the prophylactic treatment with antibiotics is 
important to prevent from early childhood death[220]. In times, when clinical facilities 
and care were less developed and when antibiotics were not available, patients with 
MyD88 and IRAK4 deficiencies must have faced a huge selective pressure; this may 
explain their rare occurrence in the population. 
Meanwhile, the hypothesis of “common disease, common variant” (CDCV) points out 
that genetic variations in multiple genes with appreciable frequencies in the population, 
but potentially low penetrance, are the major contributors to genetic susceptibility to a 
common disease [221]. With regard to this view, R214G (rs35060588) and L392V 
(rs3844283) could more likely be classified as “common disease, common variants”.  
Infection-related CRC patients with IRAK2 rs35060588 showed a decreased survival 
time. This was especially found for heterozygous carriers of the rs35060588 allele. 
However, only 4 homozygous patients were followed who did not succumb to 
disease-related death.  
It was shown that increased IL-6 expression exacerbates the prognosis of colorectal 
cancer [222]. Interestingly, the experiments in this thesis and previous studies [137] 
showed that the transcription of IL-6 was controlled by IRAK2. However, the 
rs35060588 reduced the mRNA levels of IL-6 when stimulating macrophages with 
TLR2/4/7. How exactly rs35060588 influences the progress of CRC in the organism 
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remains to be understood and requires further investigation. Of note, IRAK2 in-vitro 
studies were mainly conducted in immune cells; since IRAK2 is ubiquitously expressed, 
it worthwhile to analyse the impact of IRAK2 and the IRAK2 variants in colorectal 
cancer cells. 
The HCV case control study showed that carriage of rs3844283 (L392V) correlated 
with a decreased ability for HCV auto clearance, which results in the fact that these 
patients are susceptible to chronic HCV infection. Furthermore, IL-28B rs12979860 
and rs8099917 are known factors for high susceptibility to HCV infection. Even when 
using a multivariate analysis to exclude the impact of IL-28B rs12979860 and 
rs8099917, rs3844283 still shows up as an independent risk factor for HCV infected 
patients to progress to chronic inflammation. The clearance of the HCV virus mainly 
depends on the production of type I and type III interferons [223], and on the activation 
of the adaptive immune response [224] .  
In our experiments IRAK2 was defined as a major inducer for pro-inflammatory 
cytokines. Reconstituted macrophages produced a certain amount of IFN-β upon R848 
stimulation. Moreover, it also shown that reconstituted macrophages produce an 
appreciable amount of Ccl-5 when stimulated with TLR2, TLR4 and TLR7 agonists. 
Ccl-5 is thought to facilitate induction of chemotaxis in immune cells and activation of 
hepatic stellate cells at sites of liver inflammation during chronic hepatitis C virus 
infection [225]. Importantly, Ccl-5 participates in the establishment of T-helper 1 
responses which is crucial in controlling HCV infection outcome [225]. Moreover, 
HCV also can be cleared by RIG-I like receptors in hepatocytes [226]. Recently, it was 
shown that IRAK2 was involved in the RIG-I signalling pathway undirectly [227]. 
Conclusively, IRAK2 is involved in the TLR7 activation, Ccl-5 production and RIG-I 
like receptors signalling pathways. It is therefore conceivable that defects in IRAK2 
may impair the response to HCV, and may explain why rs3844283 carriers are 
susceptible to chronic HCV infection and show reduced abilities for the viral clearance. 
The last case control study on high-risk gastritis showed that in comparison to the 
IRAK2 WT allele, rs3844283 almost doubled the patient’s risk for progression to 
gastric cancer. Gastric cancer is the third most common cause for cancer-related death 
[228]. Interestingly, IL-1β was demonstrated to be another risk factor for gastric cancer; 
in particular, IL-1β is shown to inhibit the acid production and low amounts of gastric 
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acid are related with gastritis and gastric cancer [229].The experiments here show that 
IRAK2 affects the transcription of IL-1β. However, IRAK2 L392V (rs3844283) 
reduced the IL-1β production by in the in-vitro assay which is controversial to the 
observation that IL-1β induces gastritis and gastric cancer. How exactly rs3822283 
impacts on the progression of gastritis still needs to be studied. In this context it may be 
worthwhile to analyse in in-vitro studies the functional effects of IRAK2 in parietal 
cells response to IL-1β. In theory, the similar method also can be applied for the study 
of the response to HCV in hepatocytes.          
It is first time to discover the association between SNPs of IRAK2 and diseases in 
human. Overall, these three diseases are all infection-related diseases. It is known that 
IRAK2 plays a central role in regulating the production of pro-inflammatory cytokines. 
However, the precise role of IRAK2 in the progress of those diseases is not clear. Does 
IRAK2 and the TLR signalling pathway cooperate with other PRR signalling pathway? 
How does IRAK2 particularly functions in the response to pathogen? The mechanism 
underlying this epidemiological association are yet unknown and require further studies 
in these disease-related in-vitro or in-vivo models. In this work causal relationships 
were investigated in gastritis, HCV auto clearance and colorectal cancer case control 
studies. In addition to these, it is conceivable that IRAK2, as a central regulator of 
innate immune signalling pathways, is also having an impact on many other 
infection-related diseases. Referring to the CDCV hypothesis, IRAK2 may be 
emphasized as a common variant that does not show immediate impact (“penetrance”) 
in the population and in response to disease. However, in combination with certain 
environmental cues and physiological conditions, IRAK2 may represent a risk factor, 
that contributes to disease. At this point it is noteworthy, that IRAK2 SNPs are 
occurring with different frequencies in different ethnic groups, the studies here mainly 
focused on Caucasian populations. The analysis in different cohorts may further 
provide insights if IRAK2 may differently impact disease in certain ethnicities.  
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Conclusion 
This chapter concludes the research in this thesis by summarizing contributions and 
proposing some thoughts for future work.  
Although IRAK2 has been studied in numerous molecular studies, this is the first time 
using SNPs as probes to investigate the integrity importance of IRAK2 in human 
system and in reconstituted mouse Irak2 knock out macrophages. Meanwhile, this is 
also the first time to investigate the causal relationship between hypofunctional 
polymorphisms of IRAK2 and human diseases. Based on the in-depth research in this 
dissertation, several contributions have been achieved, which also provides some 
implication for future research. 
4.1 IRAK2 generally plays a central role in TLR-NF-κB signalling 
pathway    
First, from the molecular point, LUMIER results first indicate that the full-length 
MyD88, IRAK4 and IRAK2 also generate the multimeric complex in mammalian cells 
as well, and this full-length complex also formed highly in order. It is consistent with 
published the Myddosome structure which consists of only DDs of MyD88, IRAK4 
and IRAK2 in bacterial system[86]. However, the stoichiometry of these full-length 
molecular still needs further investigation. Interestingly, only IRAK2 further interacts 
with IRAK1 and IRAK3, which so far has not been investigated. It implies that IRAK2 
plays a vital role in mediating or adjusting the TLR-NF-κB signal transduction.  
Moreover, our research displayed that the kinase domain of IRAK2 also has impact on 
the assembly of the Myddosome by adopting the genetic variants R214G and L392V. 
IRAK2 R214G increased the interaction with IRAK4 and itself whereas the redisue 
L392V decreased the interaction with IRAK4 and itself in comparison with IRAK WT. 
However, these two variants still kept the interaction with TRAF6.  Moreover, the 
adopted 3D model of IRAK2 kinase domain further displayed that residue R214 is 
exposed on the surface and faces the ATP loop region, in where the invariant lysine 
K237 and the gatekeeper Y286 is located. In contrast to R214, residue L392 is buried in 
the proximity of the putative activation loop of IRAK2. These two variants provided 
further information on the structure of IRAK2, which still need to be verified by using 
X-ray to reveal the crystal structure of IRAK2. 
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To further investigate the reason of defect activation of two IRAK2 variants, TRAF6 
ubiquitination experiment was performed. IRAK2 was thought as a trigger of the 
ubiquitination of TRAF6 which is a critical step to induce the activation of NF-κB. Our 
results revealed that the two hypofunctional genetic variants R214G and L392V 
reduced the NF-κB activation by reducing the ubiquitiantion level of TRAF6 but 
maintained the same interaction intensity with TRAF6 in comparison to IRAK2 WT, 
which is consistent with the behaviour of mutation IRAK2 E528A[88]. To further 
address the mechanism of the reduced ubiquitination of TRAF6, 2D gel electrophoresis 
was carried out to seek differences between IRAK2 WT and genetic variants in 
post-translational modifications, which has so far not been delineated in detail. Our 
experiments indicate that these modifications are critical for signal transduction. 
However, the precise nature of these modifications is not known yet and further studies 
in this field are required. For instance, elucidation of the crystal structure of IRAK2 or 
the phosphorylation/ubiquitination mass spectrometry analysis of IRAK2 would be 
profound studies on the molecular mechanism of IRAK2 signalling properties. 
To further investigate the role of IRAK2 in innate immunity, human IRAK2 
reconstituted mouse IRAK2 knockout macrophages were generated. The TNF-a 
production was significantly enhanced in the reconstituted IRAK2 WT macrophages 
upon stimulation with TLR2, 4 and 7 ligands. This finding denoted that IRAK2 is 
specific for the production of pro-inflammatory cytokines upon TLR2, 4 and 7 
activations. Although previous research indicated that the production of TNF-α and 
IL-8 was impaired in the IRAK2 silenced human PBMCs by stimulating with TLR4 
and TLR7 ligands[193]. Whether IRAK2 has specificity for certain kinds of TLR 
ligands still needs further investigation. Due to the difference between mouse 
macrophages and human PBMC, the function of IRAK2 might be redefined according 
to different cell types, since IRAK2 is expressed universally. 
Previous experiments indicate that IRAK2 plays an essential role in sustaining NF-κB 
activation in later time points[137]. In this thesis, it confirmed that IRAK2 does have an 
essential role both in the early time points of NF-κB activation. Stimulating the human 
IRAK2 reconstituted mouse macrophages with TLR ligands, phosphor p38, p65 and 
ERK were detected within 30mins. Additionally, our studies first revealed that IRAK2 
is unique and essential for the phosphorylation of Akt upon the stimulation of TLR 
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ligands. Akt is mainly responsible for the cell proliferation and apoptosis. Importantly, 
the deregulated Akt pathway is associated with variety of human cancers, and several 
small molecular inhibitors targeting Akt have been developed and already tested in the 
clinical trial [230]. The fact that IRAK2 regulates Akt implies that IRAK2 may be 
involved in the progression of chronic inflammation to cancer.  
Although it is known that the deficiency of IRAK2 impaired the transcriptional 
activation of Il-6 [137]. Here, the experiments emphasize that the transcriptional 
activation of Il-1β is highly dependent on IRAK2 as well. Additionally, the 
transcriptional activation of Il-1β and Il-6 was impaired when reconstituting the KO 
macrophages with IRAK2 R214G and L392V. Thus, it further confirmed that IRAK2 
has a unique role in regulating transcriptional activation of Il-1β and Il-6. Intriguingly, 
the precursor IL-1β can be produced by activating TLR-induced transcription factor 
NF-κB and the bioactive IL-1β was processed by cleavage of the activation of 
caspase-1 which is the key component in the large complex inflammasome. Then the 
bioactive IL-1β was released into the extracellular space and bound to IL-1R to activate 
the pro-inflammatory cytokines production (see figure 1.9). IRAK2 is the downstream 
kinase of TLR and IL-1R, which might indicate that IRAK2 is involved into the IL-1β 
production. Since deregulation of IL-1β production is related with several 
auto-inflammatory conditions, such as Mukle-Wells syndrome, Type-1 diabetes and 
gout [68, 231, 232], it is worth to investigate the role of IRAK2 in these diseases. 
4.2 IRAK2 genetic variants are related with the progression or 
prognosis of certain kinds of diseases. 
Meanwhile, the impaired transcriptional activation in Il-1β and Il-6 implies that these 
genetic variants of IRAK2 may have an impact on the progression and prognosis of 
certain kinds of infection-related diseases. It is known that genetic variants in IRAK1 
are highly related with the pathogenesis of SLE [135] and the deficiency of IRAK4 is 
correlated with recurrent pyogenic bacterial infection in childhood[164].The minor 
allele frequencies of IRAK2 R214G (rs35060588) and L392V (rs3844283) in the 
human population are relatively high which might affect diseases susceptibility in a 
large number of individuals. Epidemiological studies reveal that the carriage of R214G 
decreased the survival time in the infection related colorectal cancer patients. 
Interestingly, high level IL-6 is tightly related with the unfavorite prognosis of CRC. 
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Moreover, two independent HCV cohort studies found that IRAK2 L392V carriers 
could reduced HCV clearance ability, and were therefore more susceptible to chronic 
HCV infection. It is known that HCV was eliminated by type I and type III IFN, which 
are mainly produced by RIG-I like receptor and TLR3 activation. So far, the IRAK2 
function in TLR3 and RIG-I like receptor has not been addressed in detail. Interestingly, 
the Ccl5 is another key factor to facilitate the adaptive immunity, which is crucial in 
controlling the outcome of HCV infection. In our studies, Ccl5 production was also 
impaired in the two genetic variants, which may imply that IRAK2 plays a special role 
in TLR7 activation. Due to the universal expression of IRAK2 in organism, the IRAK2 
function in hepatocytes needs to be further investigated. Additionally, the case control 
study on the progression from high risk gastritis to gastric cancer patients revealed that 
IRAK2 L392V doubled the risk for high risk gastritis patients to progress to a gastric 
cancer. Additionally, high amount of IL-1β is a risk factor for gastric cancer and it was 
impaired in our L392V reconstituted macrophages. However, the results are 
controversial which need in-depth research of IRAK2 in the gastritis environment.    
How the genetic variants contribution to individual susceptibility to common complex 
diseases such as diabetes, osteoporosis, and cancer, there are two major hypotheses.  
One is the ‘Common Disease, Common Variant (CDCV)’ hypothesis argues that 
genetic variations with appreciable frequency in the population at large, but relatively 
low ‘penetrance’ (or the probability that a carrier of the relevant variants will express 
the disease), are the major contributors to genetic susceptibility to common diseases, 
such as hypertension. Another one is the ‘Common Disease, Rare Variant (CDRV)’ 
hypothesis, on the contrary, argues that multiple rare DNA sequence variations, each 
with relatively high penetrance, are the major contributors to genetic susceptibility to 
common diseases, such as familial breast cancer induced by BRCA1 and BRCA2 
mutations[221]. Regarding the ‘common disease, common variants’ hypothesis, 
IRAK2 R214G and L392V might be considered as common variants that do not 
response to diseases immediately. However, in co-incidence with certain environmental 
cues and physiological conditions, IRAK2 may serve as a risk factor and contributed to 
the pathogenesis of diseases. Furthermore, only two hypofunctional variants were 
analyzed in this dissertation, it is worthwhile to perform adequate hyperfunctional 
variants functional and epidemiological studies to prove our results from another angel. 
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4.3 Could IRAK2 be a therapeutic target? 
Collectively, our research highlights the need for further research on IRAK2, especially 
the relationship between genetic variants and susceptibility to certain kinds of diseases. 
Taking genetic variants as probes can help us to understand the complex interplay of 
signalling transduction and the relationship with certain kinds of diseases. IRAK2 may 
represent a suitable target in the treatment of disease, especially in those cases where 
genetic variants of IRAK2 may contribute to progression of the disease. As more and 
more researches have been conducted, the IRAK family members exhibit their specific 
functions in certain immune response branch. For instance, IRAK1 is specific for the 
production of type I IFN upon activation of TLR7 and TLR9; IRAK2 are mainly 
responsible for the production of pro-inflammatory cytokines. Regarding the fact that 
IRAK4 is the initiating kinase in the NF-κB activation, inhibition of the kinase activity 
of IRAK4 might interfere the activation of IRAK1 or IRAK3. The inhibitor of IRAK2 
would be more specific for controlling over produced pro-inflammatory cytokines. 
Moreover, high levels of IL-1β and IL-6 are related with some autoimmunity diseases 
and genetic variants of IRAK2 altered the production of IL-1β and IL-6, which 
indicates that IRAK2 might be involved into the pathogenesis of autoimmunity 
diseases.  
As an approach for personalized therapy, the design of specific IRAK2 kinase 
antagonists/agonists may help patients to conquer the chronic inflammation related 
diseases (HCV) or autoimmune diseases (rheumatoid arthritis). 
 
  
 142 
 
 
 143 
Reference 
1. Beck, G. and G.S. Habicht, Immunity and the invertebrates. Sci Am, 1996. 275(5): p. 60-3, 66. 
2. Charles A Janeway, J., Paul Travers, Mark Walport, and Mark J Shlomchik., The Immune 
system in Health and Disease2001, New York and London: Garland science. 
3. Alberts, B.A.J., Julian Lewis, Martin Raff, Keith Roberts, and Peter Walters, in Molecular 
Biology of the Cell2002, Garland Science: New York and London. 
4. Stvrtinová, V.J.J.a.I.H., Inflammation and Fever from Pathophysiology: Principles of Disease, 
1995, Slovak Academy of Sciences:Academic Electronic Press.: Computing Centre. 
5. Alt, F.W., et al., VDJ recombination. Immunol Today, 1992. 13(8): p. 306-14. 
6. Janeway Jr, C., Approaching the asymptote? Evolution and revolution in immunolog. Cold 
Spring Harb Symposia on Quantitative Biology. , 1989. 54(1): p. 1-13. 
7. Gutcher, I. and B. Becher, APC-derived cytokines and T cell polarization in autoimmune 
inflammation. J Clin Invest, 2007. 117(5): p. 1119-27. 
8. Watanabe, N., et al., Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ 
regulatory T cells in human thymus. Nature, 2005. 436(7054): p. 1181-5. 
9. Mauri, C. and A. Bosma, Immune regulatory function of B cells. Annu Rev Immunol, 2012. 30: 
p. 221-41. 
10. Medzhitov, R. and C.A. Janeway, Jr., Innate immunity: the virtues of a nonclonal system of 
recognition. Cell, 1997. 91(3): p. 295-8. 
11. Piccinini, A.M. and K.S. Midwood, DAMPening inflammation by modulating TLR signalling. 
Mediators Inflamm, 2010. 2010. 
12. Palm, N.W. and R. Medzhitov, Pattern recognition receptors and control of adaptive 
immunity. Immunol Rev, 2009. 227(1): p. 221-33. 
13. Takeuchi, O. and S. Akira, Pattern recognition receptors and inflammation. Cell, 2010. 140(6): 
p. 805-20. 
14. Meylan, E., J. Tschopp, and M. Karin, Intracellular pattern recognition receptors in the host 
response. Nature, 2006. 442(7098): p. 39-44. 
15. Anderson, K.V., G. Jurgens, and C. Nusslein-Volhard, Establishment of dorsal-ventral polarity 
in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell, 1985. 
42(3): p. 779-89. 
16. Lemaitre, B., et al., The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the 
potent antifungal response in Drosophila adults. Cell, 1996. 86(6): p. 973-83. 
17. Nomura, N., et al., Prediction of the coding sequences of unidentified human genes. I. The 
coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly 
sampled cDNA clones from human immature myeloid cell line KG-1. DNA Res, 1994. 1(1): p. 
27-35. 
18. Taguchi, T., et al., Chromosomal localization of TIL, a gene encoding a protein related to the 
Drosophila transmembrane receptor Toll, to human chromosome 4p14. Genomics, 1996. 
32(3): p. 486-8. 
19. Poltorak, A., et al., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in 
Tlr4 gene. Science, 1998. 282(5396): p. 2085-8. 
20. Medzhitov, R., P. Preston-Hurlburt, and C.A. Janeway, Jr., A human homologue of the 
Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997. 388(6640): p. 
394-7. 
21. Bowie, A. and L.A. O'Neill, The interleukin-1 receptor/Toll-like receptor superfamily: signal 
generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol, 2000. 
67(4): p. 508-14. 
22. Hashimoto, C., K.L. Hudson, and K.V. Anderson, The Toll gene of Drosophila, required for 
dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell, 1988. 
52(2): p. 269-79. 
 144 
23. Akira, S., S. Uematsu, and O. Takeuchi, Pathogen recognition and innate immunity. Cell, 2006. 
124(4): p. 783-801. 
24. Jin, M.S., et al., Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a 
tri-acylated lipopeptide. Cell, 2007. 130(6): p. 1071-82. 
25. Barbalat, R., et al., Toll-like receptor 2 on inflammatory monocytes induces type I interferon in 
response to viral but not bacterial ligands. Nat Immunol, 2009. 10(11): p. 1200-7. 
26. Qureshi, S.T., et al., Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J 
Exp Med, 1999. 189(4): p. 615-25. 
27. Shimazu, R., et al., MD-2, a molecule that confers lipopolysaccharide responsiveness on 
Toll-like receptor 4. J Exp Med, 1999. 189(11): p. 1777-82. 
28. Kim, H.M., et al., Crystal structure of the TLR4-MD-2 complex with bound endotoxin 
antagonist Eritoran. Cell, 2007. 130(5): p. 906-17. 
29. Park, B.S., et al., The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 
complex. Nature, 2009. 458(7242): p. 1191-5. 
30. Kaisho, T., et al., Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol, 
2001. 166(9): p. 5688-94. 
31. Hayashi, F., et al., The innate immune response to bacterial flagellin is mediated by Toll-like 
receptor 5. Nature, 2001. 410(6832): p. 1099-103. 
32. Yonekura, K., S. Maki-Yonekura, and K. Namba, Complete atomic model of the bacterial 
flagellar filament by electron cryomicroscopy. Nature, 2003. 424(6949): p. 643-50. 
33. Alexopoulou, L., et al., Recognition of double-stranded RNA and activation of NF-kappaB by 
Toll-like receptor 3. Nature, 2001. 413(6857): p. 732-8. 
34. Kato, H., et al., Differential roles of MDA5 and RIG-I helicases in the recognition of RNA 
viruses. Nature, 2006. 441(7089): p. 101-5. 
35. Zhang, S.Y., et al., TLR3 deficiency in patients with herpes simplex encephalitis. Science, 2007. 
317(5844): p. 1522-7. 
36. Mancuso, G., et al., Bacterial recognition by TLR7 in the lysosomes of conventional dendritic 
cells. Nat Immunol, 2009. 10(6): p. 587-94. 
37. Schlaepfer, E. and R.F. Speck, TLR8 activates HIV from latently infected cells of 
myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T 
cells indirectly via TNF-alpha. J Immunol, 2011. 186(7): p. 4314-24. 
38. Rasmussen, S.B., et al., Type I interferon production during herpes simplex virus infection is 
controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial 
antiviral signaling protein pathway, and novel recognition systems. J Virol, 2007. 81(24): p. 
13315-24. 
39. Krug, A., et al., Herpes simplex virus type 1 activates murine natural interferon-producing cells 
through toll-like receptor 9. Blood, 2004. 103(4): p. 1433-7. 
40. Krug, A., et al., TLR9-dependent recognition of MCMV by IPC and DC generates coordinated 
cytokine responses that activate antiviral NK cell function. Immunity, 2004. 21(1): p. 107-19. 
41. Parroche, P., et al., Malaria hemozoin is immunologically inert but radically enhances innate 
responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci U S A, 2007. 
104(6): p. 1919-24. 
42. Coban, C., et al., Toll-like receptor 9 mediates innate immune activation by the malaria 
pigment hemozoin. J Exp Med, 2005. 201(1): p. 19-25. 
43. Barton, G.M. and J.C. Kagan, A cell biological view of Toll-like receptor function: regulation 
through compartmentalization. Nat Rev Immunol, 2009. 9(8): p. 535-42. 
44. Sims, J.E., et al., cDNA expression cloning of the IL-1 receptor, a member of the 
immunoglobulin superfamily. Science, 1988. 241(4865): p. 585-9. 
45. Gay, N.J. and F.J. Keith, Drosophila Toll and IL-1 receptor. Nature, 1991. 351(6325): p. 355-6. 
46. O'Neill, L.A., The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. 
Immunol Rev, 2008. 226: p. 10-8. 
47. Greenfeder, S.A., et al., Molecular cloning and characterization of a second subunit of the 
interleukin 1 receptor complex. J Biol Chem, 1995. 270(23): p. 13757-65. 
48. Huang, J., et al., Recruitment of IRAK to the interleukin 1 receptor complex requires 
interleukin 1 receptor accessory protein. Proc Natl Acad Sci U S A, 1997. 94(24): p. 12829-32. 
 145 
49. Christian korherr, R.H., Werner Falk, IL-1 receptor internalisation requires the cytoplasmic 
part of the IL-1 receptor accessory protein. Cytokine, 1997. 9: p. 946. 
50. Robinson, D., et al., IGIF does not drive Th1 development but synergizes with IL-12 for 
interferon-gamma production and activates IRAK and NFkappaB. Immunity, 1997. 7(4): p. 
571-81. 
51. Schmitz, J., et al., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related 
protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005. 23(5): p. 
479-90. 
52. Sutton, C., et al., A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells 
that mediate autoimmune encephalomyelitis. J Exp Med, 2006. 203(7): p. 1685-91. 
53. Yoneyama, M. and T. Fujita, Structural mechanism of RNA recognition by the RIG-I-like 
receptors. Immunity, 2008. 29(2): p. 178-81. 
54. Yoneyama, M., et al., The RNA helicase RIG-I has an essential function in double-stranded 
RNA-induced innate antiviral responses. Nat Immunol, 2004. 5(7): p. 730-7. 
55. Kato, H., et al., Cell type-specific involvement of RIG-I in antiviral response. Immunity, 2005. 
23(1): p. 19-28. 
56. Yoneyama, M., et al., Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, 
and LGP2 in antiviral innate immunity. J Immunol, 2005. 175(5): p. 2851-8. 
57. Saito, T., et al., Regulation of innate antiviral defenses through a shared repressor domain in 
RIG-I and LGP2. Proc Natl Acad Sci U S A, 2007. 104(2): p. 582-7. 
58. Kato, H., et al., Length-dependent recognition of double-stranded ribonucleic acids by retinoic 
acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med, 2008. 
205(7): p. 1601-10. 
59. Cui, S., et al., The C-terminal regulatory domain is the RNA 5'-triphosphate sensor of RIG-I. 
Mol Cell, 2008. 29(2): p. 169-79. 
60. Takahasi, K., et al., Solution structures of cytosolic RNA sensor MDA5 and LGP2 C-terminal 
domains: identification of the RNA recognition loop in RIG-I-like receptors. J Biol Chem, 2009. 
284(26): p. 17465-74. 
61. Kawai, T., et al., IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon 
induction. Nat Immunol, 2005. 6(10): p. 981-8. 
62. Meylan, E., et al., Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted 
by hepatitis C virus. Nature, 2005. 437(7062): p. 1167-72. 
63. Seth, R.B., et al., Identification and characterization of MAVS, a mitochondrial antiviral 
signaling protein that activates NF-kappaB and IRF 3. Cell, 2005. 122(5): p. 669-82. 
64. Xu, L.G., et al., VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol 
Cell, 2005. 19(6): p. 727-40. 
65. Philpott, D.J. and S.E. Girardin, Nod-like receptors: sentinels at host membranes. Curr Opin 
Immunol, 2010. 22(4): p. 428-34. 
66. Kim, D.H. and F.M. Ausubel, Evolutionary perspectives on innate immunity from the study of 
Caenorhabditis elegans. Curr Opin Immunol, 2005. 17(1): p. 4-10. 
67. Tschopp, J., F. Martinon, and K. Burns, NALPs: a novel protein family involved in inflammation. 
Nat Rev Mol Cell Biol, 2003. 4(2): p. 95-104. 
68. Davis, B.K., H. Wen, and J.P. Ting, The inflammasome NLRs in immunity, inflammation, and 
associated diseases. Annu Rev Immunol, 2011. 29: p. 707-35. 
69. Martinon, F. and J. Tschopp, NLRs join TLRs as innate sensors of pathogens. Trends Immunol, 
2005. 26(8): p. 447-54. 
70. Creagh, E.M. and L.A. O'Neill, TLRs, NLRs and RLRs: a trinity of pathogen sensors that 
co-operate in innate immunity. Trends Immunol, 2006. 27(8): p. 352-7. 
71. Ogura, Y., et al., Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and 
activates NF-kappaB. J Biol Chem, 2001. 276(7): p. 4812-8. 
72. Bertin, J., et al., Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that 
activates NF-kappaB. J Biol Chem, 1999. 274(19): p. 12955-8. 
73. Martinon, F. and J. Tschopp, Inflammatory caspases: linking an intracellular innate immune 
system to autoinflammatory diseases. Cell, 2004. 117(5): p. 561-74. 
 146 
74. Martinon, F., K. Burns, and J. Tschopp, The inflammasome: a molecular platform triggering 
activation of inflammatory caspases and processing of proIL-beta. Mol Cell, 2002. 10(2): p. 
417-26. 
75. Mariathasan, S., et al., Cryopyrin activates the inflammasome in response to toxins and ATP. 
Nature, 2006. 440(7081): p. 228-32. 
76. Kanneganti, T.D., et al., Bacterial RNA and small antiviral compounds activate caspase-1 
through cryopyrin/Nalp3. Nature, 2006. 440(7081): p. 233-6. 
77. O'Neill, L.A., K.A. Fitzgerald, and A.G. Bowie, The Toll-IL-1 receptor adaptor family grows to 
five members. Trends Immunol, 2003. 24(6): p. 286-90. 
78. Xu, Y., et al., Structural basis for signal transduction by the Toll/interleukin-1 receptor 
domains. Nature, 2000. 408(6808): p. 111-5. 
79. O'Neill, L.A. and A.G. Bowie, The family of five: TIR-domain-containing adaptors in Toll-like 
receptor signalling. Nat Rev Immunol, 2007. 7(5): p. 353-64. 
80. Lord, K.A., B. Hoffman-Liebermann, and D.A. Liebermann, Nucleotide sequence and 
expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response 
gene induced by IL6. Oncogene, 1990. 5(7): p. 1095-7. 
81. Wesche, H., et al., MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. 
Immunity, 1997. 7(6): p. 837-47. 
82. Medzhitov, R., et al., MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling 
pathways. Mol Cell, 1998. 2(2): p. 253-8. 
83. Kawai, T., et al., Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity, 1999. 
11(1): p. 115-22. 
84. Li, S., et al., IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. 
Proc Natl Acad Sci U S A, 2002. 99(8): p. 5567-72. 
85. Motshwene, P.G., et al., An oligomeric signaling platform formed by the Toll-like receptor 
signal transducers MyD88 and IRAK-4. J Biol Chem, 2009. 284(37): p. 25404-11. 
86. Lin, S.C., Y.C. Lo, and H. Wu, Helical assembly in the MyD88-IRAK4-IRAK2 complex in 
TLR/IL-1R signalling. Nature, 2010. 465(7300): p. 885-90. 
87. Kobayashi, K., et al., IRAK-M is a negative regulator of Toll-like receptor signaling. Cell, 2002. 
110(2): p. 191-202. 
88. Keating, S.E., et al., IRAK-2 participates in multiple toll-like receptor signaling pathways to 
NFkappaB via activation of TRAF6 ubiquitination. J Biol Chem, 2007. 282(46): p. 33435-43. 
89. Wang, C., et al., TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature, 2001. 
412(6844): p. 346-51. 
90. Yi, A.K. and A.M. Krieg, CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma 
apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of 
nuclear factor-kappa B/c-Rel. J Immunol, 1998. 160(3): p. 1240-5. 
91. Beinke, S., et al., Lipopolysaccharide activation of the TPL-2/MEK/extracellular 
signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IkappaB 
kinase-induced proteolysis of NF-kappaB1 p105. Mol Cell Biol, 2004. 24(21): p. 9658-67. 
92. Zhong, J. and J.M. Kyriakis, Dissection of a signaling pathway by which pathogen-associated 
molecular patterns recruit the JNK and p38 MAPKs and trigger cytokine release. J Biol Chem, 
2007. 282(33): p. 24246-54. 
93. Kawai, T., et al., Interferon-alpha induction through Toll-like receptors involves a direct 
interaction of IRF7 with MyD88 and TRAF6. Nat Immunol, 2004. 5(10): p. 1061-8. 
94. Uematsu, S., et al., Interleukin-1 receptor-associated kinase-1 plays an essential role for 
Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med, 2005. 
201(6): p. 915-23. 
95. Takaoka, A., et al., Integral role of IRF-5 in the gene induction programme activated by 
Toll-like receptors. Nature, 2005. 434(7030): p. 243-9. 
96. Yamamoto, M., et al., Essential role for TIRAP in activation of the signalling cascade shared by 
TLR2 and TLR4. Nature, 2002. 420(6913): p. 324-9. 
97. Kagan, J.C. and R. Medzhitov, Phosphoinositide-mediated adaptor recruitment controls 
Toll-like receptor signaling. Cell, 2006. 125(5): p. 943-55. 
 147 
98. Dunne, A., et al., Structural complementarity of Toll/interleukin-1 receptor domains in 
Toll-like receptors and the adaptors Mal and MyD88. J Biol Chem, 2003. 278(42): p. 
41443-51. 
99. Mansell, A., et al., Mal interacts with tumor necrosis factor receptor-associated factor 
(TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4. J Biol Chem, 
2004. 279(36): p. 37227-30. 
100. Gray, P., et al., MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during 
TLR2 and TLR4 signal transduction. J Biol Chem, 2006. 281(15): p. 10489-95. 
101. Khor, C.C., et al., A Mal functional variant is associated with protection against invasive 
pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet, 2007. 39(4): p. 
523-8. 
102. Hawn, T.R., et al., A polymorphism in Toll-interleukin 1 receptor domain containing adaptor 
protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis, 2006. 194(8): p. 
1127-34. 
103. Miggin, S.M., et al., NF-kappaB activation by the Toll-IL-1 receptor domain protein MyD88 
adapter-like is regulated by caspase-1. Proc Natl Acad Sci U S A, 2007. 104(9): p. 3372-7. 
104. Yamamoto, M., et al., Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter 
that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J 
Immunol, 2002. 169(12): p. 6668-72. 
105. Oshiumi, H., et al., TICAM-1, an adaptor molecule that participates in Toll-like receptor 
3-mediated interferon-beta induction. Nat Immunol, 2003. 4(2): p. 161-7. 
106. Yamamoto, M., et al., Role of adaptor TRIF in the MyD88-independent toll-like receptor 
signaling pathway. Science, 2003. 301(5633): p. 640-3. 
107. Hirotani, T., et al., Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 
domain containing adaptor inducing IFN-beta. Biochem Biophys Res Commun, 2005. 328(2): 
p. 383-92. 
108. Sato, S., et al., Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) 
associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates 
two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like 
receptor signaling. J Immunol, 2003. 171(8): p. 4304-10. 
109. Jiang, Z., et al., Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at 
Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A, 
2004. 101(10): p. 3533-8. 
110. Meylan, E., et al., RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B 
activation. Nat Immunol, 2004. 5(5): p. 503-7. 
111. Rowe, D.C., et al., The myristoylation of TRIF-related adaptor molecule is essential for Toll-like 
receptor 4 signal transduction. Proc Natl Acad Sci U S A, 2006. 103(16): p. 6299-304. 
112. McGettrick, A.F., et al., Trif-related adapter molecule is phosphorylated by PKC{epsilon} 
during Toll-like receptor 4 signaling. Proc Natl Acad Sci U S A, 2006. 103(24): p. 9196-201. 
113. Carty, M., et al., The human adaptor SARM negatively regulates adaptor protein 
TRIF-dependent Toll-like receptor signaling. Nat Immunol, 2006. 7(10): p. 1074-81. 
114. Martin, M., et al., Interleukin-1-induced activation of a protein kinase co-precipitating with 
the type I interleukin-1 receptor in T cells. Eur J Immunol, 1994. 24(7): p. 1566-71. 
115. Cao, Z., W.J. Henzel, and X. Gao, IRAK: a kinase associated with the interleukin-1 receptor. 
Science, 1996. 271(5252): p. 1128-31. 
116. Rosati, O. and M.U. Martin, Identification and characterization of murine IRAK-M. Biochem 
Biophys Res Commun, 2002. 293(5): p. 1472-7. 
117. Flannery, S. and A.G. Bowie, The interleukin-1 receptor-associated kinases: critical regulators 
of innate immune signalling. Biochem Pharmacol, 2010. 80(12): p. 1981-91. 
118. Neumann, D., et al., Threonine 66 in the death domain of IRAK-1 is critical for interaction with 
signaling molecules but is not a target site for autophosphorylation. J Leukoc Biol, 2008. 84(3): 
p. 807-13. 
119. Kollewe, C., et al., Sequential autophosphorylation steps in the interleukin-1 
receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J 
Biol Chem, 2004. 279(7): p. 5227-36. 
 148 
120. Michael U. Martin, C.k., Interleukin-1 receptor-associated kinase-1 (IRAK-1): A self-regulatory 
adapter molecule in the signaling cascade of the Toll/IL-1 receptor family. Signal Transduction, 
2001. 1(1-2): p. 37-50. 
121. Wang, Z., et al., Crystal structures of IRAK-4 kinase in complex with inhibitors: a 
serine/threonine kinase with tyrosine as a gatekeeper. Structure, 2006. 14(12): p. 1835-44. 
122. Kuglstatter, A., et al., Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel 
features and multiple conformations. J Immunol, 2007. 178(5): p. 2641-5. 
123. Ye, H., et al., Distinct molecular mechanism for initiating TRAF6 signalling. Nature, 2002. 
418(6896): p. 443-7. 
124. Ringwood, L. and L. Li, The involvement of the interleukin-1 receptor-associated kinases 
(IRAKs) in cellular signaling networks controlling inflammation. Cytokine, 2008. 42(1): p. 1-7. 
125. Liu, G., Y.J. Park, and E. Abraham, Interleukin-1 receptor-associated kinase (IRAK) -1-mediated 
NF-kappaB activation requires cytosolic and nuclear activity. FASEB J, 2008. 22(7): p. 2285-96. 
126. Su, J., et al., Differential regulation of interleukin-1 receptor associated kinase 1 (IRAK1) splice 
variants. Mol Immunol, 2007. 44(5): p. 900-5. 
127. Yamin, T.T. and D.K. Miller, The interleukin-1 receptor-associated kinase is degraded by 
proteasomes following its phosphorylation. J Biol Chem, 1997. 272(34): p. 21540-7. 
128. Windheim, M., et al., Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 
receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha 
kinase. Mol Cell Biol, 2008. 28(5): p. 1783-91. 
129. Huang, Y., et al., IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced 
interleukin-10 gene expression. J Biol Chem, 2004. 279(49): p. 51697-703. 
130. Thomas, J.A., et al., Impaired cytokine signaling in mice lacking the IL-1 receptor-associated 
kinase. J Immunol, 1999. 163(2): p. 978-84. 
131. Kanakaraj, P., et al., Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for 
optimal induction of multiple IL-1 signaling pathways and IL-6 production. J Exp Med, 1998. 
187(12): p. 2073-9. 
132. Schoenemeyer, A., et al., The interferon regulatory factor, IRF5, is a central mediator of 
toll-like receptor 7 signaling. J Biol Chem, 2005. 280(17): p. 17005-12. 
133. Balkhi, M.Y., K.A. Fitzgerald, and P.M. Pitha, Functional regulation of MyD88-activated 
interferon regulatory factor 5 by K63-linked polyubiquitination. Mol Cell Biol, 2008. 28(24): p. 
7296-308. 
134. Oganesyan, G., et al., Critical role of TRAF3 in the Toll-like receptor-dependent and 
-independent antiviral response. Nature, 2006. 439(7073): p. 208-11. 
135. Jacob, C.O., et al., Identification of IRAK1 as a risk gene with critical role in the pathogenesis 
of systemic lupus erythematosus. Proc Natl Acad Sci U S A, 2009. 106(15): p. 6256-61. 
136. Muzio, M., et al., IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of 
IL-1 signaling. Science, 1997. 278(5343): p. 1612-5. 
137. Kawagoe, T., et al., Sequential control of Toll-like receptor-dependent responses by IRAK1 and 
IRAK2. Nat Immunol, 2008. 9(6): p. 684-91. 
138. Maloney, G., M. Schroder, and A.G. Bowie, Vaccinia virus protein A52R activates p38 
mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10. J 
Biol Chem, 2005. 280(35): p. 30838-44. 
139. Hardy, M.P. and L.A. O'Neill, The murine IRAK2 gene encodes four alternatively spliced 
isoforms, two of which are inhibitory. J Biol Chem, 2004. 279(26): p. 27699-708. 
140. Wan, Y., et al., Interleukin-1 receptor-associated kinase 2 is critical for 
lipopolysaccharide-mediated post-transcriptional control. J Biol Chem, 2009. 284(16): p. 
10367-75. 
141. Wesche, H., et al., IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated 
kinase (IRAK) family. J Biol Chem, 1999. 274(27): p. 19403-10. 
142. Li, H., et al., IL-1 receptor-associated kinase M is a central regulator of osteoclast 
differentiation and activation. J Exp Med, 2005. 201(7): p. 1169-77. 
143. Su, J., et al., The interleukin-1 receptor-associated kinase M selectively inhibits the alternative, 
instead of the classical NFkappaB pathway. J Innate Immun, 2009. 1(2): p. 164-74. 
144. del Fresno, C., et al., Tumor cells deactivate human monocytes by up-regulating IL-1 receptor 
associated kinase-M expression via CD44 and TLR4. J Immunol, 2005. 174(5): p. 3032-40. 
 149 
145. Zhou, H., et al., IRAK-M mediates Toll-like receptor/IL-1R-induced NFkappaB activation and 
cytokine production. EMBO J, 2013. 32(4): p. 583-96. 
146. Suzuki, N., et al., Severe impairment of interleukin-1 and Toll-like receptor signalling in mice 
lacking IRAK-4. Nature, 2002. 416(6882): p. 750-6. 
147. Burns, K., et al., Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the 
alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med, 
2003. 197(2): p. 263-8. 
148. Koziczak-Holbro, M., et al., IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- 
and toll-like receptor 7-mediated signaling and gene expression. J Biol Chem, 2007. 282(18): p. 
13552-60. 
149. Koziczak-Holbro, M., et al., IRAK-4 kinase activity-dependent and -independent regulation of 
lipopolysaccharide-inducible genes. Eur J Immunol, 2008. 38(3): p. 788-96. 
150. Kawagoe, T., et al., Essential role of IRAK-4 protein and its kinase activity in Toll-like 
receptor-mediated immune responses but not in TCR signaling. J Exp Med, 2007. 204(5): p. 
1013-24. 
151. Kim, T.W., et al., A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate 
immunity. J Exp Med, 2007. 204(5): p. 1025-36. 
152. Qin, J., et al., IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated 
kinase phosphorylation and IL-1 responsiveness. J Biol Chem, 2004. 279(25): p. 26748-53. 
153. Picard, C., et al., Inherited human IRAK-4 deficiency: an update. Immunol Res, 2007. 38(1-3): 
p. 347-52. 
154. Kersse, K., et al., The death-fold superfamily of homotypic interaction motifs. Trends Biochem 
Sci, 2011. 36(10): p. 541-52. 
155. George, J., et al., Two human MYD88 variants, S34Y and R98C, interfere with 
MyD88-IRAK4-myddosome assembly. J Biol Chem, 2011. 286(2): p. 1341-53. 
156. Pickart, C.M. and D. Fushman, Polyubiquitin chains: polymeric protein signals. Curr Opin 
Chem Biol, 2004. 8(6): p. 610-6. 
157. Keating, S.E. and A.G. Bowie, Role of non-degradative ubiquitination in interleukin-1 and 
toll-like receptor signaling. J Biol Chem, 2009. 284(13): p. 8211-5. 
158. Conze, D.B., et al., Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 
receptor- and toll-like receptor-mediated NF-kappaB activation. Mol Cell Biol, 2008. 28(10): p. 
3538-47. 
159. Butler, M.P., J.A. Hanly, and P.N. Moynagh, Kinase-active interleukin-1 receptor-associated 
kinases promote polyubiquitination and degradation of the Pellino family: direct evidence for 
PELLINO proteins being ubiquitin-protein isopeptide ligases. J Biol Chem, 2007. 282(41): p. 
29729-37. 
160. Jiang, X. and Z.J. Chen, The role of ubiquitylation in immune defence and pathogen evasion. 
Nat Rev Immunol, 2012. 12(1): p. 35-48. 
161. Chang, M., W. Jin, and S.C. Sun, Peli1 facilitates TRIF-dependent Toll-like receptor signaling 
and proinflammatory cytokine production. Nat Immunol, 2009. 10(10): p. 1089-95. 
162. Tseng, P.H., et al., Different modes of ubiquitination of the adaptor TRAF3 selectively activate 
the expression of type I interferons and proinflammatory cytokines. Nat Immunol, 2010. 11(1): 
p. 70-5. 
163. Casanova, J.L. and L. Abel, The human model: a genetic dissection of immunity to infection in 
natural conditions. Nat Rev Immunol, 2004. 4(1): p. 55-66. 
164. Picard, C., et al., Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science, 
2003. 299(5615): p. 2076-9. 
165. Casanova, J.L. and L. Abel, Primary immunodeficiencies: a field in its infancy. Science, 2007. 
317(5838): p. 617-9. 
166. Doffinger, R., et al., X-linked anhidrotic ectodermal dysplasia with immunodeficiency is 
caused by impaired NF-kappaB signaling. Nat Genet, 2001. 27(3): p. 277-85. 
167. Courtois, G., et al., A hypermorphic IkappaBalpha mutation is associated with autosomal 
dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest, 2003. 
112(7): p. 1108-15. 
 150 
168. Ku, C.L., et al., Selective predisposition to bacterial infections in IRAK-4-deficient children: 
IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med, 2007. 
204(10): p. 2407-22. 
169. Netea, M.G., C. Wijmenga, and L.A. O'Neill, Genetic variation in Toll-like receptors and 
disease susceptibility. Nat Immunol, 2012. 13(6): p. 535-42. 
170. Puente, X.S., et al., Whole-genome sequencing identifies recurrent mutations in chronic 
lymphocytic leukaemia. Nature, 2011. 475(7354): p. 101-5. 
171. Ngo, V.N., et al., Oncogenically active MYD88 mutations in human lymphoma. Nature, 2011. 
470(7332): p. 115-9. 
172. Casrouge, A., et al., Herpes simplex virus encephalitis in human UNC-93B deficiency. Science, 
2006. 314(5797): p. 308-12. 
173. Perez de Diego, R., et al., Human TRAF3 adaptor molecule deficiency leads to impaired 
Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity, 2010. 
33(3): p. 400-11. 
174. Sancho-Shimizu, V., et al., Herpes simplex encephalitis in children with autosomal recessive 
and dominant TRIF deficiency. J Clin Invest, 2011. 121(12): p. 4889-902. 
175. Arbour, N.C., et al., TLR4 mutations are associated with endotoxin hyporesponsiveness in 
humans. Nat Genet, 2000. 25(2): p. 187-91. 
176. Lorenz, E., et al., Relevance of mutations in the TLR4 receptor in patients with gram-negative 
septic shock. Arch Intern Med, 2002. 162(9): p. 1028-32. 
177. Ogus, A.C., et al., The Arg753GLn polymorphism of the human toll-like receptor 2 gene in 
tuberculosis disease. Eur Respir J, 2004. 23(2): p. 219-23. 
178. Schroder, N.W., et al., Heterozygous Arg753Gln polymorphism of human TLR-2 impairs 
immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J 
Immunol, 2005. 175(4): p. 2534-40. 
179. Hawn, T.R., et al., A common dominant TLR5 stop codon polymorphism abolishes flagellin 
signaling and is associated with susceptibility to legionnaires' disease. J Exp Med, 2003. 
198(10): p. 1563-72. 
180. Dunstan, S.J., et al., Host susceptibility and clinical outcomes in toll-like receptor 5-deficient 
patients with typhoid fever in Vietnam. J Infect Dis, 2005. 191(7): p. 1068-71. 
181. Hawn, T.R., et al., A stop codon polymorphism of Toll-like receptor 5 is associated with 
resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A, 2005. 102(30): p. 
10593-7. 
182. Gewirtz, A.T., et al., Dominant-negative TLR5 polymorphism reduces adaptive immune 
response to flagellin and negatively associates with Crohn's disease. Am J Physiol 
Gastrointest Liver Physiol, 2006. 290(6): p. G1157-63. 
183. George, J., et al., MyD88 adaptor-like D96N is a naturally occurring loss-of-function variant of 
TIRAP. J Immunol, 2010. 184(6): p. 3025-32. 
184. Dubois, P.C., et al., Multiple common variants for celiac disease influencing immune gene 
expression. Nat Genet, 2010. 42(4): p. 295-302. 
185. Ishida, R., et al., Association of a haplotype (196Phe/532Ser) in the 
interleukin-1-receptor-associated kinase (IRAK1) gene with low radial bone mineral density in 
two independent populations. J Bone Miner Res, 2003. 18(3): p. 419-23. 
186. Lakoski, S.G., et al., The association between innate immunity gene (IRAK1) and C-reactive 
protein in the Diabetes Heart Study. Exp Mol Pathol, 2007. 82(3): p. 280-3. 
187. Arcaroli, J., et al., Variant IRAK-1 haplotype is associated with increased nuclear 
factor-kappaB activation and worse outcomes in sepsis. Am J Respir Crit Care Med, 2006. 
173(12): p. 1335-41. 
188. Zhang, H., et al., IRAK1 rs3027898 C/A polymorphism is associated with risk of rheumatoid 
arthritis. Rheumatol Int, 2012. 
189. Balaci, L., et al., IRAK-M is involved in the pathogenesis of early-onset persistent asthma. Am J 
Hum Genet, 2007. 80(6): p. 1103-14. 
190. Barrios-Rodiles, M., et al., High-throughput mapping of a dynamic signaling network in 
mammalian cells. Science, 2005. 307(5715): p. 1621-5. 
191. Smith, P.K., et al., Measurement of protein using bicinchoninic acid. Anal Biochem, 1985. 
150(1): p. 76-85. 
 151 
192. Janssens, S. and R. Beyaert, Functional diversity and regulation of different interleukin-1 
receptor-associated kinase (IRAK) family members. Mol Cell, 2003. 11(2): p. 293-302. 
193. Flannery, S.M., et al., Human interleukin-1 receptor-associated kinase-2 is essential for 
Toll-like receptor-mediated transcriptional and post-transcriptional regulation of tumor 
necrosis factor alpha. J Biol Chem, 2011. 286(27): p. 23688-97. 
194. Nagpal, K., et al., Natural loss-of-function mutation of myeloid differentiation protein 88 
disrupts its ability to form Myddosomes. J Biol Chem, 2011. 286(13): p. 11875-82. 
195. Nagpal, K., et al., A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of 
MyD88 binding and reduced TLR2/TLR4 signaling. J Biol Chem, 2009. 284(38): p. 25742-8. 
196. Neumann, D., et al., IL-1beta-induced phosphorylation of PKB/Akt depends on the presence of 
IRAK-1. Eur J Immunol, 2002. 32(12): p. 3689-98. 
197. Harte, M.T., et al., The poxvirus protein A52R targets Toll-like receptor signaling complexes to 
suppress host defense. J Exp Med, 2003. 197(3): p. 343-51. 
198. Conner, J.R., Smirnova, II, and A. Poltorak, A mutation in Irak2c identifies IRAK-2 as a central 
component of the TLR regulatory network of wild-derived mice. J Exp Med, 2009. 206(7): p. 
1615-31. 
199. Liu, Y.C., et al., TLR2 signaling depletes IRAK1 and inhibits induction of type I IFN by TLR7/9. J 
Immunol, 2012. 188(3): p. 1019-26. 
200. Gog, J.R., et al., Dynamics of Salmonella infection of macrophages at the single cell level. J R 
Soc Interface, 2012. 9(75): p. 2696-707. 
201. Cook, P., et al., Salmonella-induced SipB-independent cell death requires Toll-like receptor-4 
signalling via the adapter proteins Tram and Trif. Immunology, 2007. 122(2): p. 222-9. 
202. Reading, P.C., et al., Influenza viruses differ in ability to infect macrophages and to induce a 
local inflammatory response following intraperitoneal injection of mice. Immunol Cell Biol, 
2010. 88(6): p. 641-50. 
203. Yang, W.L., et al., Regulation of Akt signaling activation by ubiquitination. Cell Cycle, 2010. 
9(3): p. 487-97. 
204. Tsukamoto, K., et al., Critical roles of the p110 beta subtype of phosphoinositide 3-kinase in 
lipopolysaccharide-induced Akt activation and negative regulation of nitrite production in 
RAW 264.7 cells. J Immunol, 2008. 180(4): p. 2054-61. 
205. Chaurasia, B., et al., Phosphoinositide-dependent kinase 1 provides negative feedback 
inhibition to Toll-like receptor-mediated NF-kappaB activation in macrophages. Mol Cell Biol, 
2010. 30(17): p. 4354-66. 
206. Cahill, C.M., J.T. Rogers, and W.A. Walker, The role of phosphoinositide 3-kinase signaling in 
intestinal inflammation. J Signal Transduct, 2012. 2012: p. 358476. 
207. Santos-Sierra, S., et al., Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. 
EMBO J, 2009. 28(14): p. 2018-27. 
208. Fitzgerald, K.A., et al., Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal 
transduction. Nature, 2001. 413(6851): p. 78-83. 
209. Marmiroli, S., et al., Phosphatidylinositol 3-kinase is recruited to a specific site in the activated 
IL-1 receptor I. FEBS Lett, 1998. 438(1-2): p. 49-54. 
210. Cenni, V., et al., Interleukin-1-receptor-associated kinase 2 (IRAK2)-mediated 
interleukin-1-dependent nuclear factor kappaB transactivation in Saos2 cells requires the 
Akt/protein kinase B kinase. Biochem J, 2003. 376(Pt 1): p. 303-11. 
211. Weintz, G., et al., The phosphoproteome of toll-like receptor-activated macrophages. Mol 
Syst Biol, 2010. 6: p. 371. 
212. Yin, W., et al., The kinase activity of interleukin-1 receptor-associated kinase 2 is essential for 
lipopolysaccharide-mediated cytokine and chemokine mRNA stability and translation. J 
Interferon Cytokine Res, 2011. 31(5): p. 415-22. 
213. Chin, K.C., G.G. Li, and J.P. Ting, Importance of acidic, proline/serine/threonine-rich, and 
GTP-binding regions in the major histocompatibility complex class II transactivator: 
generation of transdominant-negative mutants. Proc Natl Acad Sci U S A, 1997. 94(6): p. 
2501-6. 
214. Rao, S., et al., SPI-B activates transcription via a unique proline, serine, and threonine domain 
and exhibits DNA binding affinity differences from PU.1. J Biol Chem, 1999. 274(16): p. 
11115-24. 
 152 
215. Tun-Kyi, A., et al., Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling 
and type I interferon-mediated immunity. Nat Immunol, 2011. 12(8): p. 733-41. 
216. Gay, N.J., M. Gangloff, and L.A. O'Neill, What the Myddosome structure tells us about the 
initiation of innate immunity. Trends Immunol, 2011. 32(3): p. 104-9. 
217. Akira, S. and K. Takeda, Toll-like receptor signalling. Nat Rev Immunol, 2004. 4(7): p. 499-511. 
218. Brikos, C., et al., Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) 
receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 
as the stable components. Mol Cell Proteomics, 2007. 6(9): p. 1551-9. 
219. Prasad, L., et al., Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol, 
2007. 36(4): p. 731-7. 
220. Picard, C., et al., Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. 
Medicine (Baltimore), 2010. 89(6): p. 403-25. 
221. Schork, N.J., et al., Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet 
Dev, 2009. 19(3): p. 212-9. 
222. Waldner, M.J., S. Foersch, and M.F. Neurath, Interleukin-6--a key regulator of colorectal 
cancer development. Int J Biol Sci, 2012. 8(9): p. 1248-53. 
223. Thomas, E., et al., HCV infection induces a unique hepatic innate immune response associated 
with robust production of type III interferons. Gastroenterology, 2012. 142(4): p. 978-88. 
224. Rehermann, B., Hepatitis C virus versus innate and adaptive immune responses: a tale of 
coevolution and coexistence. J Clin Invest, 2009. 119(7): p. 1745-54. 
225. Katsounas, A., J.F. Schlaak, and R.A. Lempicki, CCL5: a double-edged sword in host defense 
against the hepatitis C virus. Int Rev Immunol, 2011. 30(5-6): p. 366-78. 
226. Eksioglu, E.A., et al., Characterization of HCV interactions with Toll-like receptors and RIG-I in 
liver cells. PLoS One, 2011. 6(6): p. e21186. 
227. Hou, J., et al., MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in 
macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol, 2009. 183(3): p. 2150-8. 
228. Jemal, A., et al., Global cancer statistics. CA Cancer J Clin, 2011. 61(2): p. 69-90. 
229. Shanks, A.M. and E.M. El-Omar, Helicobacter pylori infection, host genetics and gastric cancer. 
J Dig Dis, 2009. 10(3): p. 157-64. 
230. Liu, P., et al., Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug 
Discov, 2009. 8(8): p. 627-44. 
231. Dunne, A., Inflammasome activation: from inflammatory disease to infection. Biochem Soc 
Trans, 2011. 39(2): p. 669-73. 
232. Mitroulis, I., K. Kambas, and K. Ritis, Neutrophils, IL-1beta, and gout: is there a link? Semin 
Immunopathol, 2013. 
 
 
  
 153 
 
 
 
 
Appendix 
 
  
 154 
 155 
Appendix A: Reagent and buffers 
A1: Cloning primers 
Prime
r pair 
Name 
 
Sequence Properties 
1 
pENTR1A 
based FL 
hIRAK2 
F 
ATATAG GATCC CA 
ATGGCCTGCTACATCTACCAG 
Overhang+ BamHI +Start 
codon+IRAK2 
R1 
ATATC GCGGCCGC CTA 
GGGGCCAAAGAGCTCAATGCT 
Overhang+ NotI + Stop 
codon +end part of IRAK2 
R2 
ATATC GCGGCCGC GA 
GGGGCCAAAGAGCTCAATGCT  
Overhang+ NotI 
+open+end part of IRAK2 
2 
pENTR1A 
based DD 
hIRAK2 
(1-112 aa) 
F 
ATATA GGATCC CA 
ATGGCCTGCTACATCTACCAG 
Overhang+ BamHI +Start 
codon+IRAK2 
R1 
ATATC  GCGGCCGC CTA 
TGGCTTCACAGAGTCAGGGAA 
Overhang+ NotI + Stop 
codon +DD IRAK2 
R2 
ATATC  GCGGCCGC CT    
TGGCTTCACAGAGTCAGGGAA 
Overhang+ NotI 
+open+DDIRAK2 
3 
pENTR1A 
based DD 
hIRAK(1-
109aa) 
F 
ATATA GGATCC CA 
ATGGCCGGGGGGCCGGGCCCG 
Overhang+ BamHI +Start 
codon+IRAK1 
R1 
ATATC GCGGCCGC CTA 
CGGAAGCGGGGCGGGAGGGTG 
Overhang+ NotI + Stop 
codon +DD IRAK1 
R2 
ATATC GCGGCCGC CT 
CGGAAGCGGGGCGGGAGGGTG 
Overhang+ NotI 
+open+DDIRAK1 
4 
pENTR1A 
based DD 
hIRAK3(1
-109aa) 
F 
TATATA GGTACC AC 
ATGGCGGGGAACTGTGGGGCC 
Overhang+ KpnI +Start 
codon+IRAK1 
R1 
TATATA GCGGCCGC TCA 
TCCATAGTTTGTAATTAAATG 
Overhang+ NotI + Stop 
codon +DD IRAK3 
R2 
TATATA GCGGCCGC CA 
TCCATAGTTTGTAATTAAATG 
Overhang+ NotI 
+open+DDIRAK3 
5 
N-HA 
tagged 
IRAK2  
F 
TCGACTTAATTAAGCCGCCACCATGTA
CCCATACGACGTCCCAGACTACGCTGG 
Insertion an in-frame 
Met-HA tag at the 
N-terminus of IRAK2 
following the att site 
R1 
GATCCCAGCGTAGTCTGGGACGTCGTA
TGGGTACATGGTGGCGGCTTAATTAAG 
6 
C-HA 
tagged 
IRAK2  
F 
GGCCGCACTACCCATACGACGTCCCAG
ACTACGCTTAGC 
 Insertion an HA tag at the 
C-terminus of IRAK2 
prior to the att site R1 
TCGAGCTAAGCGTAGTCTGGGACGTCG
TATGGGTAGTGC 
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A2: Mutagenesis primers 
Primer 
Pair 
Name Sequence Properties 
1 IRAK2 R43Q 
F_catggacttgatcttctgcagctgggtcaggtc 
SNP 
R_gacctgacccagctgcagaagatcaagtccatg 
2 IRAK2 S47Y 
F_gcacccgctccatgtacttgatcttccgc 
SNP 
R_gcggaagatcaagtacatggagcgggtgc 
3 IRAK2 L78M 
F_ctccaggcggcacatgaggtccacaagtt 
SNP 
R_aacttgtggacctcatgtgccgcctggag 
4 IRAK2 I99V 
F_ggaatgggacacctgacttcaggagccggtttc 
SNP 
R_gaaaccggctcctgaagtcaggtgtcccattcc 
5 IRAK2 R214G 
F_cccctggctgattttgccgttttgattgaagtcat 
SNP 
R_atgacttcaatcaaaacggcaaaatcagccagggg 
6 
IRAK2 
L358M 
F_tttgttgacaggacacatatgagccattgggtgag 
SNP 
R_ctcacccaatggctcatatgtgtcctgtcaacaaa 
7 IRAK2 L392V 
F_actcgctttgtcacctgccccacccg 
SNP 
R_cgggtggggcaggtgacaaagcgagt 
8 IRAK2 D431E 
F_cgaggcggtgctgcttggaatttcactgaggag 
SNP 
R_ctcctcagtgaaattccaagcagcaccgcctcg 
9 IRAK2 L439V 
F_cgtcttcctggagcagaccgaggcggt 
SNP 
R_accgcctcggtctgctccaggaagacg 
10 
IRAK2 
A498G 
F_ccgctcttccacaccagccacagagcc 
SNP 
R_ggctctgtggctggtgtggaagagcgg 
11 IRAK2 E501G 
F_cctcggagccgcccttccacagcag 
SNP 
R_ctgctgtggaagggcggctccgagg 
12 IRAK2 L503I 
F_gtctcccgacctcggatccgctcttc 
SNP 
R_gaagagcggatccgaggtcgggagac 
13 
IRAK2 
K237A 
F_gggaagccattcgtcttcgcgaagctcagagagacag
c Mutation 
R_gctgtctctctgagcttcgcgaagacgaatggcttccc 
14 IRAK2 E528A 
F_ccaacaccccagaggcaacagacgacgttga 
Mutation 
R_tcaacgtcgtctgttgcctctggggtgttgg 
A3: qPCR primers 
qPCR primers Catalog Number (Life Technology) 
TNFa Mm00443260_g1 
IL-6 Mm00446190_m1 
IL-1B Mm00434228_m1 
CCL5 Mm01302427_m1 
Tbp Mm00446971_m1 
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A4: Overview of purchased and gifted plasmids  
Gene Properties Source 
EGFP 
Enhanced green fluorescent protein (EGFP) encoding 
plasmids (pC1-EGFP vector) 
BD Clontech. 
NF-κB Firefly 
reporter  
Firefly luciferase reporter gene under the control of a 
synthetic NF-κB promoter 
Stratagene 
Renilla 
Luciferase 
Renilla luciferase repoter gene constitutively 
expressed under the control of TK promoter 
Promega 
IRAK1 stop 
Entry clone 
pENTR221 based entry clone containing isoform 
A,712aa 
imaGenes; 
OCAAo5051C0298
D 
IRAK1 open 
Entry clone 
pENTR221 based entry clone containing isoform 
A,712aa 
imaGenes; 
OCAAo5051C0299
D 
IRAK2 TOPO 
plasmid 
Human IRAK2 containg 625aa  
imaGENES, 
IRCMp5012D0935D 
IRAK3 Entry 
clone open 
pDONR223 based entry clone containing 
isoformA,596aa 
DKFZ Core Facility, 
Germany 
pENTR1A Gateway compatible entry clone Invitrogen 
Jun Protein A 
pT-REx-DEST30 based vector backbone encoding N 
terminal tagged Jun-Protein A 
DKFZ Core Facility, 
Germany 
Fos Renilla 
pcDNA3 based vector encoding C-terminally tagged 
Fos-Renilla 
DKFZ Core Facility, 
Germany 
Flip 
recombinase 
pOG44 vector encoding for the Flp recombinase 
Dr. Andreas 
Pichlmair,CeMM, 
Vienna, Austria 
Strep-HA 
pcDNATM5/FR
T 
Destination gateway clone for N-terminal Strep-HA 
tagging; gene is under the control of a 
tetracyclineregulated, hybrid CMV/TetO2 promoter; 
the plasmid contains FRT site for stable transfection 
Renilla pcDNA3 
nt Renilla 
Destination gateway vector for N-terminal Renilla 
tags 
DKFZ Core Facility, 
Germany 
Protein A 
Pt-Rex-DEST30 
Destination gateway vector for N-terminal Protein-A 
tags 
DKFZ Core Facility, 
Germany 
TRAF6 pDONR223 based entry clone 
DKFZ Core Facility, 
Germany 
Flag destination 
clone 
pDONR223 based entry clone 
Dr.Stefan Push, 
Uni-HD, Germany 
pMXs-IP-puro  MMLV based retroviral tranduction vector 
Dr. Kevin-Michael 
Dennehy, University 
of Tübingen, 
Germany 
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A5: Overview of antibodies list 
Name Species 
Dilution 
ratio 
Working buffer Company 
Catalog 
number 
Anti-HA mouse 1:5000 
TBS-Tween 0.5%+ 3% 
skimed milk 
Sigma H9658 
Anti-HA rabbit 1:5000 
TBS-Tween 0.5%+ 3% 
skimed milk 
CST C2954 
Anti-Flag rabbit 1:2500 
TBS-Tween 0.5%+ 3% 
skimed milk 
Sigma F7425 
Anti-TRAF6 mouse 1:1000 
TBS-Tween 0.5%+ 3% 
skimed milk 
Santa 
cruz 
sc-8409 
Anti-TRAF6 rabbit 1:1000 
TBS-Tween 0.5%+ 3% 
skimed milk 
Santa 
cruz 
sc-7221 
Anti-rabbit HRP goat 1:5000 
TBS-Tween 0.5%+ 3% 
skimed milk 
Vector PI-1000 
Anti-mouse HRP goat 1:5000 
TBS-Tween 0.5%+ 3% 
skimed milk 
Promega W4023 
Anti-Renilla mouse 1:2500 
TBS-Tween 0.5%+ 3% 
skimed milk 
Millipore MAB4400 
Anti-ProteinA rabbit 1:60000 
TBS-Tween 0.5%+ 3% 
skimed milk   
Anti-Tubulin mouse 1:2500 
TBS-Tween 0.5%+ 3% 
skimed milk 
Sigma T4026 
Anti-Ubiquitin  mouse 1:1000 
TBS-Tween 0.5%+ 3% 
skimed milk 
Santa 
cruz 
  
A6: TLR ligands 
Ligands name Working concentration Company 
Pam2CSK4 1μg/ml Invivogen 
Poly I:C 10μg/ml Axxora 
LPS 0.05μg/ml Invivogen 
Flagellin 50ng.ml Imgenex 
R848 1μg/ml Invivogen 
CpG 2006 0.5μg/ml Tip Biomol 
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A7: Recipes of buffers  
Buffer name Recipe 
Lysis buffer 1 
20 mM Tris, pH 7.5, 250 mM NaCl, 1 % Triton-X100, 10 mM 
EDTA, 10 mM DTT,protease and phosphatase inhibitors 
Lysis buffer 2 
50 mM HEPES, 150 mM NaCl, 1 % NP-40, 20 mM 
β-glycerophosphate, 2 mM DTT, 1mM sodium orthovanadate and 
protease inhibitors (Roche) 
Lysis buffer 3 
7 M urea, 2 M thiourea, 2 % CHAPS, 40 mM DTT, protease 
inhibitors (Roche) and 0.5 %of immobilized pH gradient buffer 
3-10 NL (GE Healthcare) 
Lysis buffer 4 
50 mM HEPES, pH7.5, 200 mM NaCl, 1 mM EDTA, 10% (v/v) 
glycerol, 1% (v/v) NP40, freshly added Complete proteinase 
inhibitors (Roche), Phos-Stop phosphatase inhibitor (Roche) and 
10 uM Iodoactetamide 
Rehydration buffer 
7 M urea, 2 M thiourea, 2 % CHAPS, 40 mM DTT, protease 
inhibitors (Roche) and 0.5 % of immobilized pH gradient buffer 
3-10 NL (GE Healthcare) 
PBS 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, add with dH2O to 1 l, pH 
7.4 
TBS 50 mM Tris HCl, pH 7.4 and 150 mM NaCl 
TBS-Tween 0.1% TBS+0.1% Tween 
Renilla substrate 
buffer 
220 mM potassium phosphate buffer (1 M K2HPO4, 1 M 
KH2PO4, pH 5.1), 1.1 M NaCl, 2.2 mM EDTA and 0.44 mg/ml 
BSA 
Sodium Borate buffer 5 mM di-sodium borate 
stop solution 2N H2SO4 
HBS 
50 mM HEPES pH 7.05,10 mM KCl,12 mM Dextrose,280 mM 
NaCl,1.5 mM Na2HPO4 
Polybrene 4mg/ml stock  
HBSS 
0.137mM NaCl, 5.4mM KCl, 0.25mM Na2HPO4, 0.44mMKH2PO4, 
1.3Mm CaCl2, 1.0m M, 4.2Mm NaHCO3 
 
A8: Recipes of medium 
Medium Recipe 
LB media  5 g Bacto-Tryptone, 5 g Bacto-Yeast, and 10 g NaCl, add with dH2O to 1 l 
NZY+ broth 
 5 g NaCl, 2 g MgSO4*7H2O, 5 g Bacto-Yeast Extract, 10 g NZ amine, add 
with dH2O to 1 l 
SOC  
20 g Bacto-Tryptone, 5 g Bacto-Yeast extract, 0.5 g NaCl, 2.5 ml of 1 M KCl, 
20 ml of 1M glucose, add with dH2O to 1 l 
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Appendix B1: The signalling properties of defect mutants of IRAK2 
In order to confirm the signalling properties of selected negative controls such as 
double mutants R214G +L392V, K237A and E528A, NF-κB reporter dual luciferase 
assay and IL-8 ELISA assay were performed. See figure 5.1. 
Overexpression IRAK2 K237A and E528A in HEK293T cells, these two mutants 
almost completely abrogated the activation of NF-κB and the production of IL-8. The 
double mutant has slightly stronger defect than the single mutations.   
 
Figure B1: The signalling properties of defect mutants of IRAK2. Overexpression each plasmid 
into HEK293T cells as indicate doses. (a): Cell were lysed 48 hours post-transfection with passive lysis 
buffer and the NF-κB luminescence were measured with flurostar (Biotech).(b): Supernatant were 
harvest 48 hours post-transfection and the amount of IL-8 were measured by ELISA.
Appendix B2: The signalling properties of defect mutants of IRAK3 
Overexpression IRAK3 WT, DD, Y180X, K192A and empty vector in HEK293T cells. 
K192A dimished the NF-κB activation completely. 
 
Figure B2: The signalling properties of defect mutants of IRAK3. Overexpression each plasmid 
into HEK293T cells as indicate doses. Cell were lysed 48 hours post-transfection with passive lysis 
buffer and the NF-κB luminescence were measured with flurostar (Biotech). 
